Ionic liquid composition
Conjugating proteins or peptides with ions in ionic liquid formulations addresses the limitations of existing treatments, enhancing their therapeutic delivery and efficacy for diseases like obesity and metabolic disorders.
Patent Information
- Application Number
- JP2024527534
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-19
- Filing Date
- 2022-11-10
- Publication Date
- 2024-12-05
AI Technical Summary
Existing compositions for treating diseases such as obesity and metabolic disorders using ionic liquids do not effectively utilize proteins or peptides, limiting their therapeutic efficacy.
Modifying proteins or peptides by non-covalently or covalently conjugating them with ions present in the ionic liquid formulations, enhancing their therapeutic delivery and efficacy when administered orally.
Improved therapeutic delivery and efficacy of proteins or peptides for treating diseases like obesity and metabolic disorders through enhanced solubility and bioavailability.
Smart Images

Figure 2024544920000001_ABST
Abstract
Description
[Technical Field]
[0001] cross reference
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 380,125, filed October 19, 2022, U.S. Provisional Patent Application No. 63 / 334,410, filed April 25, 2022, U.S. Provisional Patent Application No. 63 / 295,197, filed December 30, 2021, and U.S. Provisional Patent Application No. 63 / 277,878, filed November 10, 2021, each of which is incorporated by reference in its entirety into this specification.
[0002] Technical Field TECHNICAL FIELD
[0002] The technology described herein relates to ionic liquids and deep eutectic liquids for the treatment of diseases including obesity, metabolic disorders, and gastrointestinal inflammation. Summary of the Invention [Problem to be solved by the invention]
[0003]
[0003] Provided herein are compositions and methods of use for the treatment of diseases or disorders. [Means for solving the problem]
[0004] The present inventors have discovered that certain modifications to proteins surprisingly improve their use with ionic liquid compositions for formulation and delivery, and these formulations can be delivered orally to patients for the purpose of treating the patients.
[0005]
[0005] In one embodiment of the present specification, a composition is described in which a protein or peptide is non-covalently conjugated to one or more ions, and such ions are also present in the ionic liquid present in the formulation.
[0006]
[0006] In one embodiment of the present specification, a composition is described in which a protein or peptide is covalently conjugated to one or more ions, and such ions are also present in the ionic liquid present in the formulation.
[0007] In certain aspects herein, inter alia, compounds of formula I:
[0008] [ka]
[0009] [In the formula, R 1 , R 2 , and R 3 are independently C1-C5 alkyl; R 4 is a C2-C5 alkyl, wherein the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls; R 5 is a therapeutic agent] Compounds according to the formula:
[0010] In some embodiments, R 1 , R 2 , and R 3 is methyl. In some embodiments, R 1 , R 2 , and R 3 is ethyl. In some embodiments, R 1 , R 2 , and R 3 is propyl.
[0011] In some embodiments, R 1 and R 2 is methyl and R 3 is ethyl.
[0012] In some embodiments, R 1 and R 3is methyl and R 2 is ethyl.
[0012]
[0013] In some embodiments, R 1 and R 2 is ethyl, and R 3 is methyl.
[0014] In some embodiments, R 1 and R 3 is ethyl, and R 2 is methyl.
[0013]
[0015] In some embodiments, R 1 and R 2 is propyl, and R 3 is methyl.
[0016] In some embodiments, R 1 and R 3 is propyl, and R 2 is methyl.
[0014]
[0017] In some embodiments, R 4 is a C2-C5 alkyl substituted with hydroxyl.
[0018] In some embodiments, R 4 teeth,
[0015] [ka]
[0016] is.
[0019] In some embodiments, the compound has Formula Ia:
[0017] [ka]
[0018] It is a compound according to the following:
[0020] In some embodiments, the compound has Formula Ib:
[0019] [ka]
[0020] It is a compound according to the following:
[0021] In some embodiments, the compound has formula Ic:
[0021] [ka]
[0022] It is a compound according to the following:
[0022] In some embodiments, the therapeutic agent is a GLP-1 analog or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
[0023] In some embodiments, the therapeutic agent is a GLP-1 analog or a functional variant thereof, or a mimetic thereof.
[0024] In some embodiments, the compound comprises the structure shown in FIG.
[0024]
[0025] In some embodiments, the compound is
[0025] [ka]
[0026] of,
[0027] [ka]
[0028] The molar ratio to is about 1:1 to about 1:60. In some embodiments, the compound is
[0029] [ka]
[0030] of,
[0031] [ka]
[0032] The molar ratio of the compound to the compound is about 1:1 to about 1:30. In some embodiments, the compound is
[0033] [ka]
[0034] of,
[0035] [ka]
[0036] The molar ratio to is about 1:1. In some embodiments, the compound is
[0037] [ka]
[0038] of,
[0039] [ka]
[0040] The molar ratio to is about 1:3. In some embodiments, the compound is
[0041] [ka]
[0042] of,
[0043] [ka]
[0044] The molar ratio to is about 1:4. In some embodiments, the compound is
[0045] [ka]
[0046] The molar ratio of In some embodiments, the compound is
[0047] [ka]
[0048] The molar ratio of In some embodiments, the compound is
[0049] [ka]
[0050] The molar ratio of In some embodiments, the compound is
[0051] [ka]
[0052] The molar ratio of In some embodiments, the compound is
[0053] [ka]
[0054] The molar ratio of In some embodiments, the therapeutic agent is amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof.
[0055] In some embodiments, the therapeutic agent is an amylin analog or a functional variant thereof, or a mimetic or analog thereof. In some embodiments, the therapeutic agent is [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide or a functional variant thereof, or a mimetic or analog thereof.
[0056] In some embodiments, the therapeutic agent is an amylin analog having a structure shown in Figure 2, Figure 3, or Figure 4, or a functional variant thereof, or a mimetic or analog thereof.
[0057]
[0039] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
[0058] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, that comprises the N14E amino acid substitution. In some embodiments, the compound is
[0059] [ka]
[0060] of,
[0061] [ka]
[0062] The molar ratio of the compound to the compound is about 1:1 to about 1:30. In some embodiments, the compound is
[0063] [ka]
[0064] of,
[0065] [ka]
[0066] The molar ratio to is about 1:1. In some embodiments, the compound is
[0067] [ka]
[0068] of,
[0069] [ka]
[0070] The molar ratio to is about 1:3. In some embodiments, the compound is
[0071] [ka]
[0072] The molar ratio of In some embodiments, the compound is
[0073] [ka]
[0074] of,
[0075] [ka]
[0076] The molar ratio to is about 1:12. In some embodiments, the compound is
[0077] [ka]
[0078] The molar ratio of
[0047] In some embodiments, the therapeutic agent is an antibody or antibody fragment thereof.
[0048] In some embodiments, the therapeutic agent is any one selected from the group consisting of infliximab or its antibody fragment, adalimumab or its antibody fragment, ustekinumab or its antibody fragment, golimumab or its antibody fragment, natalizumab or its antibody fragment, vedolizumab or its antibody fragment, and certolizumab pegol or its antibody fragment.
[0079] In some embodiments, the therapeutic agent is (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof. Includes.
[0080] In some embodiments, the therapeutic agent is (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6, or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof Includes.
[0081] In some embodiments, the therapeutic agent is (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences of SEQ ID NO: 3 and SEQ ID NO: 6, the sequences of SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences of SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 Includes.
[0082]
[0052] In some embodiments, the therapeutic agent is infliximab or an antibody fragment thereof.
[0053] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:1 or SEQ ID NO:24 and the sequence of SEQ ID NO:2.
[0083] In some embodiments, the compound is
[0084] [ka]
[0085] of,
[0086] [ka]
[0087] The molar ratio to is about 1:1 to about 1:164. In some embodiments, the compound is
[0088] [ka]
[0089] of,
[0090] [ka]
[0091] The molar ratio to is about 1:1. In some embodiments, the compound is
[0092] [ka]
[0093] of,
[0094] [ka]
[0095] The molar ratio to is about 1:33. In some embodiments, the compound is
[0096] [ka]
[0097] of,
[0098] [ka]
[0099] The molar ratio to is about 1:41. In some embodiments, the compound is
[0100] [ka]
[0101] of,
[0102] [ka]
[0103] The molar ratio to is about 1:66. In some embodiments, the compound is
[0104] [ka]
[0105] of,
[0106] [ka]
[0107] The molar ratio to is about 1:82. In some embodiments, the compound is
[0108] [ka]
[0109] of,
[0110] [ka]
[0111] The molar ratio to is about 1:132. In some embodiments, the compound is
[0112] [ka]
[0113] of,
[0114] [ka]
[0115] The molar ratio to is about 1:164.
[0062] In some embodiments, the therapeutic agent is adalimumab or an antibody fragment thereof.
[0063] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:3 and the sequence of SEQ ID NO:6, the sequence of SEQ ID NO:4 and the sequence of SEQ ID NO:6, or the sequence of SEQ ID NO:5 and the sequence of SEQ ID NO:7.
[0116] In some embodiments, the compound is
[0117] [ka]
[0118] of,
[0119] [ka]
[0120] The molar ratio to is about 1:1 to about 1:144.
[0065] In some embodiments, the therapeutic agent is ustekinumab or an antibody fragment thereof.
[0066] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:8 and the sequence of SEQ ID NO:9.
[0121] In some embodiments, the compound is
[0122] [ka]
[0123] of,
[0124] [ka]
[0125] The molar ratio to is about 1:1 to about 1:140.
[0068] In some embodiments, the therapeutic agent is golimumab or an antibody fragment thereof.
[0069] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:10 and the sequence of SEQ ID NO:11.
[0126] In some embodiments, the compound is
[0127] [ka]
[0128] of,
[0129] [ka]
[0130] The molar ratio of the compound to the compound is about 1:1 to about 1:80. In some embodiments, the therapeutic agent is natalizumab or an antibody fragment thereof.
[0072] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:12 and the sequence of SEQ ID NO:14, or the sequence of SEQ ID NO:13 and the sequence of SEQ ID NO:15.
[0131] In some embodiments, the compound is
[0132] [ka]
[0133] of,
[0134] [ka]
[0135] The molar ratio to is about 1:1 to about 1:156.
[0074] In some embodiments, the therapeutic agent is vedolizumab or an antibody fragment thereof.
[0075] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:16 and the sequence of SEQ ID NO:17.
[0136] In some embodiments, the compound is
[0137] [ka]
[0138] of,
[0139] [ka]
[0140] The molar ratio to is about 1:1 to about 1:256.
[0077] In some embodiments, the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
[0141]
[0078] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:18 and the sequence of SEQ ID NO:19. In some embodiments, the compound is
[0142] [ka]
[0143] of,
[0144] [ka]
[0145] The molar ratio to is about 1:1 to about 1:70.
[0080] In some embodiments, the therapeutic agent is an antibody or antibody fragment thereof comprising a [one or more choline or choline derivatives]-peptide salt formed at the C-terminus of the light chain, the C-terminus of the heavy chain, or a combination thereof.
[0146]
[0081] In some embodiments, the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
[0082] In some embodiments, the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0147]
[0083] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:25.
[0084] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0148]
[0085] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO:25.
[0086] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25.
[0149] In some embodiments, the compound is
[0150] [ka]
[0151] of,
[0152] [ka]
[0153] The molar ratio to is about 1:1 to about 1:20. In some embodiments, the compound is
[0154] [ka]
[0155] of,
[0156] [ka]
[0157] The molar ratio to is about 1:1. In some embodiments, the compound is
[0158] [ka]
[0159] of,
[0160] [ka]
[0161] The molar ratio to is about 1:2. In some embodiments, the compound is
[0162] [ka]
[0163] of,
[0164] [ka]
[0165] The molar ratio to is about 1:3. In some embodiments, the compound is
[0166] [ka]
[0167] of,
[0168] [ka]
[0169] The molar ratio to is about 1:4. In some embodiments, the compound is
[0170] [ka]
[0171] of,
[0172] [ka]
[0173] The molar ratio to is about 1:5. In some embodiments, the compound is
[0174] [ka]
[0175] of,
[0176] [ka]
[0177] The molar ratio to is about 1:10. In some embodiments, the compound is
[0178] [ka]
[0179] of,
[0180] [ka]
[0181] The molar ratio to is about 1:20. In some embodiments, the compound comprises a therapeutic agent having a modified structure.
[0096] In some embodiments, the compound comprises a therapeutic agent having a modified structure with choline or a choline derivative.
[0182] In some embodiments, the compound comprises a therapeutic agent having a cationic moiety that comprises a choline or a choline derivative. In some embodiments, the compound comprises a therapeutic agent having a cationic moiety that includes a choline or choline derivative-like residue.
[0183]
[0099] In some embodiments, the compound comprises a therapeutic agent comprising a [one or more choline or choline derivatives]-peptide derivative formed at a Glu residue, an Asp residue, or a combination thereof.
[0184]
[0100] In some embodiments, the compound includes a therapeutic agent that includes a linker that includes one or more gamma glutamic acid (γGlu) residues, one or more 8-amino-3,6-dioxaoctanoic acid (OEG) residues, or a combination thereof.
[0185]
[0101] In some embodiments, the compound comprises a therapeutic agent that includes a linker that includes one or more gamma glutamic acid (γGlu) residues.
[0102] In some embodiments, the compound comprises a therapeutic agent that includes a [choline or choline derivative]-peptide salt formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0186]
[0103] In some embodiments, the compound comprises a therapeutic agent that includes a [choline or choline derivative]-peptide ester formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0187] In some embodiments, the compound comprises a therapeutic agent that includes a diacid that is 10, 12, 14, 16, 18, or 20 carbons in length.
[0105] In some embodiments, the diacid comprises a C10, C12, C14, C16, C18, or C20 fatty diacid.
[0188]
[0106] In some embodiments, the diacid comprises 1,20-icosane diacid. In another aspect herein, a compound of formula II:
[0189] [ka]
[0190] [In the formula, R 6 is a therapeutic agent; R 7 , R 8 , and R 9 are independently C1-C5 alkyl; n is 1, 2, 3, 4, or 5] Compounds according to the formula:
[0191] In some embodiments, R 7 , R 8 , and R 9 is methyl. In some embodiments, R 7 , R 8 , and R 9is ethyl. In some embodiments, R 7 , R 8 , and R 9 is propyl.
[0192] In some embodiments, R 7 and R 8 is methyl and R 9 is ethyl. In some embodiments, R 7 and R 9 is methyl and R 8 is ethyl.
[0193] In some embodiments, R 7 and R 8 is ethyl, and R 9 is methyl. In some embodiments, R 7 and R 9 is ethyl, and R 8 is methyl.
[0194] In some embodiments, R 7 and R 8 is propyl, and R 9 is methyl. In some embodiments, R 7 and R 9 is propyl, and R 8 is methyl.
[0195] In some embodiments, n is 1. In some embodiments, the compound has Formula IIa:
[0196] [ka]
[0197] It is a compound according to the following: In some embodiments, the compound has Formula IIb:
[0198] [ka]
[0199] It is a compound according to the following: In some embodiments, the compound has Formula IIc:
[0200] [ka]
[0201] It is a compound according to the following:
[0121] In some embodiments, the therapeutic agent is a GLP-1 analog or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
[0202]
[0122] In some embodiments, the therapeutic agent is a GLP-1 analog or a functional variant thereof, or a mimetic thereof. In some embodiments, the compound comprises the structure shown in Figure 17B.
[0203]
[0124] In some embodiments, the therapeutic agent is amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof.
[0204] In some embodiments, the therapeutic agent is an amylin analog or a functional variant thereof, or a mimetic or analog thereof. In some embodiments, the therapeutic agent is: [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide or a functional variant thereof, or a mimetic or analog thereof.
[0205] In some embodiments, the therapeutic agent is an amylin analog having a structure shown in Figure 2, Figure 3, or Figure 4, or a functional variant thereof, or a mimetic or analog thereof.
[0206]
[0128] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
[0207]
[0129] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising the N14E amino acid substitution.
[0130] In some embodiments, the therapeutic agent is an antibody or antibody fragment thereof.
[0208]
[0131] In some embodiments, the therapeutic agent is any one selected from the group consisting of infliximab or its antibody fragment, adalimumab or its antibody fragment, ustekinumab or its antibody fragment, golimumab or its antibody fragment, natalizumab or its antibody fragment, vedolizumab or its antibody fragment, and certolizumab pegol or its antibody fragment.
[0209] In some embodiments, the therapeutic agent is: (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof. Includes.
[0210] In some embodiments, the therapeutic agent is: (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6, or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof Includes.
[0211] In some embodiments, the therapeutic agent is: (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences of SEQ ID NO: 3 and SEQ ID NO: 6, the sequences of SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences of SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 Includes.
[0212]
[0135] In some embodiments, the therapeutic agent is infliximab or an antibody fragment thereof.
[0136] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:1 or SEQ ID NO:24 and the sequence of SEQ ID NO:2.
[0213]
[0137] In some embodiments, the therapeutic agent is adalimumab or an antibody fragment thereof.
[0138] In some embodiments, the therapeutic agent comprises the sequences of SEQ ID NO:3 and SEQ ID NO:6, the sequences of SEQ ID NO:4 and SEQ ID NO:6, or the sequences of SEQ ID NO:5 and SEQ ID NO:7.
[0214]
[0139] In some embodiments, the therapeutic agent is ustekinumab or an antibody fragment thereof.
[0140] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:8 and the sequence of SEQ ID NO:9.
[0215]
[0141] In some embodiments, the therapeutic agent is golimumab or an antibody fragment thereof.
[0142] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:10 and the sequence of SEQ ID NO:11.
[0216]
[0143] In some embodiments, the therapeutic agent is natalizumab or an antibody fragment thereof.
[0144] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:12 and the sequence of SEQ ID NO:14, or the sequence of SEQ ID NO:13 and the sequence of SEQ ID NO:15.
[0217]
[0145] In some embodiments, the therapeutic agent is vedolizumab or an antibody fragment thereof.
[0146] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:16 and the sequence of SEQ ID NO:17.
[0218]
[0147] In some embodiments, the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
[0148] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:18 and the sequence of SEQ ID NO:19.
[0219]
[0149] In some embodiments, the therapeutic agent is an antibody or antibody fragment thereof comprising a [one or more choline or choline derivatives]-peptide ester formed at the C-terminus of the light chain, the C-terminus of the heavy chain, or a combination thereof.
[0220]
[0150] In some embodiments, the therapeutic agent is an antibody or antibody fragment thereof that includes a [one or more choline or choline derivatives]-peptide ester formed at a Cys residue, a Lys residue, or any combination thereof.
[0221]
[0151] In some embodiments, the [one or more choline or choline derivatives]-peptide esters formed at Cys residues have a linker-to-antibody ratio of 2 to 8, and the [one or more choline or choline derivatives]-peptide esters formed at Lys residues have a linker-to-antibody ratio of 2 to 4, or a combination thereof.
[0222]
[0152] In some embodiments, the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
[0153] In some embodiments, the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0223]
[0154] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:25. In some embodiments, the therapeutic agent is a C conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25. 20 Contains diacid-γ-Glu-(AEEA)2.
[0224] In some embodiments, the therapeutic agent is a C conjugated to a residue of the sequence of SEQ ID NO: 25. 20 Contains diacid-γ-Glu-(AEEA)2. In some embodiments, the therapeutic agent comprises a C 1 -C 2 -amino acid conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25. 20 Contains diacid-γ-Glu-(AEEA)2.
[0225]
[0158] In some embodiments, the compound comprises a therapeutic agent having a modified structure with choline or a choline derivative.
[0159] In some embodiments, the compound comprises a therapeutic agent having a salt structure modified with choline or a choline derivative.
[0226] In some embodiments, the compound comprises a therapeutic agent having a cationic moiety that comprises a choline or a choline derivative.
[0161] In some embodiments, the compound comprises a therapeutic agent having an ester structure modified with choline or a choline derivative.
[0227] In some embodiments, the compound comprises a therapeutic agent having a cationic moiety that includes a choline or choline derivative-like residue.
[0163] In some embodiments, the compound comprises a therapeutic agent comprising a [one or more choline or choline derivatives]-peptide ester formed at a Cys residue, a Lys residue, or any combination thereof.
[0228]
[0164] In some embodiments, the [one or more choline or choline derivatives]-peptide esters formed at Cys residues have a linker to therapeutic agent ratio of 2 to 8, and the [one or more choline or choline derivatives]-peptide esters formed at Lys residues have a linker to therapeutic agent ratio of 2 to 4, or a combination thereof.
[0229]
[0165] In some embodiments, the compound comprises a therapeutic agent that includes a linker that includes one or more gamma glutamic acid (γGlu) residues, one or more 8-amino-3,6-dioxaoctanoic acid (OEG) residues, or a combination thereof.
[0230] In some embodiments, the compound comprises a therapeutic agent that includes a linker that includes one or more gamma glutamic acid (γGlu) residues.
[0167] In some embodiments, the compound comprises a therapeutic agent that includes a [choline or choline derivative]-peptide salt formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0231]
[0168] In some embodiments, the compound includes a therapeutic agent that includes a [choline or choline derivative]-peptide ester formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0232] In some embodiments, the compound comprises a therapeutic agent that includes a diacid that is 10, 12, 14, 16, 18, or 20 carbons in length. In some embodiments, the diacid is C 10 , C 12 , C 14 , C 16 , C 18 , or C 20Contains fatty diacids.
[0233]
[0171] In some embodiments, the diacid comprises 1,20-icosane diacid. In another aspect herein, a compound of formula III:
[0234] [ka]
[0235] [In the formula, R 10 is a therapeutic agent; R 11 is substituted C5~C 10 , or unsubstituted C5-C 10 and; X 1 teeth,
[0236] [ka]
[0237] , -S-, or -NH-; L 1 is a covalent bond or a linker] Compounds according to the formula:
[0238] In some embodiments, L 1 is a non-cleavable linker. In some embodiments, L 1 comprises a maleimidoalkane linker or a maleimidocyclohexane linker.
[0239] In some embodiments, L 1 teeth,
[0240] [ka]
[0241] Includes. In some embodiments, L 1 is a chemically cleavable linker. In some embodiments, L 1 comprises a hydrazone linker or a disulfide linker.
[0242] In some embodiments, L 1 teeth,
[0243] [ka]
[0244] Includes. In some embodiments, R 11 is a substitution C 10 or unsubstituted C 10 is.
[0180] In some embodiments, the therapeutic agent is a GLP-1 analog or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
[0245]
[0181] In some embodiments, the therapeutic agent is a GLP-1 analog or a functional variant thereof, or a mimetic thereof.
[0182] In some embodiments, the therapeutic agent is amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof.
[0246]
[0183] In some embodiments, the therapeutic agent is an amylin analog or a functional variant thereof, or a mimetic or analog thereof. In some embodiments, the therapeutic agent is: [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide or a functional variant thereof, or a mimetic or analog thereof.
[0247]
[0185] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
[0248]
[0186] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising the N14E amino acid substitution.
[0187] In some embodiments, the therapeutic agent is an antibody or antibody fragment thereof.
[0249]
[0188] In some embodiments, the therapeutic agent is any one selected from the group consisting of infliximab or its antibody fragment, adalimumab or its antibody fragment, ustekinumab or its antibody fragment, golimumab or its antibody fragment, natalizumab or its antibody fragment, vedolizumab or its antibody fragment, and certolizumab pegol or its antibody fragment.
[0250] In some embodiments, the therapeutic agent is: (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof. Includes.
[0251] In some embodiments, the therapeutic agent is: (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6, or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof Includes.
[0252] In some embodiments, the therapeutic agent is: (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences of SEQ ID NO: 3 and SEQ ID NO: 6, the sequences of SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences of SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 Includes.
[0253]
[0192] In some embodiments, the therapeutic agent is infliximab or an antibody fragment thereof.
[0193] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:1 or SEQ ID NO:24 and the sequence of SEQ ID NO:2.
[0254]
[0194] In some embodiments, the therapeutic agent is adalimumab or an antibody fragment thereof.
[0195] In some embodiments, the therapeutic agent comprises the sequences of SEQ ID NO:3 and SEQ ID NO:6, the sequences of SEQ ID NO:4 and SEQ ID NO:6, or the sequences of SEQ ID NO:5 and SEQ ID NO:7.
[0255]
[0196] In some embodiments, the therapeutic agent is ustekinumab or an antibody fragment thereof.
[0197] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:8 and the sequence of SEQ ID NO:9.
[0256]
[0198] In some embodiments, the therapeutic agent is golimumab or an antibody fragment thereof.
[0199] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:10 and the sequence of SEQ ID NO:11.
[0257]
[0200] In some embodiments, the therapeutic agent is natalizumab or an antibody fragment thereof.
[0201] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:12 and the sequence of SEQ ID NO:14, or the sequence of SEQ ID NO:13 and the sequence of SEQ ID NO:15.
[0258]
[0202] In some embodiments, the therapeutic agent is vedolizumab or an antibody fragment thereof.
[0203] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:16 and the sequence of SEQ ID NO:17.
[0259]
[0204] In some embodiments, the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
[0205] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:18 and the sequence of SEQ ID NO:19.
[0260] In some embodiments, the therapeutic agent comprises one or more R linked to the C-terminus of the light chain, the C-terminus of the heavy chain, or a combination thereof. 11 or an antibody fragment thereof comprising:
[0261]
[0207] In some embodiments, the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
[0208] In some embodiments, the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0262]
[0209] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:25.
[0210] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0263]
[0211] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO:25.
[0212] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25.
[0264]
[0213] In some embodiments, the compound comprises a therapeutic agent having a modified structure with choline or a choline derivative.
[0214] In some embodiments, the compound comprises a therapeutic agent having a salt structure modified with choline or a choline derivative.
[0265]
[0215] In some embodiments, the compound comprises a therapeutic agent having a cationic moiety that comprises a choline or a choline derivative.
[0216] In some embodiments, the compound comprises a therapeutic agent having an ester structure modified with choline or a choline derivative.
[0266]
[0217] In some embodiments, the compound comprises a therapeutic agent having a cationic moiety that includes a choline or choline derivative-like residue. In some embodiments, the compound comprises one or more R linked to a Lys residue, a Cys residue, or any combination thereof. 11 Therapeutic agents include:
[0267] In some embodiments, R 11 is linked to a Lys residue with a linker to therapeutic agent ratio of 2-4, or R 11 is linked to a Cys residue at a linker to therapeutic agent ratio of 2-8, or at a linker to therapeutic agent ratio of 4, or a combination thereof.
[0268]
[0220] In some embodiments, the compound comprises a therapeutic agent that comprises a dual conjugation.
[0221] In some embodiments, the dual conjugation has a linker to therapeutic agent ratio of 1-2.
[0269]
[0222] In some embodiments, the compound comprises a therapeutic agent that includes a linker that includes one or more gamma glutamic acid (γGlu) residues, one or more 8-amino-3,6-dioxaoctanoic acid (OEG) residues, or a combination thereof.
[0270]
[0223] In some embodiments, the compound comprises a therapeutic agent that includes a linker that includes one or more gamma glutamic acid (γGlu) residues.
[0224] In some embodiments, the compound includes a therapeutic agent that includes a [choline or choline derivative]-peptide salt formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0271]
[0225] In some embodiments, the compound comprises a therapeutic agent that includes a [choline or choline derivative]-peptide ester formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0272]
[0226] In some embodiments, the compound comprises a therapeutic agent that includes a diacid that is 10, 12, 14, 16, 18, or 20 carbons in length. In some embodiments, the diacid is C 10 , C 12 , C 14 , C 16 , C 18 , or C 20 Contains fatty diacids.
[0273]
[0228] In some embodiments, the diacid comprises 1,20-icosane diacid.
[0229] In another aspect, provided herein are compositions comprising the compounds provided herein and one or more ionic liquids.
[0274]
[0230] In some embodiments, the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
[0275]
[0231] In some embodiments, the one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine. In some embodiments, the one or more ionic liquids are independently selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid, and the like. Protocatechuic acid, 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)- Galactonic acid, decanoic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-ascorbic acid Partic acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), sorbic acid, stearic acid, succinic acid, syringic acid, tiglic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
[0276]
[0233] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydroxycinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0277]
[0234] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0278]
[0235] In some embodiments, the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
[0279]
[0236] In some embodiments, the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
[0280]
[0237] In some embodiments, the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
[0281]
[0238] In some embodiments, the compositions presented herein further comprise at least one penetration enhancer. In some embodiments, the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
[0282]
[0240] In some embodiments, the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof.
[0283]
[0241] In some embodiments, the compositions presented herein further comprise at least one pharmaceutically acceptable excipient.
[0242] Another aspect of the present invention is a method for treating a pulmonary arthritis, comprising: (i) GLP-1 analogs or functional variants thereof, or mimetics thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) GIP / GLP-1 receptor dual agonist or a functional variant thereof A composition is presented in which:
[0284]
[0243] In some embodiments, the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
[0285]
[0244] In some embodiments, the one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine. In some embodiments, the one or more ionic liquids are independently selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid, and the like. Protocatechuic acid, 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)- Galactonic acid, decanoic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-ascorbic acid Partic acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), sorbic acid, stearic acid, succinic acid, syringic acid, tiglic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
[0286]
[0246] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydroxycinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0287]
[0247] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0288]
[0248] In some embodiments, the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
[0289]
[0249] In some embodiments, the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
[0290]
[0250] In some embodiments, the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
[0291]
[0251] In some embodiments, the solubility of the therapeutic agent is increased compared to the therapeutic agent in the composition without the ionic liquid.
[0252] In some embodiments, the delivery efficiency of the therapeutic agent in a subject in need thereof is enhanced or improved when administered to a subject compared to the therapeutic agent in a composition without the ionic liquid.
[0292]
[0253] In some embodiments, the compositions presented herein further comprise at least one penetration enhancer. In some embodiments, the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
[0293]
[0255] In some embodiments, the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof.
[0294]
[0256] In another aspect of the present specification, there is provided a pharmaceutical composition comprising a compound presented herein or a composition presented herein and at least one pharmaceutically acceptable excipient.
[0295]
[0257] In some embodiments, the pharmaceutical compositions presented herein further comprise at least one penetration enhancer. In some embodiments, the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
[0296]
[0259] In some embodiments, the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof.
[0297]
[0260] In another aspect herein, provided is a method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound presented herein, a composition presented herein, or a pharmaceutical composition presented herein, wherein the administering is effective to treat the disease or disorder in the subject.
[0298] In some embodiments, the disease or disorder is a metabolic disease or disorder.
[0262] In some embodiments, the disease or disorder is diabetes.
[0299] In some embodiments, the disease or disorder is type 1 diabetes mellitus (T1DM). In some embodiments, the disease or disorder is type 2 diabetes mellitus (T2DM).
[0265] In some embodiments, the disease or disorder is non-alcoholic steatohepatitis (NASH).
[0300]
[0266] In some embodiments, the disease or disorder is obesity or overweight.
[0267] In some embodiments, the administration activates GIP receptor signaling, GLP-1 receptor signaling, or a combination thereof.
[0301]
[0268] In some embodiments, administration increases or improves glucose-dependent insulin secretion, improves glucose tolerance, or a combination thereof.
[0302]
[0269] In some embodiments, administration increases or improves glycemic control.
[0270] In some embodiments, administration decreases or reduces fasting serum glucose.
[0303]
[0271] In some embodiments, administration results in or reduces body weight, reduces or reduces food intake, or a combination thereof.
[0304]
[0272] In some embodiments, administration effects improvement in glycemic control, body weight, or a combination thereof. In some embodiments, the disease or disorder is an autoimmune disease or disorder, or an immune disease or disorder.
[0305]
[0274] In some embodiments, the disease or disorder is Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Behcet's disease, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis, plaque psoriasis, multiple sclerosis, or eosinophilic esophagitis.
[0306]
[0275] In another aspect herein, provided is a method for treating obesity, preventing weight gain, or reducing weight in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound presented herein, a composition presented herein, or a pharmaceutical composition presented herein, wherein the administering step is effective to treat a disease or disorder in the subject.
[0307]
[0276] In some embodiments, the composition, compound, or pharmaceutical composition is administered via subcutaneous administration, intravenous administration, or oral administration. In some embodiments, the composition, compound, or pharmaceutical composition is administered orally.
[0308]
[0278] In some embodiments, the composition, compound, or pharmaceutical composition is administered as a liquid-filled capsule. In some embodiments, the composition, compound, or pharmaceutical composition is administered in multiple doses.
[0309]
[0280] In some embodiments, the composition, compound, or pharmaceutical composition is administered in a single dose.
[0281] In some embodiments, the composition, compound, or pharmaceutical composition is administered to a mucosa.
[0310]
[0282] In some embodiments, the composition, compound, or pharmaceutical composition is administered via subcutaneous administration, intravenous administration, or oral administration.
[0283] In some embodiments, the concentration of a compound presented herein is at least 0.1% weight per volume.
[0311]
[0284] In some embodiments, the concentration of a compound presented herein is at least 0.05M.
[0285] In some embodiments, the composition further comprises one or more additional agents.
[0312]
[0286] In some embodiments, the one or more additional agents are selected from the group consisting of nucleic acids, small molecules, and polypeptides.
[0287] In some embodiments, the one or more additional agents is a nucleic acid.
[0313] In some embodiments, the one or more additional agents are small molecules.
[0289] In some embodiments, the one or more additional agents is a polypeptide.
[0314]
[0290] In some embodiments, the one or more additional agents is a polypeptide.
[0291] In some embodiments, the one or more additional agents are therapeutic agents that treat a metabolic disease or disorder.
[0315]
[0292] In some embodiments, the one or more additional agents is a therapeutic agent that treats diabetes.
[0293] In some embodiments, the one or more additional agents is a therapeutic agent that treats type 2 diabetes mellitus (T2DM).
[0316]
[0294] In some embodiments, the one or more additional agents is a therapeutic agent that treats obesity or overweight.
[0295] In another aspect herein, there is provided a method for increasing the solubility of a therapeutic agent, comprising:
[0317] [ka]
[0318] [In the formula, R 1 , R 2 , and R 3 are independently C1-C5 alkyl; R 4is a C2-C5 alkyl, wherein the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls; R 5 is a therapeutic agent; The therapeutic agent is (i) GLP-1 analogs or functional variants thereof, or mimetics thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; (iv) GIP / GLP-1 receptor dual agonist or a functional variant thereof is] A method is presented comprising preparing a composition comprising a compound according to
[0319]
[0296] In another aspect herein, there is provided a method for enhancing or improving the delivery efficiency of a therapeutic agent in a subject in need thereof, comprising administering to a subject a compound of Formula I:
[0320] [ka]
[0321] [In the formula, R 1 , R 2 , and R 3 are independently C1-C5 alkyl; R 4 is a C2-C5 alkyl, wherein the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls; R 5 is a therapeutic agent; The therapeutic agent is (i) GLP-1 analogs or functional variants thereof, or mimetics thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; (iv) GIP / GLP-1 receptor dual agonist or a functional variant thereof is] A method is presented comprising preparing a composition comprising a compound according to
[0322] In some embodiments, R 1 , R 2 , and R 3 is methyl. In some embodiments, R 1 , R 2 , and R 3 is ethyl. In some embodiments, R 1 , R 2 , and R 3 is propyl.
[0323] In some embodiments, R 1 and R 2 is methyl and R 3 is ethyl. In some embodiments, R 1 and R 3 is methyl and R 2 is ethyl.
[0324] In some embodiments, R 1 and R 2 is ethyl, and R 3 is methyl. In some embodiments, R 1and R 3 is ethyl, and R 2 is methyl.
[0325] In some embodiments, R 1 and R 2 is propyl, and R 3 is methyl. In some embodiments, R 1 and R 3 is propyl, and R 2 is methyl.
[0326] In some embodiments, R 4 is a C2-C5 alkyl substituted with hydroxyl. In some embodiments, R 4 teeth,
[0327] [ka]
[0328] is. In some embodiments, the compound has Formula Ia:
[0329] [ka]
[0330] It is a compound according to the following: In some embodiments, the compound has Formula Ib:
[0331] [ka]
[0332] It is a compound according to the following: In some embodiments, the compound has Formula Ic:
[0333] [ka]
[0334] It is a compound according to the following:
[0311] In some embodiments, the therapeutic agent is a GLP-1 analog or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
[0335]
[0312] In some embodiments, the therapeutic agent is a GLP-1 analog or a functional variant thereof, or a mimetic thereof. In some embodiments, the compound comprises the structure shown in FIG.
[0336] In some embodiments, the compound is
[0337] [ka]
[0338] of,
[0339] [ka]
[0340] The molar ratio to is about 1:1 to about 1:60. In some embodiments, the compound is
[0341] [ka]
[0342] of,
[0343] [ka]
[0344] The molar ratio of the compound to the compound is about 1:1 to about 1:30. In some embodiments, the compound is
[0345] [ka]
[0346] of,
[0347] [ka]
[0348] The molar ratio to is about 1:1. In some embodiments, the compound is
[0349] [ka]
[0350] of,
[0351] [ka]
[0352] The molar ratio to is about 1:3. In some embodiments, the compound is
[0353] [ka]
[0354] of,
[0355] [ka]
[0356] The molar ratio to is about 1:4. In some embodiments, the compound is
[0357] [ka]
[0358] The molar ratio of In some embodiments, the compound is
[0359] [ka]
[0360] The molar ratio of In some embodiments, the compound is
[0361] [ka]
[0362] The molar ratio of In some embodiments, the compound is
[0363] [ka]
[0364] The molar ratio of In some embodiments, the compound is
[0365] [ka]
[0366] The molar ratio of
[0324] In some embodiments, the therapeutic agent is amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof.
[0367]
[0325] In some embodiments, the therapeutic agent is an amylin analog or a functional variant thereof, or a mimetic or analog thereof. In some embodiments, the therapeutic agent is: [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide or a functional variant thereof, or a mimetic or analog thereof.
[0368]
[0327] In some embodiments, the therapeutic agent is an amylin analog having a structure shown in Figure 2, Figure 3, or Figure 4, or a functional variant thereof, or a mimetic or analog thereof.
[0369]
[0328] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
[0370]
[0329] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising the N14E amino acid substitution. In some embodiments, the compound is
[0371] [ka]
[0372] of,
[0373] [ka]
[0374] The molar ratio of the compound to the compound is about 1:1 to about 1:30. In some embodiments, the compound is
[0375] [ka]
[0376] of,
[0377] [ka]
[0378] The molar ratio to is about 1:1. In some embodiments, the compound is
[0379] [ka]
[0380] of,
[0381] [ka]
[0382] The molar ratio to is about 1:3. In some embodiments, the compound is
[0383] [ka]
[0384] The molar ratio of In some embodiments, the compound is
[0385] [ka]
[0386] of,
[0387] [ka]
[0388] The molar ratio to is about 1:12. In some embodiments, the compound is
[0389] [ka]
[0390] The molar ratio of
[0336] In some embodiments, the therapeutic agent is an antibody or antibody fragment thereof.
[0337] In some embodiments, the therapeutic agent is any one selected from the group consisting of infliximab or its antibody fragment, adalimumab or its antibody fragment, ustekinumab or its antibody fragment, golimumab or its antibody fragment, natalizumab or its antibody fragment, vedolizumab or its antibody fragment, and certolizumab pegol or its antibody fragment.
[0391] In some embodiments, the therapeutic agent is: (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof. Includes.
[0392] In some embodiments, the therapeutic agent is: (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6, or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof Includes.
[0393] In some embodiments, the therapeutic agent is: (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences of SEQ ID NO: 3 and SEQ ID NO: 6, the sequences of SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences of SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 Includes.
[0394]
[0341] In some embodiments, the therapeutic agent is infliximab or an antibody fragment thereof.
[0342] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:1 or SEQ ID NO:24 and the sequence of SEQ ID NO:2.
[0395] In some embodiments, the compound is
[0396] [ka]
[0397] of,
[0398] [ka]
[0399] The molar ratio to is about 1:1 to about 1:164. In some embodiments, the compound is
[0400] [ka]
[0401] of,
[0402] [ka]
[0403] The molar ratio to is about 1:1. In some embodiments, the compound is
[0404] [ka]
[0405] of,
[0406] [ka]
[0407] The molar ratio to is about 1:33. In some embodiments, the compound is
[0408] [ka]
[0409] of,
[0410] [ka]
[0411] The molar ratio to is about 1:41. In some embodiments, the compound is
[0412] [ka]
[0413] of,
[0414] [ka]
[0415] The molar ratio to is about 1:66. In some embodiments, the compound is
[0416] [ka]
[0417] of,
[0418] [ka]
[0419] The molar ratio to is about 1:82. In some embodiments, the compound is
[0420] [ka]
[0421] of,
[0422] [ka]
[0423] The molar ratio to is about 1:132. In some embodiments, the compound is
[0424] [ka]
[0425] of,
[0426] [ka]
[0427] The molar ratio to is about 1:164.
[0351] In some embodiments, the therapeutic agent is adalimumab or an antibody fragment thereof.
[0352] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:3 and the sequence of SEQ ID NO:6, the sequence of SEQ ID NO:4 and the sequence of SEQ ID NO:6, or the sequence of SEQ ID NO:5 and the sequence of SEQ ID NO:7.
[0428] In some embodiments, the compound is
[0429] [ka]
[0430] of,
[0431] [ka]
[0432] The molar ratio to is about 1:1 to about 1:144.
[0354] In some embodiments, the therapeutic agent is ustekinumab or an antibody fragment thereof.
[0355] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:8 and the sequence of SEQ ID NO:9.
[0433] In some embodiments, the compound is
[0434] [ka]
[0435] of,
[0436] [ka]
[0437] The molar ratio to is about 1:1 to about 1:140.
[0357] In some embodiments, the therapeutic agent is golimumab or an antibody fragment thereof.
[0358] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:10 and the sequence of SEQ ID NO:11.
[0438] In some embodiments, the compound is
[0439] [ka]
[0440] of,
[0441] [ka]
[0442] The molar ratio of the compound to the compound is about 1:1 to about 1:80.
[0360] In some embodiments, the therapeutic agent is natalizumab or an antibody fragment thereof.
[0361] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15.
[0443] In some embodiments, the compound is
[0444] [ka]
[0445] of,
[0446] [ka]
[0447] The molar ratio to is about 1:1 to about 1:156.
[0363] In some embodiments, the therapeutic agent is vedolizumab or an antibody fragment thereof.
[0364] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:16 and the sequence of SEQ ID NO:17.
[0448] In some embodiments, the compound is
[0449] [ka]
[0450] of,
[0451] [ka]
[0452] The molar ratio to is about 1:1 to about 1:256.
[0366] In some embodiments, the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
[0453]
[0367] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:18 and the sequence of SEQ ID NO:19. In some embodiments, the compound is
[0454] [ka]
[0455] of,
[0456] [ka]
[0457] The molar ratio to is about 1:1 to about 1:70.
[0369] In some embodiments, the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
[0458] In some embodiments, R 5 comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25. In some embodiments, R 5 comprises the sequence of SEQ ID NO:25.
[0459] In some embodiments, R 5 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0460] In some embodiments, R 5 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO:25. In some embodiments, R 5 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25.
[0461] In some embodiments, the compound is
[0462] [ka]
[0463] of,
[0464] [ka]
[0465] The molar ratio to is about 1:1 to about 1:20. In some embodiments, the compound is
[0466] [ka]
[0467] of,
[0468] [ka]
[0469] The molar ratio to is about 1:1. In some embodiments, the compound is
[0470] [ka]
[0471] of,
[0472] [ka]
[0473] The molar ratio to is about 1:2. In some embodiments, the compound is
[0474] [ka]
[0475] of,
[0476] [ka]
[0477] The molar ratio to is about 1:3. In some embodiments, the compound is
[0478] [ka]
[0479] of,
[0480] [ka]
[0481] The molar ratio to is about 1:4. In some embodiments, the compound is
[0482] [ka]
[0483] of,
[0484] [ka]
[0485] The molar ratio to is about 1:5. In some embodiments, the compound is
[0486] [ka]
[0487] of,
[0488] [ka]
[0489] The molar ratio to is about 1:10. In some embodiments, the compound is
[0490] [ka]
[0491] of,
[0492] [ka]
[0493] The molar ratio to is about 1:20.
[0383] In another aspect herein, there is provided a method for increasing the solubility of a therapeutic agent, comprising:
[0494] [ka]
[0495] [In the formula, R 6 is a therapeutic agent, and the therapeutic agent is (i) GLP-1 analogs or functional variants thereof, or mimetics thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) GIP / GLP-1 receptor dual agonist or a functional variant thereof and; R 7 , R 8 , and R 9 are independently unsubstituted C1-C5 alkyl or substituted C1-C5 alkyl; n is 1, 2, 3, 4, or 5] A method is presented comprising preparing a composition comprising a compound according to
[0496]
[0384] In another aspect herein, there is provided a method for enhancing or improving the delivery efficiency of a therapeutic agent in a subject in need thereof, comprising administering to a subject a compound of Formula II:
[0497] [ka]
[0498] [In the formula, R 6 is a therapeutic agent, and the therapeutic agent is (i) GLP-1 analogs or functional variants thereof, or mimetics thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) GIP / GLP-1 receptor dual agonist or a functional variant thereof and; R 7 , R 8 , and R 9 are independently unsubstituted C1-C5 alkyl or substituted C1-C5 alkyl; n is 1, 2, 3, 4, or 5] preparing a composition comprising a compound according to Administering the composition to a subject A method is presented that includes:
[0499] In some embodiments, R 7 , R 8 , and R 9 is methyl. In some embodiments, R 7 , R 8 , and R 9 is ethyl. In some embodiments, R 7 , R 8 , and R 9 is propyl.
[0500] In some embodiments, R 7 and R 8is methyl and R 9 is ethyl. In some embodiments, R 7 and R 9 is methyl and R 8 is ethyl.
[0501] In some embodiments, R 7 and R 8 is ethyl, and R 9 is methyl. In some embodiments, R 7 and R 9 is ethyl, and R 8 is methyl.
[0502] In some embodiments, R 7 and R 8 is propyl, and R 9 is methyl. In some embodiments, R 7 and R 9 is propyl, and R 8 is methyl.
[0503] In some embodiments, n is 1. In some embodiments, the compound has Formula IIa:
[0504] [ka]
[0505] It is a compound according to the following: In some embodiments, the compound has Formula IIb:
[0506] [ka]
[0507] It is a compound according to the following: In some embodiments, the compound has Formula IIc:
[0508] [ka]
[0509] It is a compound according to the following:
[0398] In some embodiments, the therapeutic agent is a GLP-1 analog or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
[0510]
[0400] In some embodiments, the therapeutic agent is a GLP-1 analog or a functional variant thereof, or a mimetic thereof.
[0400] In some embodiments, the compound comprises the structure shown in Figure 17B.
[0511]
[0401] In some embodiments, the therapeutic agent is amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof.
[0512]
[0402] In some embodiments, the therapeutic agent is an amylin analog or a functional variant thereof, or a mimetic or analog thereof. In some embodiments, the therapeutic agent is: [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide or a functional variant thereof, or a mimetic or analog thereof.
[0513]
[0404] In some embodiments, the therapeutic agent is an amylin analog having a structure shown in Figure 2, Figure 3, or Figure 4, or a functional variant thereof, or a mimetic or analog thereof.
[0514]
[0405] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
[0515]
[0406] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising the N14E amino acid substitution.
[0407] In some embodiments, the therapeutic agent is an antibody or antibody fragment thereof.
[0516]
[0408] In some embodiments, the therapeutic agent is any one selected from the group consisting of infliximab or its antibody fragment, adalimumab or its antibody fragment, ustekinumab or its antibody fragment, golimumab or its antibody fragment, natalizumab or its antibody fragment, vedolizumab or its antibody fragment, and certolizumab pegol or its antibody fragment.
[0517] In some embodiments, the therapeutic agent is: (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof. Includes.
[0518] In some embodiments, the therapeutic agent is: (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6, or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof Includes.
[0519] In some embodiments, the therapeutic agent is: (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences of SEQ ID NO: 3 and SEQ ID NO: 6, the sequences of SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences of SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 Includes.
[0520]
[0412] In some embodiments, the therapeutic agent is infliximab or an antibody fragment thereof.
[0413] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:1 or SEQ ID NO:24 and the sequence of SEQ ID NO:2.
[0521]
[0414] In some embodiments, the therapeutic agent is adalimumab or an antibody fragment thereof.
[0415] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:3 and the sequence of SEQ ID NO:6, the sequence of SEQ ID NO:4 and the sequence of SEQ ID NO:6, or the sequence of SEQ ID NO:5 and the sequence of SEQ ID NO:7.
[0522]
[0416] In some embodiments, the therapeutic agent is ustekinumab or an antibody fragment thereof.
[0417] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:8 and the sequence of SEQ ID NO:9.
[0523]
[0418] In some embodiments, the therapeutic agent is golimumab or an antibody fragment thereof.
[0419] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:10 and the sequence of SEQ ID NO:11.
[0524]
[0420] In some embodiments, the therapeutic agent is natalizumab or an antibody fragment thereof.
[0421] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15.
[0525]
[0422] In some embodiments, the therapeutic agent is vedolizumab or an antibody fragment thereof.
[0423] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:16 and the sequence of SEQ ID NO:17.
[0526]
[0424] In some embodiments, the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
[0425] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:18 and the sequence of SEQ ID NO:19.
[0527]
[0426] In some embodiments, the therapeutic agent is a GLP-1 analog or functional variant thereof, or a mimetic thereof, liraglutide. In some embodiments, R 6 comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0528] In some embodiments, R 6 comprises the sequence of SEQ ID NO:25. In some embodiments, R 6 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0529] In some embodiments, R 6 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO:25. In some embodiments, R 6 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25.
[0530]
[0432] In some embodiments, the composition further comprises one or more ionic liquids.
[0433] In some embodiments, the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
[0531]
[0434] In some embodiments, the one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine. In some embodiments, the one or more ionic liquids are independently selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid, and the like. Protocatechuic acid, 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)- Galactonic acid, decanoic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-ascorbic acid Partic acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), sorbic acid, stearic acid, succinic acid, syringic acid, tiglic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
[0532]
[0436] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydrocinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0533]
[0437] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0534]
[0438] In some embodiments, the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
[0535]
[0439] In some embodiments, the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
[0536]
[0440] In some embodiments, the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
[0537]
[0441] In another aspect herein, there is provided a method for increasing the solubility of a therapeutic agent, comprising preparing a composition comprising the therapeutic agent and one or more ionic liquids; The therapeutic agent, (i) GLP-1 analogs or functional variants thereof, or mimetics thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) GIP / GLP-1 receptor dual agonist or a functional variant thereof A method is presented.
[0538]
[0442] Another aspect of the present specification provides a method of enhancing or improving delivery efficiency of a therapeutic agent in a subject in need thereof, the method comprising the steps of preparing a composition comprising the therapeutic agent and one or more ionic liquids; administering the composition to a subject; The therapeutic agent, (i) GLP-1 analogs or functional variants thereof, or mimetics thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) GIP / GLP-1 receptor dual agonist or a functional variant thereof A method is presented.
[0539]
[0443] In some embodiments, the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
[0540]
[0444] In some embodiments, the one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine. In some embodiments, the one or more ionic liquids are independently selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid, and the like. Protocatechuic acid, 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)- Galactonic acid, decanoic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-ascorbic acid Partic acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), sorbic acid, stearic acid, succinic acid, syringic acid, tiglic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
[0541]
[0446] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydrocinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0542]
[0447] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0543]
[0448] In some embodiments, the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
[0544]
[0449] In some embodiments, the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
[0545]
[0450] In some embodiments, the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
[0546]
[0451] In another aspect herein, there is provided a method for increasing the hydrophobicity of a therapeutic agent, comprising: 12 to a therapeutic agent, R 12 However, substitution C5~C 10 , or unsubstituted C5-C 10 and; The therapeutic agent, (i) GLP-1 analogs or functional variants thereof, or mimetics thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) GIP / GLP-1 receptor dual agonist or a functional variant thereof A method is presented.
[0547] In some embodiments, R 12 is the therapeutic agent
[0548] [ka]
[0549] , -S-, or -NH-. In some embodiments, R 12 is linked to the therapeutic agent via a covalent bond or a linker.
[0550]
[0454] In some embodiments, the linker is a non-cleavable linker.
[0455] In some embodiments, the linker comprises a maleimidoalkane linker or a maleimidocyclohexane linker.
[0551] In some embodiments, the linker is:
[0552] [ka]
[0553] Includes.
[0457] In some embodiments, the linker is a chemically cleavable linker.
[0458] In some embodiments, the linker comprises a hydrazone linker or a disulfide linker.
[0554] In some embodiments, the linker is:
[0555] [ka]
[0556] Includes. In some embodiments, R 12 is a substitution C 10 or unsubstituted C 10 is.
[0461] In some embodiments, the therapeutic agent is a GLP-1 analog or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
[0557]
[0462] In some embodiments, the therapeutic agent is a GLP-1 analog or a functional variant thereof, or a mimetic thereof.
[0463] In some embodiments, the therapeutic agent is amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof.
[0558]
[0464] In some embodiments, the therapeutic agent is an amylin analog or a functional variant thereof, or a mimetic or analog thereof. In some embodiments, the therapeutic agent is: [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide or a functional variant thereof, or a mimetic or analog thereof.
[0559]
[0466] In some embodiments, the therapeutic agent is an amylin analog having a structure shown in Figure 2, Figure 3, or Figure 4, or a functional variant thereof, or a mimetic or analog thereof.
[0560]
[0467] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
[0561]
[0468] In some embodiments, the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising the N14E amino acid substitution.
[0469] In some embodiments, the therapeutic agent is an antibody or antibody fragment thereof.
[0562]
[0470] In some embodiments, the therapeutic agent is any one selected from the group consisting of infliximab or its antibody fragment, adalimumab or its antibody fragment, ustekinumab or its antibody fragment, golimumab or its antibody fragment, natalizumab or its antibody fragment, vedolizumab or its antibody fragment, and certolizumab pegol or its antibody fragment.
[0563] In some embodiments, the therapeutic agent is: (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof. Includes.
[0564] In some embodiments, the therapeutic agent is: (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6, or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof Includes.
[0565] In some embodiments, the therapeutic agent is: (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences of SEQ ID NO: 3 and SEQ ID NO: 6, the sequences of SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences of SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 Includes.
[0566]
[0474] In some embodiments, the therapeutic agent is infliximab or an antibody fragment thereof.
[0475] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:1 or SEQ ID NO:24 and the sequence of SEQ ID NO:2.
[0567]
[0476] In some embodiments, the therapeutic agent is adalimumab or an antibody fragment thereof.
[0477] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:3 and the sequence of SEQ ID NO:6, the sequence of SEQ ID NO:4 and the sequence of SEQ ID NO:6, or the sequence of SEQ ID NO:5 and the sequence of SEQ ID NO:7.
[0568]
[0478] In some embodiments, the therapeutic agent is ustekinumab or an antibody fragment thereof.
[0479] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:8 and the sequence of SEQ ID NO:9.
[0569]
[0480] In some embodiments, the therapeutic agent is golimumab or an antibody fragment thereof.
[0481] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:10 and the sequence of SEQ ID NO:11.
[0570]
[0482] In some embodiments, the therapeutic agent is natalizumab or an antibody fragment thereof.
[0483] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15.
[0571]
[0484] In some embodiments, the therapeutic agent is vedolizumab or an antibody fragment thereof.
[0485] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:16 and the sequence of SEQ ID NO:17.
[0572]
[0486] In some embodiments, the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
[0487] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:18 and the sequence of SEQ ID NO:19.
[0573]
[0488] In some embodiments, the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
[0489] In some embodiments, the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0574]
[0490] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:25.
[0491] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 25.
[0575]
[0492] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO:25.
[0493] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25.
[0576]
[0494] In some embodiments, the therapeutic agent is linked to one or more fatty acids or carboxylic acid-containing molecules.
[0495] In some embodiments, the therapeutic agent is linked to one or more fatty acids or carboxylic acid-containing molecules via dual conjugation.
[0577]
[0496] In some embodiments, the one or more fatty acid or carboxylic acid-containing molecules include cinnamic acid.
[0497] In some embodiments, one or more fatty acids or carboxylic acid-containing molecules are non-covalently associated with a free amine of the therapeutic agent.
[0578]
[0500] In some embodiments, one or more fatty acids or carboxylic acid-containing molecules are non-covalently associated with the N-terminal amine within the peptide backbone of the therapeutic agent.
[0499] In some embodiments, one or more fatty acid or carboxylic acid-containing molecules are non-covalently associated with an amine group of a Gln residue, an amine group of an Asn residue, an amine group of an Arg residue, an amine group of a Lys residue, an amine group of a His residue, or a combination thereof, of a therapeutic agent.
[0579]
[0500] In some embodiments, one or more fatty acids or carboxylic acid-containing molecules are covalently conjugated to a free amine of the therapeutic agent.
[0501] In some embodiments, one or more fatty acids or carboxylic acid-containing molecules are covalently conjugated to the N-terminal amine within the peptide backbone of the therapeutic agent.
[0580]
[0502] In some embodiments, one or more fatty acid or carboxylic acid-containing molecules are covalently conjugated to an amine group of a Gln residue, an amine group of an Asn residue, an amine group of an Arg residue, an amine group of a Lys residue, an amine group of a His residue, or a combination thereof, of a therapeutic agent.
[0581]
[0503] In another aspect, the present specification provides a method for enhancing or improving the delivery efficiency of a therapeutic agent in a subject in need thereof, the method comprising adding at least one penetration enhancer to a compound presented herein, a composition presented herein, or a pharmaceutical composition presented herein, and administering the composition, compound, or pharmaceutical composition to the subject.
[0582]
[0504] In some embodiments, the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
[0583]
[0505] In some embodiments, the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof. [Brief explanation of the drawings]
[0584] [Figure 1]
[0506] Figure depicting the structure of exemplary amylin analogs or functional variants thereof, or mimetics thereof. [Figure 2]
[0507] A diagram depicting an exemplary embodiment of an amylin analog or a functional variant thereof, or a mimic thereof, with a modified structure of the amylin analog or a functional variant thereof, or a mimic thereof. [Figure 3]
[0508] A figure depicting an exemplary embodiment of an amylin analog or a functional variant thereof, or a mimic thereof, with a derivative structure of the amylin analog or a functional variant thereof, or a mimic thereof, modified by choline. [Figure 4]
[0509] A figure depicting an exemplary embodiment of an amylin analog or a functional variant thereof, or a mimic thereof, with the ester structure of the amylin analog or a functional variant thereof, or a mimic thereof, modified by choline. [Figure 5]
[0510] Figure 1 depicts an exemplary embodiment of an antibody or antibody fragment thereof comprising a choline-peptide derivative formed at the C-terminal carboxylic acid of the heavy chain. [Figure 6A]
[0511] Figure 6A depicts an exemplary embodiment of an antibody or antibody fragment thereof comprising a choline-peptide ester formed at the C-terminal carboxylic acid of the heavy chain. Figure 6B depicts an exemplary chemical reaction for preparing a covalent choline derivative of an antibody or antibody fragment thereof (e.g., choline-antibody conjugation via a covalent ester). [Figure 6B]
[0511] Figure 6A depicts an exemplary embodiment of an antibody or antibody fragment thereof comprising a choline-peptide ester formed at the C-terminal carboxylic acid of the heavy chain. Figure 6B depicts an exemplary chemical reaction for preparing a covalent choline derivative of an antibody or antibody fragment thereof (e.g., choline-antibody conjugation via a covalent ester). [Figure 7]
[0512] Figure 1 depicts exemplary embodiments of an antibody or antibody fragment thereof comprising a choline-peptide ester formed at a Cys or Lys residue of the heavy chain of the antibody or antibody fragment thereof. In some embodiments, the linker-to-antibody ratio (LAR) for cysteine conjugation is 2 to 8. In some embodiments, the linker-to-antibody ratio (LAR) for lysine conjugation is 2 to 4. [Figure 8A]
[0513] Figure 1 depicts an exemplary embodiment of an antibody or antibody fragment thereof linked to a fatty acid on the C-terminal carboxylic acid of the heavy chain. The fatty acid can include other lengths between C5 (hexanoic acid) and C10 (decanoic acid). [Figure 8B] FIG. 1 depicts an exemplary chemical reaction for preparing an antibody or antibody fragment thereof linked to a fatty acid. [Figure 8C] FIG. 1 depicts exemplary linkers that can be used to link an antibody or antibody fragment thereof linked to a fatty acid. [Figure 8D] FIG. 1 depicts exemplary fatty acids that can be linked to an antibody or antibody fragment thereof. [Figure 9A]
[0514] Figure 1 depicts exemplary embodiments of an antibody or antibody fragment thereof linked to a fatty acid via dual conjugation, or a fatty acid at a Lys or Cys residue of an antibody or antibody fragment thereof, or a fatty acid of the heavy chain. In some embodiments, the linker-to-antibody ratio (LAR) is 2 to 4 for lysine conjugation. In some embodiments, the linker-to-antibody ratio (LAR) is 2 to 8 for cysteine conjugation. In some embodiments, the linker-to-antibody ratio (LAR) is 4 for cysteine conjugation. In some embodiments, the linker-to-antibody ratio (LAR) is 1 to 2 for an antibody or antibody fragment thereof linked to a fatty acid via dual conjugation. [Figure 9B]FIG. 1 depicts an exemplary chemical reaction for preparing an antibody or antibody fragment thereof linked to a fatty acid via dual conjugation. [Figure 10]
[0515] Figure 1 depicts exemplary choline and choline derivatives. [Figure 11]
[0516] Figure 1 depicts the structure of an exemplary GIP / GLP-1 receptor dual agonist. [Figure 12]
[0517] Figure 1 depicts structural schematics for exemplary GIP / GLP-1 receptor dual agonists. [Figure 13]
[0518] Figure 1 depicts exemplary embodiments of ionic derivative structures of choline-modified GIP / GLP-1 receptor dual agonists using an exemplary GIP / GLP-1 receptor dual agonist scaffold. Circles indicate exemplary sites of ionizable amino acid side chains or carboxyl groups. [Figure 14]
[0519] Figure 1 depicts exemplary embodiments of ester structures of choline-modified GIP / GLP-1 receptor dual agonists using an exemplary GIP / GLP-1 receptor dual agonist scaffold. Circles indicate exemplary sites of potential esterification. [Figure 15A]
[0520] Figure 1 depicts the sequences of exemplary GLP-1 analogs or functional variants thereof, or mimetics thereof. [Figure 15B]
[0521] Figure 1 depicts the sequence of another exemplary GLP-1 analog or functional variant thereof, or mimic thereof. [Figure 16]
[0522] Figure 1 depicts an exemplary embodiment for a compound according to Formula I. [Figure 17A]
[0523] A diagram depicting an exemplary form of covalent bonding. [Figure 17B]
[0524] Figure 1 depicts an exemplary embodiment for a compound according to Formula II. [Figure 18]
[0525] Figure 1 depicts the chemical structures of exemplary forms of cinnamic acid derivatives. [Figure 19]
[0526] Figure 1 depicts an exemplary process in which an ionic liquid is prepared by mixing an acid with a bicarbonate salt of choline or a choline derivative. [Figure 20A]
[0527] Figures 20A-20D depict exemplary chemical structure variations of choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof]. Figure 20A depicts the chemical structure of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof. [Figure 20B] Figures 20A-20D depict exemplary chemical structure variations of choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof]. Figure 20B depicts an exemplary structure of choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof] in a 1:1 ratio. In some embodiments, ionization of choline could occur at either of the -COOH sites. [Figure 20C] Figures 20A-20D depict exemplary chemical structure variations of choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof]. Figure 20C depicts an exemplary structure of choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof] at a ratio of 7:1. [Figure 20D] Figures 20A-20D depict exemplary chemical structure variations of choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof]. Figure 20D depicts an exemplary structure of choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof] in a ratio of 28:1. In some embodiments, an excess of bicarbonate ions is also present in a ratio of 28:1. [Figure 21]
[0528] Figure 3 depicts Table 3 showing mass normalization calculations for exemplary GLP-1 analogs or functional variants thereof, or mimetics thereof ("GLP-1 analogs"). [Figure 22]
[0529] Figure 1 shows exemplary analytical characterization of exemplary GLP-1 analogs or functional variants thereof, or mimetics thereof ("GLP-1 analogs") based on high performance liquid chromatography (HPLC). [Figure 23A]
[0530] Figures 23A-23D depict exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on pH. Figure 23A depicts the results of an exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on pH using a 2 mg / mL aqueous solution. The results are not normalized to the mass of the exemplary GLP-1 analog or functional variant thereof, or mimic thereof. [Figure 23B] Figures 23A-23D depict exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on pH. Figure 23B depicts the results of an exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on pH using a 2 mg / mL aqueous solution. The results for choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof] are normalized to the mass of the exemplary GLP-1 analog or functional variant thereof, or mimic thereof. [Figure 23C]Figures 23A-23D depict exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on pH. Figure 23C depicts the results of an exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on pH using a 2 mg / mL aqueous solution in which the exemplary reaction using choline bicarbonate shown in the graph above was used. The results for choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof] are normalized to the mass of the exemplary GLP-1 analog or functional variant thereof, or mimic thereof. [Figure 23D] Figures 23A-23D depict exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on pH. Figure 23D depicts the results of an exemplary analytical characterization of a negative control of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on pH using a 2 mg / mL aqueous solution in which the exemplary reaction using choline chloride shown in the graph above was used. The results for choline-Cl- [exemplary GLP-1 analog or functional variant thereof, or mimic thereof] are normalized to the mass of the exemplary GLP-1 analog or functional variant thereof, or mimic thereof. [Figure 24A]
[0531] Figures 24A-24D depict exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on conductivity. Figure 24A depicts the results of an exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on conductivity using a 2 mg / mL aqueous solution. The results are not normalized to the mass of the exemplary GLP-1 analog or functional variant thereof, or mimic thereof. [Figure 24B]Figures 24A-24D depict exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on conductivity. Figure 24B depicts the results of an exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on conductivity using a 2 mg / mL aqueous solution. The results for choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof] are normalized to the mass of the exemplary GLP-1 analog or functional variant thereof, or mimic thereof. [Figure 24C] Figures 24A-24D depict exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on conductivity. Figure 24C depicts the results of an exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on conductivity using a 2 mg / mL aqueous solution in which the exemplary reaction using choline bicarbonate shown in the graph above was used. The results for choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof] are normalized to the mass of the exemplary GLP-1 analog or functional variant thereof, or mimic thereof. [Figure 24D]Figures 24A-24D depict exemplary analytical characterization of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on conductivity. Figure 24D depicts the results of an exemplary analytical characterization of a negative control of an exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog") based on conductivity, using a 2 mg / mL aqueous solution of choline chloride, in which the exemplary reaction shown in the graph above was used. The results for choline-Cl- [exemplary GLP-1 analog or functional variant thereof, or mimic thereof] are normalized to the mass of the exemplary GLP-1 analog or functional variant thereof, or mimic thereof. [Figure 25A]
[0532] Figures 25A and 25B depict exemplary analytical characterizations of the NMR-based choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog")] ratio. Figure 25A depicts the results of an exemplary analytical characterization of the NMR-based choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog")] ratio. [Figure 25B] Figures 25A and 25B depict an exemplary analytical characterization of the NMR-based choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog")] ratio. Figure 25B depicts a zoomed-in result of an exemplary analytical characterization of the NMR-based choline-[exemplary GLP-1 analog or functional variant thereof, or mimic thereof ("GLP-1 analog")] ratio. [Figure 26]
[0533] Figure 1 shows an exemplary analytical characterization based on Fourier transform infrared spectroscopy (FTIR). [Figure 27]
[0534] Figure 1 depicts an exemplary embodiment of a cinnamic acid-[glucagon-like peptide (GLP-1) analog or functional variant thereof, or mimetic thereof]. DETAILED DESCRIPTION OF THE INVENTION
[0585] The present invention describes the modification of drugs with ions to improve their formulation with ionic liquids for oral administration to treat patients. Oral administration can be achieved through any one of the following dosage forms: pill, caplet, capsule, aerosol spray, or liquid. The ionic liquid or drug delivered with the ionic liquid can be encapsulated in a capsule. The ionic liquid-containing dosage form can be in any of the following physical forms: clear, pure ionic liquid, a homogeneous mixture of the ionic liquid with a pharmaceutically acceptable diluent, an emulsion, or a suspension. Oral administration can also be administered as a syrup, spray, or aerosol. Any of the oral administration compositions disclosed herein can contain a predetermined amount of ionic liquid and, optionally, a drug, and can be prepared by methods well known to those skilled in the art.
[0586]
[0536] In one embodiment, described herein is a method of treating a patient comprising orally administering an oral formulation of insulin in combination with an ionic liquid.
[0537] In one embodiment, the present specification describes a method for treating diabetes, comprising orally administering an oral formulation of an amylin analog or functional variant thereof, or a mimetic thereof, or a GLP-1 polypeptide, or a mimetic or analog thereof, in combination with an ionic liquid.
[0587]
[0538] As described elsewhere herein, ionic liquids are capable of safely transporting active compounds across mucous membranes with which they are contacted upon oral administration. As described in the Examples herein, ionic liquids enhance drug solubilization and delivery to the systemic circulation, making them particularly suitable as delivery vehicles to / through mucosal membranes.
[0588] In one embodiment, an ionic liquid may be combined with another solvent to enhance solubility and / or delivery. The solvent may be aqueous or non-aqueous. In one embodiment, the purpose of the solvent is to control the dose of ionic liquid that contacts the mucosa or gastrointestinal tract. Dilution of the ionic liquid with a solvent is used to deliver a safe dose to the subject. In another embodiment, the purpose of the solvent is to improve the solubility of the drug. Such improvement may result from the solvent's ability to control the physicochemical environment of the ionic liquid to match the chemical properties of the drug. In one embodiment, a solvent may be used to improve delivery across mucosa.
[0589]
[0541] Solvents used in any of the embodiments include, but are not limited to, sterile water, saline solution, glycerin, propylene glycol, ethanol, oil, ethyl oleate, isopropyl myristate, benzyl benzoate, or surfactants.
[0590]
[0542] In one embodiment, the solvent is selected so as not to adversely affect the compatibility of the ionic liquid with the capsule. As used herein, the term "ionic liquid" refers to an organic salt or mixture of organic salts that is in a liquid state at room temperature. Ionic liquids have been shown to be useful in a variety of fields, including industrial processing, catalysis, medicine, and electrochemistry. Ionic liquids contain at least one anionic component and at least one cationic component. Ionic liquids can include additional hydrogen bond donors (i.e., any molecule that can provide an -OH or -NH group); examples include, but are not limited to, alcohols, fatty acids, and amines. The anionic and cationic components can be present in any molar ratio. Exemplary molar ratios (cation:anion ratio) include, but are not limited to, 1:1, 1:2, 2:1, and ranges between these ratios. In some embodiments, the ionic liquid or solvent exists as a liquid below 100°C. In some embodiments, the ionic liquid or solvent exists as a liquid at room temperature. In some embodiments, the ionic liquid includes more than one anionic component and one cationic component. In some embodiments, the ionic liquid comprises choline or a choline derivative, cinnamic acid, and mandelic acid.
[0591] In some embodiments, ionic liquids are dominated by ionic interactions between anions and cations. In some embodiments, ionic liquids are dominated by hydrogen bonding interactions between anions and cations. The relative dominance of ionic and hydrogen bonding interactions can vary depending on the nature of the ions.
[0592]
[0545] As used herein, "in combination with" refers to two or more substances present in the same dosage form, in any form, administered to a subject. In some embodiments, the drug(s) may form micelles or other self-assembled structures, which may occur only in the presence of an ionic liquid.
[0593] As used herein, the terms "therapeutic agent" and "drug" are used interchangeably. A therapeutic agent or drug is any agent that has an effect on a target cell or target organism. The drug may be selected from the group including: a chemical; a small organic or inorganic molecule; a peptide; a protein; or a nucleic acid. Non-limiting examples of active compounds contemplated for use in the methods described herein include small molecules, polypeptides, nucleic acids, antibodies, vaccines, antibodies or antibody fragments thereof, GLP-1 polypeptides or mimetics or analogs thereof, amylin, amylin analogs or functional variants thereof or mimetics thereof, PYY, pramlintide, and insulin.
[0594]
[0548] In some embodiments, the terms "mimetic," "functional variant," "functional analog," or "functional homolog" may be used interchangeably. GIP / GLP-1 receptor dual agonist or functional variant thereof, or mimic or functional analogue thereof, or functional homologue thereof In some embodiments, the GIP (glucose-dependent insulinotropic polypeptide) / GLP-1 (glucagon-like peptide-1) receptor dual agonist or functional variant thereof is tirzepatide or a functional variant thereof, or a mimetic or functional analog thereof, or a functional homolog thereof. As used herein, "tirzepatide," also known as LY3298176 and GIP / GLP-1 RA, refers to a fatty acid-modified peptide with glucose-dependent insulinotropic polypeptide (GIP) / glucagon-like peptide-1 (GLP-1) receptor dual agonist activity. In some embodiments, tirzepatide is a GIP / GLP-1 receptor dual agonist.
[0595] In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is a GIP-based dual incretin receptor dual agonist. In some embodiments, GIP and GLP-1 are hormones involved in glycemic control. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof activates both the GLP-1 receptor and the GIP receptor. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof activates signaling through both the GIP receptor and the GLP-1 receptor. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof improves glucose-dependent insulin secretion and glucose tolerance by acting on both the GIP receptor and the GLP-1 receptor. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof improves glycemic control. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof reduces body weight and food intake. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof exhibits metabolic effects of GIP that augment the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM). In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof reduces fasting serum glucose. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof results in weight loss. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is used to treat diabetes. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is used to treat type 2 diabetes. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is used to treat T2DM patients. In some embodiments, dual GIP / GLP-1 receptor agonists or functional variants thereof are used to effect clinically meaningful improvements in glycemic control and body weight.In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is used to achieve a clinically meaningful improvement in glycemic control. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is used to achieve a clinically meaningful improvement in body weight. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is used to treat T2DM and obesity. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is used to treat obesity. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is designed for once-weekly subcutaneous administration. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is designed for oral administration. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is designed for chronic administration.
[0596] In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is an analog of glucose-dependent insulinotropic polypeptide (GIP), a human hormone that stimulates the release of insulin from the pancreas. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is a 39-amino acid linear polypeptide that has been chemically modified by lipidation. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is a 39-amino acid linear polypeptide that has been chemically modified by lipidation to improve its uptake into cells and its stability against metabolism. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof is a compound depicted in FIG. 11 or FIG. 12.
[0597]
[0552] In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof comprises a sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence YAibEGTFTSDYSIAibLDKIAQKAFVQWLIAGGPSSGAPPPS [wherein Aib refers to alpha-aminoisobutyric acid (SEQ ID NO: 25)].
[0598]
[0553] In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof comprises the sequence YAibEGTFTSDYSIAibLDKIAQKAFVQWLIAGGPSSGAPPPS [wherein Aib refers to alpha-aminoisobutyric acid (SEQ ID NO: 25)].
[0599] In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a residue of a sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 25. ...
[0600] In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a Lys residue of a sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 25. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a Lys residue of the sequence of SEQ ID NO: 25.
[0601] In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 (from the N-terminus) of a sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 25. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 (from the N-terminus) of the sequence of SEQ ID NO: 25.
[0602] In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a residue at position 20 (from the N-terminus) of a sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 25. In some embodiments, the GIP / GLP-1 receptor dual agonist or functional variant thereof comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a residue at position 20 (from the N-terminus) of the sequence of SEQ ID NO: 25.
[0603] As used herein, "glucose-dependent insulinotropic polypeptide," also known as gastric inhibitory polypeptide, GIP, or gastric inhibitory peptide, refers to an inhibitory hormone of the secretin family of hormones. In some embodiments, glucose-dependent insulinotropic polypeptide is a weak inhibitor of gastric acid secretion. In some embodiments, the primary role of glucose-dependent insulinotropic polypeptide is to stimulate insulin secretion. As used herein, glucose-dependent insulinotropic polypeptide includes any recombinant or naturally occurring form of glucose-dependent insulinotropic polypeptide or a variant or homolog thereof that has or maintains glucose-dependent insulinotropic polypeptide activity (e.g., at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% activity). In some embodiments, a variant or homologue has at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a portion of 50, 100, 150, or 200 contiguous amino acids) compared to a naturally occurring glucose-dependent insulinotropic polypeptide.
[0604] As used herein, "glucagon-like peptide 1," also known as GLP-1, refers to a 30- or 31-amino acid-long peptide hormone derived from tissue-specific post-translational processing of the proglucagon peptide. In some embodiments, glucagon-like peptide 1 is produced and secreted by enteroendocrine L-cells and certain neurons in the nucleus of the solitary tract in the brainstem upon feeding. As used herein, glucagon-like peptide 1 includes either recombinant or naturally occurring forms of glucagon-like peptide 1 or variants or homologs thereof that have or maintain glucagon-like peptide 1 activity (e.g., at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% activity). In some embodiments, a variant or homologue has at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a portion of 50, 100, 150, or 200 contiguous amino acids) compared to naturally occurring glucagon-like peptide 1.
[0605] In some embodiments, there are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 ionizable groups on the GIP / GLP-1 receptor dual agonist or functional variant thereof associated with a cation (e.g., Figure 13). In some embodiments, the ionic derivative of choline-[GIP / GLP-1 receptor dual agonist or functional variant thereof] has a choline:[GIP / GLP-1 receptor dual agonist or functional variant thereof] ratio of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12: 1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, 40:1, 41:1, 42: 1, 43:1, 44:1, 45:1, 46:1, 47:1, 48:1, 49:1, 50:1, 51:1, 52:1, 53:1, 54:1, 55:1, 56:1, 57:1, 58:1, 59:1, 60:1, 61:1, 62:1, 63:1, 64:1, 65:1, 66:1, 67:1, 68:1, 69:1, 70:1, 71:1, 72 :1, 73:1, 74:1, 75:1, 76:1, 77:1, 78:1, 79:1, 80:1, 81:1, 82:1, 83:1, 84:1, 85:1, 86:1, 87:1, 88:1, 89:1, 90:1, 91:1, 92:1, 93:1, 94:1, 95:1, 96:1, 97:1, 98:1, 99:1, or 100:1.
[0606] In some embodiments, there are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 potential esterification sites on the GIP / GLP-1 receptor dual agonist or functional variant thereof with a cation (e.g., Figure 14). In some embodiments, ester derivatives of choline-[GIP / GLP-1 receptor dual agonist or functional variant thereof] may be formed by conjugating a cation (e.g., choline) to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 positions on the structure of the GIP / GLP-1 receptor dual agonist or functional variant thereof.
[0607] In some embodiments, the composition comprises:
[0608] [ka]
[0609] of,
[0610] [ka]
[0611] In some embodiments, the composition has a molar ratio of from about 1:1 to about 1:20.
[0612] [ka]
[0613] of,
[0614]
change
[0615] the molar ratio to the compound is about 1:1 to about 1:200, about 1:1 to about 1:199, about 1:1 to about 1:198, about 1:1 to about 1:197, about 1:1 to about 1:196, about 1:1 to about 1:195, about 1:1 to about 1:194, about 1:1 to about 1:193, about 1:1 to about 1:192, about 1:1 to about 1:191, about 1:1 to about 1:190, about 1:1 to about 1:189, about 1:1 to about 1:188, about 1:1 to about 1:187, about 1:1 to about 1:186, about 1:1 to about 1:185, about 1:1 to about 1:184, about 1:1 to about 1:183, about 1:1 to about 1:182, about 1:1 to about 1:181, About 1:1 to about 1:180, about 1:1 to about 1:179, about 1:1 to about 1:178, about 1:1 to about 1:177, about 1:1 to about 1:176, about 1:1 to about 1:175, about 1:1 to about 1:174, about 1:1 to about 1:173, about 1:1 to about 1:172, about 1:1 to about 1:171, about 1:1 to about 1:170, about 1:1 to about 1:169, about 1:1 to about 1:168, about 1:1 to about 1:167, about 1:1 to about 1:166, about 1:1 to about 1:165, about 1:1 to about 1:164, about 1:1 to about 1:163, about 1:1 to about 1:162, about 1:1 to about 1:161, about 1:1 to about 1: 160, about 1:1 to about 1:159, about 1:1 to about 1:158, about 1:1 to about 1:157, about 1:1 to about 1:156, about 1:1 to about 1:155, about 1:1 to about 1:154, about 1:1 to about 1:153, about 1:1 to about 1:152, about 1:1 to about 1:151, about 1:1 to about 1:150, about 1:1 to about 1:149, about 1:1 to about 1:148, about 1:1 to about 1:147, about 1:1 to about 1:146, about 1:1 to about 1:145, about 1:1 to about 1:144, about 1:1 to about 1:143, about 1:1 to about 1:142, about 1:1 to about 1:141, about 1:1 to about 1:140, about 1:1 to about 1:139, about 1:1 to about 1:138, about 1:1 to about 1:137, about 1:1 to about 1:136, about 1:1 to about 1:135, about 1:1 to about 1:134, about 1:1 to about 1:133, about 1:1 to about 1:132, about 1:1 to about 1:131, about 1:1 to about 1:130, about 1:1 to about 1: 129, about 1:1 to about 1:128, about 1:1 to about 1:127, about 1:1 to about 1:126, about 1:1 to about 1:125, about 1:1 to about 1:124, about 1:1 to about 1:123, about 1:1 to about 1:122, about 1:1 to about 1:121, about 1:1 to about 1:120, about 1:1 to about 1:119,about 1:1 to about 1:118, about 1:1 to about 1:117, about 1:1 to about 1:116, about 1:1 to about 1:115, about 1:1 to about 1:114, about 1:1 to about 1:113, about 1:1 to about 1:112, about 1:1 to about 1:111, about 1:1 to about 1:110, about 1:1 to about 1:109, about 1:1 to about 1:108, about 1:1 to about 1:107, about 1:1 to about 1:106, about 1:1 to about 1:105, about 1:1 to about 1:104, about 1:1 to about 1:103, about 1:1 to about 1:102, about 1:1 to about 1:101, about 1:1 to about 1:100, about 1:1 to about 1:99, about 1:1 to about 1:98 , about 1:1 to about 1:97, about 1:1 to about 1:96, about 1:1 to about 1:95, about 1:1 to about 1:94, about 1:1 to about 1:93, about 1:1 to about 1:92, about 1:1 to about 1:91, about 1:1 to about 1:90, about 1:1 to about 1:89, about 1:1 to about 1:88, about 1:1 to about 1:87, about 1: 1 to about 1:86, about 1:1 to about 1:85, about 1:1 to about 1:84, about 1:1 to about 1:83, about 1:1 to about 1:82, about 1:1 to about 1:81, about 1:1 to about 1:80, about 1:1 to about 1:79, about 1:1 to about 1:78, about 1:1 to about 1:77, about 1:1 to about 1:76, about 1:1 to about 1 :75, about 1:1 to about 1:74, about 1:1 to about 1:73, about 1:1 to about 1:72, about 1:1 to about 1:71, about 1:1 to about 1:70, about 1:1 to about 1:69, about 1:1 to about 1:68, about 1:1 to about 1:67, about 1:1 to about 1:66, about 1:1 to about 1:65, about 1:1 to about 1:64 , about 1:1 to about 1:63, about 1:1 to about 1:62, about 1:1 to about 1:61, about 1:1 to about 1:60, about 1:1 to about 1:59, about 1:1 to about 1:58, about 1:1 to about 1:57, about 1:1 to about 1:56, about 1:1 to about 1:55, about 1:1 to about 1:54, about 1:1 to about 1:53, about 1: 1 to about 1:52, about 1:1 to about 1:51, about 1:1 to about 1:50, about 1:1 to about 1:49, about 1:1 to about 1:48, about 1:1 to about 1:47, about 1:1 to about 1:46, about 1:1 to about 1:45, about 1:1 to about 1:44, about 1:1 to about 1:43, about 1:1 to about 1:42, about 1:1 to about 1 :41, about 1:1 to about 1:40, about 1:1 to about 1:39, about 1:1 to about 1:38, about 1:1 to about 1:37, about 1:1 to about 1:36, about 1:1 to about 1:35, about 1:1 to about 1:34, about 1:1 to about 1:33, about 1:1 to about 1:32, about 1:1 to about 1:31, about 1:1 to about 1:30,about 1:1 to about 1:29, about 1:1 to about 1:28, about 1:1 to about 1:27, about 1:1 to about 1:26, about 1:1 to about 1:25, about 1:1 to about 1:24, about 1:1 to about 1:23, about 1:1 to about 1:22, about 1:1 to about 1:21, about 1:1 to about 1:20, about 1:1 to about 1:19, about 1:1 to about 1:18, about 1:1 to about 1:17, about 1:1 to about 1:16 , about 1:1 to about 1:15, about 1:1 to about 1:14, about 1:1 to about 1:13, about 1:1 to about 1:12, about 1:1 to about 1:11, about 1:1 to about 1:10, about 1:1 to about 1:9, about 1:1 to about 1:8, about 1:1 to about 1:7, about 1:1 to about 1:6, about 1:1 to about 1:5, about 1:1 to about 1:4, about 1:1 to about 1:3, or about 1:1 to about 1:2.
[0616] In some embodiments, the composition comprises:
[0617] [ka]
[0618] of,
[0619] [ka]
[0620] The molar ratio of 84, approx. 1:183, approx. 1:182, approx. 1:181, approx. 1:180, approx. 1:179, approx. 1:178, approx. 1:177, approx. 1:176, approx. 1:175, approx. 1:174, approx. 1:173, approx. 1:172, approx. 1:171, approx. 1:170, approx. 1:169, approx. 1:168, approx. 1:167, approx. 1: 166, approx. 1:165, approx. 1:164, approx. 1:163, approx. 1:162, approx. 1:161, approx. 1:160, approx. 1:159, approx. 1:158, approx. 1:157, approx. 1:156, approx. 1:155, approx. 1:154, approx. 1:153, approx. 1:152, approx. 1:151, approx. 1:150, approx. 1:149, approx. 1:148, approximately 1:147, approximately 1:146, approximately 1:145, approximately 1:144, approximately 1:143, approximately 1:142, approximately 1:141, approximately 1:140, approximately 1:139, approximately 1:138, approximately 1:137, approximately 1:136, approximately 1:135, approximately 1:134, approximately 1:133, approximately 1:132, approximately 1:131, Approximately 1:130, approximately 1:129, approximately 1:128, approximately 1:127, approximately 1:126, approximately 1:125, approximately 1:124, approximately 1:123, approximately 1:122, approximately 1:121, approximately 1:120, approximately 1:119, approximately 1:118, approximately 1:117, approximately 1:116, approximately 1:115, approximately 1:114, approximately 1:11 3, approx. 1:112, approx. 1:111, approx. 1:110, approx. 1:109, approx. 1:108, approx. 1:107, approx. 1:106, approx. 1:105, approx. 1:104, approx. 1:103, approx. 1:102, approx. 1:101, approx. 1:100, approx. 1:99, approx. 1:98, approx. 1:97, approx. 1:96, approx. 1:95, approx. 1 :94, approx. 1:93, approx. 1:92, approx. 1:91, approx. 1:90, approx. 1:89, approx. 1:88, approx. 1:87, approx. 1:86, approx. 1:85, approx. 1:84, approx. 1:83, approx. 1:82, approx. 1:81, approx. 1:80, approx. 1:79, approx. 1:78, approx. 1:77, approx. 1:76, approx. 1:75, approx. 1:74, approx. 1:73, approximately 1:72, approximately 1:71, approximately 1:70, approximately 1:69, approximately 1:68, approximately 1:67, approximately 1:66, approximately 1:65, approximately 1:64, approximately 1:63, approximately 1:62, approximately 1:61, approximately 1:60, approximately 1:59, approximately 1:58, approximately 1:57, approximately 1:56, approximately 1:55, approximately 1:54, approximately 1:53,Approximately 1:52, approximately 1:51, approximately 1:50, approximately 1:49, approximately 1:48, approximately 1:47, approximately 1:46, approximately 1:45, approximately 1:44, approximately 1:43, approximately 1:42, approximately 1:41, approximately 1:40, approximately 1:39, approximately 1:38, approximately 1:37, approximately 1:36, approximately 1:35, approximately 1:34, approximately 1:33, approximately 1:32, approximately 1:31, approximately 1:30, approximately 1:29, approximately 1:28, approximately 1:2 about 1:7, about 1:26, about 1:25, about 1:24, about 1:23, about 1:22, about 1:21, about 1:20, about 1:19, about 1:18, about 1:17, about 1:16, about 1:15, about 1:14, about 1:13, about 1:12, about 1:11, about 1:10, about 1:9, about 1:8, about 1:7, about 1:6, about 1:5, about 1:4, about 1:3, about 1:2, or about 1:1.
[0621]
[0564] In some aspects herein, inter alia, compounds of Formula I:
[0622] [ka]
[0623] Compounds according to the formula: In some embodiments, R 1 , R 2 , and R 3 is independently C1-C5 alkyl. In some embodiments, R 1 is C1-C5 alkyl. In some embodiments, R 2 is C1-C5 alkyl. In some embodiments, R 3 is a C1-C5 alkyl.
[0624] In some embodiments, R 1 , R 2 , and R 3 are independently C1 to C 20 In some embodiments, R 1 is C1~C 20 In some embodiments, R 1 is C1~C 19 In some embodiments, R 1 is C1~C18 In some embodiments, R 1 is C1~C 17 In some embodiments, R 1 is C1~C 16 In some embodiments, R 1 is C1~C 15 In some embodiments, R 1 is C1~C 14 In some embodiments, R 1 is C1~C 13 In some embodiments, R 1 is C1~C 12 In some embodiments, R 1 is C1~C 11 In some embodiments, R 1 is C1~C 10 In some embodiments, R 1 is C1-C9 alkyl. In some embodiments, R 1 is C1-C8 alkyl. In some embodiments, R 1 is C1-C7 alkyl. In some embodiments, R 1 is C1-C6 alkyl. In some embodiments, R 1 is C1-C5 alkyl. In some embodiments, R 1 is C1-C4 alkyl. In some embodiments, R 1 is C1-C3 alkyl. In some embodiments, R 1 is C1-C2 alkyl. In some embodiments, R 2 is C1~C 20 In some embodiments, R 2 is C1~C 19 In some embodiments, R 2 is C1~C 18 In some embodiments, R 2 is C1~C 17 In some embodiments, R 2 is C1~C 16In some embodiments, R 2 is C1~C 15 In some embodiments, R 2 is C1~C 14 In some embodiments, R 2 is C1~C 13 In some embodiments, R 2 is C1~C 12 In some embodiments, R 2 is C1~C 11 In some embodiments, R 2 is C1~C 10 In some embodiments, R 2 is C1-C9 alkyl. In some embodiments, R 2 is C1-C8 alkyl. In some embodiments, R 2 is C1-C7 alkyl. In some embodiments, R 2 is C1-C6 alkyl. In some embodiments, R 2 is C1-C5 alkyl. In some embodiments, R 2 is C1-C4 alkyl. In some embodiments, R 2 is C1-C3 alkyl. In some embodiments, R 2 is C1-C2 alkyl. In some embodiments, R 3 is C1~C 20 In some embodiments, R 3 is C1~C 19 In some embodiments, R 3 is C1~C 18 In some embodiments, R 3 is C1~C 17 In some embodiments, R 3 is C1~C 16 In some embodiments, R 3 is C1~C 15 In some embodiments, R 3 is C1~C 14 In some embodiments, R3 is C1~C 13 In some embodiments, R 3 is C1~C 12 In some embodiments, R 3 is C1~C 11 In some embodiments, R 3 is C1~C 10 In some embodiments, R 3 is C1-C9 alkyl. In some embodiments, R 3 is C1-C8 alkyl. In some embodiments, R 3 is C1-C7 alkyl. In some embodiments, R 3 is C1-C6 alkyl. In some embodiments, R 3 is C1-C5 alkyl. In some embodiments, R 3 is C1-C4 alkyl. In some embodiments, R 3 is C1-C3 alkyl. In some embodiments, R 3 is a C1-C2 alkyl.
[0625] In some embodiments, R 1 is C alkyl. In some embodiments, R 1 is C alkyl. In some embodiments, R 1 is C alkyl. In some embodiments, R 1 is C4 alkyl. In some embodiments, R 1 is a C alkyl. In some embodiments, R 1 is C alkyl. In some embodiments, R 1 is a C alkyl. In some embodiments, R 1 is C alkyl. In some embodiments, R 1 is a C alkyl. In some embodiments, R 1 is C 10 In some embodiments, R 1 is C 11 In some embodiments, R 1 is C12 In some embodiments, R 1 is C 13 In some embodiments, R 1 is C 14 In some embodiments, R 1 is C 15 In some embodiments, R 1 is C 16 In some embodiments, R 1 is C 17 In some embodiments, R 1 is C 18 In some embodiments, R 1 is C 19 In some embodiments, R 1 is C 20 In some embodiments, R 2 is C alkyl. In some embodiments, R 2 is C alkyl. In some embodiments, R 2 is C alkyl. In some embodiments, R 2 is C4 alkyl. In some embodiments, R 2 is a C alkyl. In some embodiments, R 2 is C alkyl. In some embodiments, R 2 is a C alkyl. In some embodiments, R 2 is C alkyl. In some embodiments, R 2 is a C alkyl. In some embodiments, R 2 is C 10 In some embodiments, R 2 is C 11 In some embodiments, R 2 is C 12 In some embodiments, R 2 is C 13 In some embodiments, R 2 is C 14 In some embodiments, R 2 is C15 In some embodiments, R 2 is C 16 In some embodiments, R 2 is C 17 In some embodiments, R 2 is C 18 In some embodiments, R 2 is C 19 In some embodiments, R 2 is C 20 In some embodiments, R 3 is C alkyl. In some embodiments, R 3 is C alkyl. In some embodiments, R 3 is C alkyl. In some embodiments, R 3 is C4 alkyl. In some embodiments, R 3 is a C alkyl. In some embodiments, R 3 is C alkyl. In some embodiments, R 3 is a C alkyl. In some embodiments, R 3 is C alkyl. In some embodiments, R 3 is a C alkyl. In some embodiments, R 3 is C 10 In some embodiments, R 3 is C 11 In some embodiments, R 3 is C 12 In some embodiments, R 3 is C 13 In some embodiments, R 3 is C 14 In some embodiments, R 3 is C 15 In some embodiments, R 3 is C 16 In some embodiments, R 3 is C 17 In some embodiments, R 3 is C18 In some embodiments, R 3 is C 19 In some embodiments, R 3 is C 20 It is alkyl.
[0626] In some embodiments, R 4 is a C2-C5 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is C2~C 20 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is C2~C 19 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is C2~C 18 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is C2~C 17 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is C2~C 16 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is C2~C 15 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is C2~C 14 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is C2~C13 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is C2~C 12 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is C2~C 11 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is C2~C 10 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is a C2-C9 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is a C2-C8 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is a C2-C7 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is a C2-C6 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is a C2-C5 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 is a C2-C4 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4is a C2-C3 alkyl, where the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls. 4 are C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , or C 20 In this case, C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , or C 20 The alkyl in is unsubstituted or substituted with one or more hydroxyl groups.
[0627] In some embodiments, R 5 is a GIP / GLP-1 receptor dual agonist or a functional variant thereof. In some embodiments, R 5 is a therapeutic agent comprising a sequence with at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 25. In some embodiments, R 5 is a therapeutic agent comprising the sequence of SEQ ID NO:25.
[0628] In some embodiments, a therapeutic agent comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 25. In some embodiments, a therapeutic agent comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO: 25. In some embodiments, a therapeutic agent comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO: 25.
[0629] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a diacid 18 or 20 carbons in length. In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a diacid 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 carbons in length.
[0630] In some embodiments, the diacid is C 20 In some embodiments, the diacid comprises a fatty diacid of C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 , or C 50 Contains fatty diacids.
[0631]
[0574] In some embodiments herein, a compound of Formula II:
[0632] [ka]
[0633] Compounds according to the formula: In some embodiments, R 7 , R 8 , and R 9 is independently unsubstituted C1-C5 alkyl or substituted C1-C5 alkyl. 7 is unsubstituted C1-C5 alkyl or substituted C1-C5 alkyl. In some embodiments, R 8 is unsubstituted C1-C5 alkyl or substituted C1-C5 alkyl. In some embodiments, R 9 is unsubstituted C1 to C5 alkyl or substituted C1 to C5 alkyl.
[0634] In some embodiments, R 7 , R 8 , and R9 are independently unsubstituted C1 to C 20 Alkyl or substituted C1-C 20 In some embodiments, R 7 is unsubstituted C1 to C 20 Alkyl or substituted C1-C 20 In some embodiments, R 7 is unsubstituted C1 to C 19 Alkyl or substituted C1-C 19 In some embodiments, R 7 is unsubstituted C1 to C 18 Alkyl or substituted C1-C 18 In some embodiments, R 7 is unsubstituted C1 to C 17 Alkyl or substituted C1-C 17 In some embodiments, R 7 is unsubstituted C1 to C 16 Alkyl or substituted C1-C 16 In some embodiments, R 7 is unsubstituted C1 to C 15 Alkyl or substituted C1-C 15 In some embodiments, R 7 is unsubstituted C1 to C 14 Alkyl or substituted C1-C 14 In some embodiments, R 7 is unsubstituted C1 to C 13 Alkyl or substituted C1-C 13 In some embodiments, R 7 is unsubstituted C1 to C 12 Alkyl or substituted C1-C 12 In some embodiments, R 7 is unsubstituted C1 to C 11 Alkyl or substituted C1-C 11 In some embodiments, R 7 is unsubstituted C1 to C 10 Alkyl or substituted C1-C 10 In some embodiments, R 7is an unsubstituted C1-C9 alkyl or a substituted C1-C9 alkyl. 7 is unsubstituted C1-C8 alkyl or substituted C1-C8 alkyl. 7 is unsubstituted C1-C7 alkyl or substituted C1-C7 alkyl. In some embodiments, R 7 is unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl. In some embodiments, R 7 is unsubstituted C1-C5 alkyl or substituted C1-C5 alkyl. In some embodiments, R 7 is unsubstituted C1-C4 alkyl or substituted C1-C4 alkyl. In some embodiments, R 7 is unsubstituted C1-C3 alkyl or substituted C1-C3 alkyl. In some embodiments, R 7 is unsubstituted C1-C2 alkyl or substituted C1-C2 alkyl. In some embodiments, R 8 is unsubstituted C1 to C 20 Alkyl or substituted C1-C 20 In some embodiments, R 8 is unsubstituted C1 to C 19 Alkyl or substituted C1-C 19 In some embodiments, R 8 is unsubstituted C1 to C 18 Alkyl or substituted C1-C 18 In some embodiments, R 8 is unsubstituted C1 to C 17 Alkyl or substituted C1-C 17 In some embodiments, R 8 is unsubstituted C1 to C 16 Alkyl or substituted C1-C 16 In some embodiments, R 8 is unsubstituted C1 to C 15 Alkyl or substituted C1-C 15 In some embodiments, R 8 is unsubstituted C1 to C 14 Alkyl or substituted C1-C 14In some embodiments, R 8 is unsubstituted C1 to C 13 Alkyl or substituted C1-C 13 In some embodiments, R 8 is unsubstituted C1 to C 12 Alkyl or substituted C1-C 12 In some embodiments, R 8 is unsubstituted C1 to C 11 Alkyl or substituted C1-C 11 In some embodiments, R 8 is unsubstituted C1 to C 10 Alkyl or substituted C1-C 10 In some embodiments, R 8 is an unsubstituted C1-C9 alkyl or a substituted C1-C9 alkyl. 8 is unsubstituted C1-C8 alkyl or substituted C1-C8 alkyl. 8 is unsubstituted C1-C7 alkyl or substituted C1-C7 alkyl. In some embodiments, R 8 is unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl. In some embodiments, R 8 is unsubstituted C1-C5 alkyl or substituted C1-C5 alkyl. In some embodiments, R 8 is unsubstituted C1-C4 alkyl or substituted C1-C4 alkyl. In some embodiments, R 8 is unsubstituted C1-C3 alkyl or substituted C1-C3 alkyl. In some embodiments, R 8 is unsubstituted C1-C2 alkyl or substituted C1-C2 alkyl. In some embodiments, R 9 is unsubstituted C1 to C 20 Alkyl or substituted C1-C 20 In some embodiments, R 9 is unsubstituted C1 to C 19 Alkyl or substituted C1-C 19 In some embodiments, R 9 is unsubstituted C1 to C 18Alkyl or substituted C1-C 18 In some embodiments, R 9 is unsubstituted C1 to C 17 Alkyl or substituted C1-C 17 In some embodiments, R 9 is unsubstituted C1 to C 16 Alkyl or substituted C1-C 16 In some embodiments, R 9 is unsubstituted C1 to C 15 Alkyl or substituted C1-C 15 In some embodiments, R 9 is unsubstituted C1 to C 14 Alkyl or substituted C1-C 14 In some embodiments, R 9 is unsubstituted C1 to C 13 Alkyl or substituted C1-C 13 In some embodiments, R 9 is unsubstituted C1 to C 12 Alkyl or substituted C1-C 12 In some embodiments, R 9 is unsubstituted C1 to C 11 Alkyl or substituted C1-C 11 In some embodiments, R 9 is unsubstituted C1 to C 10 Alkyl or substituted C1-C 10 In some embodiments, R 9 is an unsubstituted C1-C9 alkyl or a substituted C1-C9 alkyl. 9 is unsubstituted C1-C8 alkyl or substituted C1-C8 alkyl. 9 is unsubstituted C1-C7 alkyl or substituted C1-C7 alkyl. In some embodiments, R 9 is unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl. In some embodiments, R 9 is unsubstituted C1-C5 alkyl or substituted C1-C5 alkyl. In some embodiments, R 9is unsubstituted C1-C4 alkyl or substituted C1-C4 alkyl. In some embodiments, R 9 is unsubstituted C1-C3 alkyl or substituted C1-C3 alkyl. In some embodiments, R 9 is unsubstituted C1-C2 alkyl or substituted C1-C2 alkyl.
[0635] In some embodiments, R 7 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 7 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 7 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 7 is an unsubstituted C4 alkyl or a substituted C4 alkyl. In some embodiments, R 7 is an unsubstituted C5 alkyl or a substituted C5 alkyl. In some embodiments, R 7 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 7 is an unsubstituted C7 alkyl or a substituted C7 alkyl. In some embodiments, R 7 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 7 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 7 is the unsubstituted C 10 Alkyl or substituted C 10 In some embodiments, R 7 is the unsubstituted C 11 Alkyl or substituted C 11 In some embodiments, R 7 is the unsubstituted C 12 Alkyl or substituted C 12 In some embodiments, R 7 is the unsubstituted C 13 Alkyl or substituted C 13 In some embodiments, R 7 is the unsubstituted C 14Alkyl or substituted C 14 In some embodiments, R 7 is the unsubstituted C 15 Alkyl or substituted C 15 In some embodiments, R 7 is the unsubstituted C 16 Alkyl or substituted C 16 In some embodiments, R 7 is the unsubstituted C 17 Alkyl or substituted C 17 In some embodiments, R 7 is the unsubstituted C 18 Alkyl or substituted C 18 In some embodiments, R 7 is the unsubstituted C 19 Alkyl or substituted C 19 In some embodiments, R 7 is the unsubstituted C 20 Alkyl or substituted C 20 In some embodiments, R 8 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 8 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 8 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 8 is an unsubstituted C4 alkyl or a substituted C4 alkyl. In some embodiments, R 8 is an unsubstituted C5 alkyl or a substituted C5 alkyl. In some embodiments, R 8 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 8 is an unsubstituted C7 alkyl or a substituted C7 alkyl. In some embodiments, R 8 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 8 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 8 is the unsubstituted C 10 Alkyl or substituted C10 In some embodiments, R 8 is the unsubstituted C 11 Alkyl or substituted C 11 In some embodiments, R 8 is the unsubstituted C 12 Alkyl or substituted C 12 In some embodiments, R 8 is the unsubstituted C 13 Alkyl or substituted C 13 In some embodiments, R 8 is the unsubstituted C 14 Alkyl or substituted C 14 In some embodiments, R 8 is the unsubstituted C 15 Alkyl or substituted C 15 In some embodiments, R 8 is the unsubstituted C 16 Alkyl or substituted C 16 In some embodiments, R 8 is the unsubstituted C 17 Alkyl or substituted C 17 In some embodiments, R 8 is the unsubstituted C 18 Alkyl or substituted C 18 In some embodiments, R 8 is the unsubstituted C 19 Alkyl or substituted C 19 In some embodiments, R 8 is the unsubstituted C 20 Alkyl or substituted C 20 In some embodiments, R 9 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 9 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 9 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 9 is an unsubstituted C4 alkyl or a substituted C4 alkyl. In some embodiments, R 9is an unsubstituted C5 alkyl or a substituted C5 alkyl. In some embodiments, R 9 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 9 is an unsubstituted C7 alkyl or a substituted C7 alkyl. In some embodiments, R 9 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 9 is an unsubstituted C alkyl or a substituted C alkyl. In some embodiments, R 9 is the unsubstituted C 10 Alkyl or substituted C 10 In some embodiments, R 9 is the unsubstituted C 11 Alkyl or substituted C 11 In some embodiments, R 9 is the unsubstituted C 12 Alkyl or substituted C 12 In some embodiments, R 9 is the unsubstituted C 13 Alkyl or substituted C 13 In some embodiments, R 9 is the unsubstituted C 14 Alkyl or substituted C 14 In some embodiments, R 9 is the unsubstituted C 15 Alkyl or substituted C 15 In some embodiments, R 9 is the unsubstituted C 16 Alkyl or substituted C 16 In some embodiments, R 9 is the unsubstituted C 17 Alkyl or substituted C 17 In some embodiments, R 9 is the unsubstituted C 18 Alkyl or substituted C 18 In some embodiments, R 9 is the unsubstituted C 19 Alkyl or substituted C 19 In some embodiments, R9 is the unsubstituted C 20 Alkyl or substituted C 20 It is alkyl.
[0636] In some embodiments, n is 1, 2, 3, 4, or 5. In some embodiments, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30.
[0637] In some embodiments, R 6 is a GIP / GLP-1 receptor dual agonist or a functional variant thereof. In some embodiments, R 6 is a therapeutic agent comprising a sequence with at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 25. In some embodiments, R 6 is a therapeutic agent comprising the sequence of SEQ ID NO:25.
[0638] In some embodiments, a therapeutic agent comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 25. In some embodiments, a therapeutic agent comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO: 25. In some embodiments, a therapeutic agent comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO: 25.
[0639]
[0582] In some embodiments, the compound comprises a dual GIP / GLP-1 receptor agonist or functional variant thereof having a cationic moiety that comprises a choline or choline derivative-like residue.
[0640]
[0583] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a [one or more choline or choline derivatives]-peptide ester formed at a Cys residue, a Lys residue, or any combination thereof.
[0641]
[0584] In some embodiments, the ratio of the [one or more choline or choline derivatives]-peptide ester formed at a Cys residue to the GIP / GLP-1 receptor dual agonist or functional variant thereof is 2 to 8, or the ratio of the [one or more choline or choline derivatives]-peptide ester formed at a Lys residue to the GIP / GLP-1 receptor dual agonist or functional variant thereof is 2 to 4, or a combination thereof.
[0642]
[0585] In some embodiments, the [one or more choline or choline derivatives]-peptide ester formed at the Cys residue has a ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, the [one or more choline or choline derivatives]-peptide esters formed at Cys residues are selected from the group consisting of a linker to GIP / GLP-1 receptor dual agonist or functional variant thereof, and a linker to GIP / GLP-1 receptor dual agonist or functional variant thereof, having a ratio of 1 to 50, 1 to 49, 1 to 48, 1 to 47, 1 to 46, 1 to 45, 1 to 44, 1 to 43, 1 to 42, 1 to 41, 1 to 40, 1 to 39, 1 to 38, 1 to 37, 1 to 49, 1 to 50, 1 to 51, 1 to 52, 1 to 53, 1 to 54, 1 to 55, 1 to 56, 1 to 57, 1 to 58, 1 to 59, 1 to 60, 1 to 61, 1 to 62, 1 to 63, 1 to 64, 1 to 65, 1 to 66, 1 to 67, 1 to 68, 1 to 69, 1 to 70, 1 to 71, 1 to 72, 1 to 73, 1 to 74, 1 to 75, 1 to 76, 1 to 77, 1 to 78, 1 to 79, 1 to 80, 1 to 81, 1 to 82, 1 to 83, 1 to 84, 1 to 85, 1 to 86, 1 to 87, 1 to 88, 1 to 89, 1 to 90, 1 to 91, 1 to 92, 1 to 93, 1 to 94, 1 to 9 ~36, 1-35, 1-34, 1-33, 1-32, 1-31, 1-30, 1-29, 1-28, 1-27, 1-26, 1-25, 1-24, 1-23, 1-22, 1-21, 1-20, 1-19, 1-18, 1-17, 1-16, 1-15, 1-14, 1-13, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2. In some embodiments, the [one or more choline or choline derivatives]-peptide esters formed at Cys residues are selected from the group consisting of a linker to GIP / GLP-1 receptor dual agonist or functional variant thereof, and a linker to GIP / GLP-1 receptor dual agonist or functional variant thereof, wherein the linker is selected from the group consisting of a choline or choline derivatives, ... 0, 19-50, 20-50, 21-50, 22-50, 23-50, 24-50, 25-50, 26-50, 27-50, 28-50, 29-50, 30-50, 31-50, 32-50, 33-50, 34-50, 35-50, 36-50, 37-50, 38-50, 39-50, 40-50, 41-50, 42-50, 43-50, 44-50, 45-50, 46-50, 47-50, 48-50, or 49-50.In some embodiments, the [one or more choline or choline derivatives]-peptide esters formed at Cys residues are selected from the group consisting of a linker to GIP / GLP-1 receptor dual agonist or functional variant thereof, and a linker to GIP / GLP-1 receptor dual agonist or functional variant thereof, wherein the ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof is 1 to 7, 2 to 8, 3 to 9, 4 to 10, 5 to 11, 6 to 12, 7 to 13, 8 to 14, 9 to 15, 10 to 16, 11 to 17, 12 to 18, 13 to 19, 14 to 20, 15 to 21, 16-22, 17-23, 18-24, 19-25, 20-26, 21-27, 22-28, 23-29, 24-30, 25-31, 26-32, 27-33, 28-34, 29-35, 30-36, 31-37, 32-38, 33-39, 34-40, 35-41, 36-42, 37-43, 38-44, 39-45, 40-46, 41-47, 42-48, 43-49, or 44-50.
[0643]
[0586] In some embodiments, the [one or more choline or choline derivatives]-peptide ester formed at the Lys residue has a ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, the [one or more choline or choline derivatives]-peptide esters formed at Lys residues are selected from the group consisting of a linker to GIP / GLP-1 receptor dual agonist or functional variant thereof, and a linker to GIP / GLP-1 receptor dual agonist or functional variant thereof, having a ratio of 1 to 50, 1 to 49, 1 to 48, 1 to 47, 1 to 46, 1 to 45, 1 to 44, 1 to 43, 1 to 42, 1 to 41, 1 to 40, 1 to 39, 1 to 38, 1 to 37, 1 to 49, 1 to 50, 1 to 51, 1 to 52, 1 to 53, 1 to 54, 1 to 55, 1 to 56, 1 to 57, 1 to 58, 1 to 59, 1 to 60, 1 to 61, 1 to 62, 1 to 63, 1 to 64, 1 to 65, 1 to 66, 1 to 67, 1 to 68, 1 to 69, 1 to 70, 1 to 71, 1 to 72, 1 to 73, 1 to 74, 1 to 75, 1 to 76, 1 to 77, 1 to 78, 1 to 79, 1 to 80, 1 to 81, 1 to 82, 1 to 83, 1 to 84, 1 to 85, 1 to 86, 1 to 87, 1 to 88, 1 to 89, 1 to 90, 1 to 91, 1 to 92, 1 to 93, 1 to 94, 1 to 9 ~36, 1-35, 1-34, 1-33, 1-32, 1-31, 1-30, 1-29, 1-28, 1-27, 1-26, 1-25, 1-24, 1-23, 1-22, 1-21, 1-20, 1-19, 1-18, 1-17, 1-16, 1-15, 1-14, 1-13, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2. In some embodiments, the [one or more choline or choline derivatives]-peptide esters formed at Lys residues are selected from the group consisting of a linker to GIP / GLP-1 receptor dual agonist or functional variant thereof, and a linker to GIP / GLP-1 receptor dual agonist or functional variant thereof, wherein the linker is 2 to 50, 3 to 50, 4 to 50, 5 to 50, 6 to 50, 7 to 50, 8 to 50, 9 to 50, 10 to 50, 11 to 50, 12 to 50, 13 to 50, 14 to 50, 15 to 50, 16 to 50, 17 to 50, 18 to 50, 19 to 50, 20 to 50, 21 to 50, 22 to 50, 23 to 50, 24 to 50, 25 to 50, 26 to 50, 27 to 50, 28 to 50, 29 to 50, 30 to 50, 31 to 50, 32 to 50, 33 to 50, 34 to 50, 35 to 50, 36 to 50, 37 to 50, 38 to 50, 39 to 60, 40 to 41, 42 to 43, 43 to 44, 44 to 45, 45 to 46, 46 to 47, 47 to 48, 48 to 49, 50 to 51, 51 to 52, 52 to 53, 53 to 54, 54 to 55, 55 to 56, 56 to 57, 57 to 58, 0, 19-50, 20-50, 21-50, 22-50, 23-50, 24-50, 25-50, 26-50, 27-50, 28-50, 29-50, 30-50, 31-50, 32-50, 33-50, 34-50, 35-50, 36-50, 37-50, 38-50, 39-50, 40-50, 41-50, 42-50, 43-50, 44-50, 45-50, 46-50, 47-50, 48-50, or 49-50.In some embodiments, the [one or more choline or choline derivatives]-peptide esters formed at Lys residues are selected from the group consisting of a linker to GIP / GLP-1 receptor dual agonist or functional variant thereof, and a functional variant thereof. ~20, 19-21, 20-22, 21-23, 22-24, 23-25, 24-26, 25-27, 26-28, 27-29, 28-30, 29-31, 30-32, 31-33, 32-34, 33-35, 34-36, 35-37, 36-38, 37-39, 38-40, 39-41, 40-42, 41-43, 42-44, 43-45, 44-46, 45-47, 46-48, 47-49, or 48-50.
[0644] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a diacid 18 or 20 carbons in length. In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a diacid 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 carbons in length.
[0645] In some embodiments, the diacid is C 20 In some embodiments, the diacid comprises a fatty diacid of C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 , or C 50 Contains fatty diacids.
[0646]
[0589] In some embodiments herein, a compound of formula III:
[0647] [ka]
[0648] [In the formula, R 10 is a therapeutic agent; R 11 is substituted C5~C 10 , or unsubstituted C5-C 10 and; X 1 teeth,
[0649] [ka]
[0650] , -S-, or -NH-; L 1 is a covalent bond or a linker] Compounds according to the formula:
[0651] In some embodiments, the compound comprises one or more R linked to a Lys residue, a Cys residue, or any combination thereof. 11 or a functional variant thereof.
[0652] In some embodiments, R 11 is linked to a Lys residue in a ratio of 2 to 4 of the linker to the GIP / GLP-1 receptor dual agonist or functional variant thereof, or R 11 is linked to a Cys residue at a ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof of 2 to 8, or at a ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof of 4, or a combination thereof.
[0653] In some embodiments, R 11 is linked to a Lys residue at a ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. 11The ratio of the linker to the GIP / GLP-1 receptor dual agonist or its functional variant is 1 to 50, 1 to 49, 1 to 48, 1 to 47, 1 to 46, 1 to 45, 1 to 44, 1 to 43, 1 to 42, 1 to 41, 1 to 40, 1 to 39, 1 to 38, 1 to 37, 1 to 36, 1 to 35, 1 to 34, 1 to 33, 1 to 32, 1 to 31, 1 to 30 , 1-29, 1-28, 1-27, 1-26, 1-25, 1-24, 1-23, 1-22, 1-21, 1-20, 1-19, 1-18, 1-17, 1-16, 1-15, 1-14, 1-13, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2. 11 The ratio of the linker to the GIP / GLP-1 receptor dual agonist or its functional variant is 2 to 50, 3 to 50, 4 to 50, 5 to 50, 6 to 50, 7 to 50, 8 to 50, 9 to 50, 10 to 50, 11 to 50, 12 to 50, 13 to 50, 14 to 50, 15 to 50, 16 to 50, 17 to 50, 18 to 50, 19 to 50, 20 to 50, 21 to 50, 22 to 50, 23 to 50, 24 to 50, 25 to 50, 26 to 50, 27 to 50, 28 to 50, 29 to 50, 30 to 50, 31 to 50, 32 to 50, 33 to 50, 34 to 50, 35 to 50, 36 to 50, 37 to 50, 38 to 50, 39 to 50, 40 to 50, 41 to 50, 42 to 50, 43 to 50, 44 to 50, 45 to 50, 46 to 50, 47 to 50, 48 to 50, 49 to 60, 51 to 51, 52 to 52, 53 to 53, 54 to 54, 55 to 55, 56 to 50, 57 to 50, 58 to 50, 59 to 61, 62 to 50, 63 to 50, 64 to 50, 65 to 50, 66 to 5 In some embodiments, R is linked to a Lys residue as 40-50, 41-50, 42-50, 43-50, 44-50, 45-50, 46-50, 47-50, 48-50, or 49-50. 11The ratio of the linker to the GIP / GLP-1 receptor dual agonist or its functional variant is 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, 18-20, 19-21, 20-22, 21-23, 22-24, 23-25, 24-26, 25-27, 26-28, 27-29, 28-30, 29-31, 30-32, 31-33, 32-34, 33-35, 34-36, 35-37, 36-38, 37-39, 38-40, 39-41, 40-42, 41-43, 42-44, 43-45, 44-46, 45-47, 46-48, 47-49, or 48-50, and linked to a Lys residue.
[0654] In some embodiments, R 11 is linked to a Cys residue at a ratio of linker to the GIP / GLP-1 receptor dual agonist or functional variant thereof of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. 11 The ratio of the linker to the GIP / GLP-1 receptor dual agonist or its functional variant is 1 to 50, 1 to 49, 1 to 48, 1 to 47, 1 to 46, 1 to 45, 1 to 44, 1 to 43, 1 to 42, 1 to 41, 1 to 40, 1 to 39, 1 to 38, 1 to 37, 1 to 36, 1 to 35, 1 to 34, 1 to 33, 1 to 32, 1 to 31, 1 to 30 , 1-29, 1-28, 1-27, 1-26, 1-25, 1-24, 1-23, 1-22, 1-21, 1-20, 1-19, 1-18, 1-17, 1-16, 1-15, 1-14, 1-13, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2. 11The ratio of the linker to the GIP / GLP-1 receptor dual agonist or its functional variant is 2 to 50, 3 to 50, 4 to 50, 5 to 50, 6 to 50, 7 to 50, 8 to 50, 9 to 50, 10 to 50, 11 to 50, 12 to 50, 13 to 50, 14 to 50, 15 to 50, 16 to 50, 17 to 50, 18 to 50, 19 to 50, 20 to 50, 21 to 50, 22 to 50, 23 to 50, 24 to 50, 25 to 50, 26 to 50, 27 to 50, 28 to 50, 29 to 50, 30 to 50, 31 to 50, 32 to 50, 33 to 50, 34 to 50, 35 to 50, 36 to 50, 37 to 50, 38 to 50, 39 to 50, 40 to 50, 41 to 50, 42 to 50, 43 to 50, 44 to 50, 45 to 50, 46 to 50, 47 to 50, 48 to 50, 49 to 60, 51 to 51, 52 to 52, 53 to 53, 54 to 54, 55 to 55, 56 to 50, 57 to 50, 58 to 50, 59 to 61, 62 to 50, 63 to 50, 64 to 50, 65 to 50, 66 to 5 In some embodiments, R is linked to a Cys residue as 2-50, 25-50, 26-50, 27-50, 28-50, 29-50, 30-50, 31-50, 32-50, 33-50, 34-50, 35-50, 36-50, 37-50, 38-50, 39-50, 40-50, 41-50, 42-50, 43-50, 44-50, 45-50, 46-50, 47-50, 48-50, or 49-50. 11 The ratio of the linker to the GIP / GLP-1 receptor dual agonist or its functional variant is 1-7, 2-8, 3-9, 4-10, 5-11, 6-12, 7-13, 8-14, 9-15, 10-16, 11-17, 12-18, 13-19, 14-20, 15-21, 16-22, 17-23, 18-24, 19-25, 20-26, 21-27, 22-29, 23-30, 24-31, 25-32, 26-33, 27-34, 28-35, 29-40, 30-36, 31-37, 32-38, 33-39, 34-41, 35-42, 36-43, 37-44, 38-45, 39-50, 40-46, 41-47, 42-48, 43-49, 44-51, 45-52, 46-53, 47-54, 48-55, 49-60, 50-61, 51-62, 52-53, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 61-62, 63-64, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 71-71, 72-73, 74-75, 75-76, 7, 22-28, 23-29, 24-30, 25-31, 26-32, 27-33, 28-34, 29-35, 30-36, 31-37, 32-38, 33-39, 34-40, 35-41, 36-42, 37-43, 38-44, 39-45, 40-46, 41-47, 42-48, 43-49, or 44-50, and linked to a Cys residue.
[0655] In some embodiments, R 11 is linked to the GIP / GLP-1 receptor dual agonist or functional variant thereof at a ratio of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 of linker to the GIP / GLP-1 receptor dual agonist or functional variant thereof.
[0656] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof, comprising a dual conjugation, in which the ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof is 1 to 2.
[0657]
[0596] In some embodiments, the dual conjugation has a ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, the dual conjugation comprises a ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof of 1 to 50, 1 to 49, 1 to 48, 1 to 47, 1 to 46, 1 to 45, 1 to 44, 1 to 43, 1 to 42, 1 to 41, 1 to 40, 1 to 39, 1 to 38, 1 to 37, 1 to 36, 1 to 35, 1 to 34, 1 to 33, 1-32, 1-31, 1-30, 1-29, 1-28, 1-27, 1-26, 1-25, 1-24, 1-23, 1-22, 1-21, 1-20, 1-19, 1-18, 1-17, 1-16, 1-15, 1-14, 1-13, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2. In some embodiments, the dual conjugation is characterized by a ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof of 2 to 50, 3 to 50, 4 to 50, 5 to 50, 6 to 50, 7 to 50, 8 to 50, 9 to 50, 10 to 50, 11 to 50, 12 to 50, 13 to 50, 14 to 50, 15 to 50, 16 to 50, 17 to 50, 18 to 50, 19 to 50, 20 to 50, 21 to 50, 22 to 50, 23 to 50, 24 to 50, 25 to 50, 26 to 50, 27 to 50, 28 to 50, 29 to 50, 30 to 50, 31 to 50, 32 to 50, 33 to 50, 34 to 50, 35 to 50, 36 to 50, 37 to 50, 38 to 50, 39 to 50, 40 to 50, 41 to 50, 42 to 50, 43 to 50, 44 to 50, 45 to 50, 46 to 50, 47 to 50, 48 to 50, 49 to 50, 50 to 51, 52 to 52, 53 to 53, 54 to 54, 55 to 55, 56 to 50, 57 to 50, 58 to 50, 59 to 60, 61 to 62, 63 to 64, 64 to 65, 65 ~50, 22~50, 23~50, 24~50, 25~50, 26~50, 27~50, 28~50, 29~50, 30~50, 31~50, 32~50, 33~50, 34~50, 35~50, 36~50, 37~50, 38~50, 39~50, 40~50, 41~50, 42~50, 43~50, 44~50, 45~50, 46~50, 47~50, 48~50, or 49~50.In some embodiments, the dual conjugation is characterized in that the ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof is 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8, 8 to 9, 9 to 10, 10 to 11, 11 to 12, 12 to 13, 13 to 14, 14 to 15, 15 to 16, 16 to 17, 17 to 18, 18 to 19, 19 to 20, 20 to 21, 21 to 22, 22 to 23, 23 to 24, 24 to 25, 25 to 26, 26 to 27, 27 to 28, 28 to 30, 30 to 31, 31 to 32, 32 to 33, 33 to 34, 34 to 35, 35 to 36, 36 to 37, 37 to 38, 38 to 39, 39 to 40, 41 to 42, 42 to 43, 43 to 44, 44 to 45, 45 to 46, 45 to 47, 46 to 48, 47 to 49, 48 to 50, 50 to 51, 51 to 52, 52 to 53, 53 to 54, 54 to 55, 55 to 56, 56 to 57, 57 to 58, 58 to 59, 59 to 60, 60 to 61, 61 to 62, 62 to 63, 63 to 64, 64 2, 22-23, 23-24, 24-25, 25-26, 26-27, 27-28, 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40, 40-41, 41-42, 42-43, 43-44, 44-45, 45-46, 46-47, 47-48, 48-49, or 49-50.
[0658]
[0600] In some embodiments, the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof. In some embodiments, a therapeutic agent comprises a sequence with at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 25. In some embodiments, a therapeutic agent comprises the sequence of SEQ ID NO:25.
[0659] In some embodiments, a therapeutic agent comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 25. In some embodiments, a therapeutic agent comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO: 25. In some embodiments, a therapeutic agent comprises a C20 diacid-γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO: 25.
[0660]
[0600] In some embodiments, the concentration of a compound described herein is at least 0.1% weight per volume.
[0601] In some embodiments, the concentration of a compound described herein is at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 99% weight per volume.
[0661] In some embodiments, the concentration of a compound described herein is at least 0.05 M. In some embodiments, the concentration of a compound described herein is at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 M.
[0662] In some embodiments, one or more ionic liquids comprise a cation independently selected from the group of cations listed in Table 2. In some embodiments, one or more ionic liquids comprise an anion independently selected from the group of anions listed in Table 1. In some embodiments, one or more ionic liquids comprise an ionic liquid independently selected from the group of ionic liquids listed in Table 2.
[0663]
[0604] In some embodiments, the compositions or pharmaceutical compositions provided herein comprise a composition provided herein or a compound provided herein and an ionic liquid of rank 1, 2, 3, 4, 5, 6, 8, 9, 10, or higher.
[0664] In some embodiments, the first, second, third, fourth, fifth, sixth, eighth, ninth, tenth, or higher ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative. In some embodiments, the first, second, third, fourth, fifth, sixth, eighth, ninth, tenth, or higher ionic liquids independently comprise a choline or a choline derivative, carnitine, or acetylcholine.
[0665] In some embodiments, the first, second, third, fourth, fifth, sixth, eighth, ninth, tenth, or higher ionic liquids are independently (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, , 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid (protocatechuic acid), 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, Citronellic acid, crotonic acid, D-(+)-galactonic acid, decanoic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-alanine Corbic acid, L-aspartic acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), sorbic acid, stearic acid, succinic acid, syringic acid, tiglic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
[0666] In some embodiments, the first, second, third, fourth, fifth, sixth, eighth, ninth, tenth, or higher ionic liquids are independently selected from the group consisting of (R)-α-lipoic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3,7-dimethyloctanoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, abietic acid, acetic acid, acetylcysteine, arabinose ... Chidonic acid, caffeic acid, cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)-galactonic acid, decanoic acid, deoxycholic acid, eicosapentanoic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, hexanoic acid, 3-phenylpropionic acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-glutathione (reduced form), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, maleic acid, malonic acid, mesaconic acid, mandelic acid, nonanoic acid, octanoic acid, oleic acid, p-toluenesulfonic acid, perillic acid, phosphoric acid, pimelic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, sorbic acid, syringic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-ferulic acid, undecanoic acid, vanillic acid, α-ketoglutaric acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid (protocatechuic acid), 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, aconitic acid The anion comprises an anion selected from the group consisting of caffeic acid, benzoic acid, chenodeoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tropic acid, eicosanedioic acid, ellagic acid, formic acid, heptanoic acid, isobutyric acid, DL-tartaric acid, lithocholic acid, malic acid, nicotinic acid, p-coumaric acid, palmitic acid, pivalic acid, salicylic acid (2-hydroxybenzoic acid), sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic acid), succinic acid, tiglic acid, valeric acid, stearic acid, and 8-[(2-hydroxybenzoyl)amino]octanoic acid.In some embodiments, the first, second, third, fourth, fifth, sixth, eighth, ninth, tenth, or higher ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydrocinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid. In some embodiments, the first, second, third, fourth, fifth, sixth, eighth, ninth, tenth, or higher ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0667]
[0608] In some embodiments, the first, second, third, fourth, fifth, sixth, eighth, ninth, tenth, or higher ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
[0668]
[0609] In some embodiments, the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
[0669]
[0610] In some embodiments, the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
[0670] In some embodiments, the first, second, third, fourth, fifth, sixth, eighth, ninth, tenth, or higher ionic liquids independently comprise a cation selected from the group of cations listed in Table 2. In some embodiments, the first, second, third, fourth, fifth, sixth, eighth, ninth, tenth, or higher ionic liquids independently comprise anions selected from the group of anions listed in Table 1. In some embodiments, the first, second, third, fourth, fifth, sixth, eighth, ninth, tenth, or higher ionic liquids independently comprise an ionic liquid selected from the group of ionic liquids listed in Table 2.
[0671] In some embodiments, to enhance the hydrophobicity of the GIP / GLP-1 receptor dual agonist or functional variant thereof, the GIP / GLP-1 receptor dual agonist or functional variant thereof is linked to one or more fatty acid or carboxylic acid-containing molecules. In some embodiments, the one or more fatty acid or carboxylic acid-containing molecules are linked to the GIP / GLP-1 receptor dual agonist or functional variant thereof via dual conjugation (or double covalent conjugation). In some embodiments, the one or more fatty acid or carboxylic acid-containing molecules comprise cinnamic acid. In some embodiments, the one or more fatty acid or carboxylic acid-containing molecules are cinnamic acid.
[0672] In some embodiments, one or more fatty acid- or carboxylic acid-containing molecules are non-covalently associated with a free amine of the GIP / GLP-1 receptor dual agonist, or functional variant thereof. In some embodiments, one or more fatty acid- or carboxylic acid-containing molecules are non-covalently associated with an N-terminal amine within the peptide backbone of the GIP / GLP-1 receptor dual agonist, or functional variant thereof. In some embodiments, one or more fatty acid- or carboxylic acid-containing molecules are non-covalently associated with an amine group of a Gln residue, an amine group of an Asn residue, an amine group of an Arg residue, an amine group of a Lys residue, an amine group of a His residue, or a combination thereof, of the GIP / GLP-1 receptor dual agonist, or functional variant thereof.
[0673] In some embodiments, one or more fatty acid- or carboxylic acid-containing molecules are covalently conjugated to a free amine of the GIP / GLP-1 receptor dual agonist, or functional variant thereof. In some embodiments, one or more fatty acid- or carboxylic acid-containing molecules are covalently conjugated to the N-terminal amine within the peptide backbone of the GIP / GLP-1 receptor dual agonist, or functional variant thereof. In some embodiments, one or more fatty acid- or carboxylic acid-containing molecules are covalently conjugated to an amine group of a Gln residue, an amine group of an Asn residue, an amine group of an Arg residue, an amine group of a Lys residue, an amine group of a His residue, or a combination thereof, of the GIP / GLP-1 receptor dual agonist, or functional variant thereof.
[0674]
[0615] In certain aspects herein, inter alia, compounds of Formula I:
[0675] [ka]
[0676] [In the formula, R 1 , R 2 , and R3 are independently C1-C5 alkyl; R 4 is a C2-C5 alkyl, wherein the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls; R 5 is a therapeutic agent] Compounds according to the formula:
[0677] In some embodiments, R 1 , R 2 , and R 3 is methyl. In some embodiments, R 1 , R 2 , and R 3 is ethyl. In some embodiments, R 1 , R 2 , and R 3 is propyl.
[0678] In some embodiments, R 1 and R 2 is methyl and R 3 is ethyl. In some embodiments, R 1 and R 3 is methyl and R 2 is ethyl.
[0679] In some embodiments, R 1 and R 2 is ethyl, and R 3 is methyl. In some embodiments, R 1 and R 3 is ethyl, and R 2 is methyl.
[0680] In some embodiments, R 1 and R 2 is propyl, and R 3 is methyl. In some embodiments, R 1 and R 3 is propyl, and R 2 is methyl.
[0681] In some embodiments, R 4 is a C2-C5 alkyl substituted with hydroxyl. In some embodiments, R 4 teeth,
[0682] [ka]
[0683] is.
[0627] In some embodiments, the compound has Formula Ia:
[0684] [ka]
[0685] It is a compound according to the following:
[0628] In some embodiments, the compound has Formula Ib:
[0686] [ka]
[0687] It is a compound according to the following:
[0629] In some embodiments, the compound has Formula Ic:
[0688] [ka]
[0689] It is a compound according to the following:
[0630] In some embodiments, the therapeutic agent is a GIP (glucose-dependent insulinotropic polypeptide) / GLP-1 (glucagon-like peptide-1) receptor dual agonist or a functional variant thereof.
[0690]
[0631] In some embodiments, the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0632] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:25.
[0691]
[0633] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 25.
[0692]
[0634] In some embodiments, the therapeutic agent comprises a C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO:25.
[0635] In some embodiments, the therapeutic agent comprises a C20 diacid -γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25.
[0693] In some embodiments, the compound is
[0694] [ka]
[0695] of,
[0696] [ka]
[0697] The molar ratio to is about 1:1 to about 1:20. In some embodiments, the compound is
[0698] [ka]
[0699] of,
[0700] [ka]
[0701] The molar ratio to is about 1:1. In some embodiments, the compound is
[0702] [ka]
[0703] of,
[0704] [ka]
[0705] The molar ratio to is about 1:2. In some embodiments, the compound is
[0706] [ka]
[0707] of,
[0708] [ka]
[0709] The molar ratio to is about 1:3. In some embodiments, the compound is
[0710] [ka]
[0711] of,
[0712] [ka]
[0713] The molar ratio to is about 1:4. In some embodiments, the compound is
[0714] [ka]
[0715] of,
[0716] [ka]
[0717] The molar ratio to is about 1:5. In some embodiments, the compound is
[0718] [ka]
[0719] of,
[0720] [ka]
[0721] The molar ratio to is about 1:10. In some embodiments, the compound is
[0722] [ka]
[0723] of,
[0724] [ka]
[0725] The molar ratio to is about 1:20.
[0644] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or a functional variant thereof having a modified structure.
[0726]
[0645] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or a functional variant thereof having a modified structure with choline or a choline derivative.
[0646] In some embodiments, the compound comprises a dual GIP / GLP-1 receptor agonist or functional variant thereof having a cationic moiety comprising choline or a choline derivative.
[0727]
[0647] In some embodiments, the compound comprises a dual GIP / GLP-1 receptor agonist or functional variant thereof having a cationic moiety that comprises a choline or choline derivative-like residue.
[0728]
[0648] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a [one or more choline or choline derivatives]-peptide derivative formed at a Glu residue, an Asp residue, or a combination thereof.
[0729]
[0649] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof, comprising a linker comprising one or more gamma glutamic acid (γGlu) residues, one or more 8-amino-3,6-dioxaoctanoic acid (OEG) residues, or a combination thereof.
[0730]
[0650] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof, which comprises a linker comprising one or more gamma glutamic acid (γGlu) residues.
[0731]
[0651] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a [choline or choline derivative]-peptide ester formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0732]
[0652] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a [choline or choline derivative]-peptide derivative formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0733]
[0653] In some embodiments, the compound comprises a dual GIP / GLP-1 receptor agonist or functional variant thereof that includes a diacid that is 18 or 20 carbons in length.
[0654] In some embodiments, the diacid is C 20 Contains fatty diacids.
[0734]
[0655] In some embodiments, the diacid comprises 1,20-icosane diacid.
[0656] In another aspect herein, a compound of formula II:
[0735] [ka]
[0736] [In the formula, R 6 is a therapeutic agent; R 7 , R 8 , and R 9 are independently C1-C5 alkyl; n is 1, 2, 3, 4, or 5] Compounds according to the formula:
[0737] In some embodiments, R 7 , R 8 , and R 9 is methyl. In some embodiments, R 7 , R 8 , and R 9 is ethyl. In some embodiments, R 7 , R 8 , and R 9 is propyl.
[0738] In some embodiments, R 7 and R 8 is methyl and R 9 is ethyl. In some embodiments, R 7 and R 9 is methyl and R 8 is ethyl.
[0739] In some embodiments, R 7 and R 8 is ethyl, and R 9 is methyl. In some embodiments, R 7 and R 9 is ethyl, and R 8 is methyl.
[0740] In some embodiments, R 7 and R 8 is propyl, and R 9 is methyl. In some embodiments, R 7 and R 9 is propyl, and R 8 is methyl.
[0741] In some embodiments, n is 1.
[0667] In some embodiments, the compound has Formula IIa:
[0742] [ka]
[0743] It is a compound according to the following:
[0668] In some embodiments, the compound has Formula IIb:
[0744] [ka]
[0745] It is a compound according to the following:
[0669] In some embodiments, the compound has Formula IIc:
[0746] [ka]
[0747] It is a compound according to the following:
[0670] In some embodiments, the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
[0748]
[0671] In some embodiments, the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0672] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:25.
[0749] In some embodiments, the therapeutic agent is a C conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25. 20 Contains diacid-γ-Glu-(AEEA)2.
[0750] In some embodiments, the therapeutic agent is a C conjugated to a residue of the sequence of SEQ ID NO:25. 20 Contains diacid-γ-Glu-(AEEA)2. In some embodiments, the therapeutic agent is a C 1 -carboxylate conjugated to the Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25. 20 Contains diacid-γ-Glu-(AEEA)2.
[0751]
[0676] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or a functional variant thereof having a modified structure with choline or a choline derivative.
[0677] In some embodiments, the compound comprises a dual GIP / GLP-1 receptor agonist or functional variant thereof having a cationic moiety comprising choline or a choline derivative.
[0752]
[0678] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or a functional variant thereof having an ester structure modified with choline or a choline derivative.
[0753]
[0679] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof having a cationic moiety that comprises a choline or choline derivative-like residue.
[0754]
[0680] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a [one or more choline or choline derivatives]-peptide ester formed at a Cys residue, a Lys residue, or any combination thereof.
[0755]
[0681] In some embodiments, the ratio of the [one or more choline or choline derivatives]-peptide ester formed at a Cys residue to the GIP / GLP-1 receptor dual agonist or functional variant thereof is 2 to 8, or the ratio of the [one or more choline or choline derivatives]-peptide ester formed at a Lys residue to the GIP / GLP-1 receptor dual agonist or functional variant thereof is 2 to 4, or a combination thereof.
[0756]
[0682] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof, comprising a linker comprising one or more gamma glutamic acid (γGlu) residues, one or more 8-amino-3,6-dioxaoctanoic acid (OEG) residues, or a combination thereof.
[0757]
[0683] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof, comprising a linker comprising one or more gamma glutamic acid (γGlu) residues.
[0758]
[0684] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a [choline or choline derivative]-peptide derivative formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0759]
[0685] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a [choline or choline derivative]-peptide ester formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0760]
[0686] In some embodiments, the compound comprises a dual GIP / GLP-1 receptor agonist or functional variant thereof that includes a diacid that is 18 or 20 carbons in length.
[0687] In some embodiments, the diacid is C 20 Contains fatty diacids.
[0761]
[0688] In some embodiments, the diacid comprises 1,20-icosane diacid.
[0689] In another aspect herein, compounds of formula III:
[0762] [ka]
[0763] [In the formula, R 10 is a therapeutic agent; R 11 is substituted C5~C 10 , or unsubstituted C5-C 10 and; X 1 teeth,
[0764] [ka]
[0765] , -S-, or -NH-; L 1 is a covalent bond or a linker] Compounds according to the formula:
[0766] In some embodiments, L 1 is a non-cleavable linker. In some embodiments, L 1 comprises a maleimidoalkane linker or a maleimidocyclohexane linker.
[0767] In some embodiments, L 1 teeth,
[0768] [ka]
[0769] Includes. In some embodiments, L 1 is a chemically cleavable linker. In some embodiments, L 1 comprises a hydrazone linker or a disulfide linker.
[0770] In some embodiments, L 1 teeth,
[0771] [ka]
[0772] Includes. In some embodiments, R 11 is a substitution C 10 or unsubstituted C 10 is.
[0697] In some embodiments, the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
[0773]
[0698] In some embodiments, the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0699] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:25.
[0774]
[0700] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 25.
[0775]
[0701] In some embodiments, the therapeutic agent comprises a C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO:25.
[0702] In some embodiments, the therapeutic agent comprises a C20 diacid -γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25.
[0776]
[0703] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or a functional variant thereof having a modified structure with choline or a choline derivative.
[0704] In some embodiments, the compound comprises a dual GIP / GLP-1 receptor agonist or functional variant thereof having a cationic moiety comprising choline or a choline derivative.
[0777]
[0705] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or a functional variant thereof having an ester structure modified with choline or a choline derivative.
[0778]
[0706] In some embodiments, the compound comprises a dual GIP / GLP-1 receptor agonist or functional variant thereof having a cationic moiety that comprises a choline or choline derivative-like residue.
[0779] In some embodiments, the compound comprises one or more R linked to a Lys residue, a Cys residue, or any combination thereof. 11 or a functional variant thereof.
[0780] In some embodiments, R 11 is linked to a Lys residue in a ratio of 2 to 4 of the linker to the GIP / GLP-1 receptor dual agonist or functional variant thereof, or R 11 is linked to a Cys residue at a ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof of 2 to 8, or at a ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof of 4, or a combination thereof.
[0781]
[0709] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof, including a dual conjugation.
[0710] In some embodiments, the dual conjugation has a ratio of linker to GIP / GLP-1 receptor dual agonist or functional variant thereof of 1-2.
[0782]
[0711] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof, comprising a linker comprising one or more gamma glutamic acid (γGlu) residues, one or more 8-amino-3,6-dioxaoctanoic acid (OEG) residues, or a combination thereof.
[0783]
[0712] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof, comprising a linker comprising one or more gamma glutamic acid (γGlu) residues.
[0784]
[0713] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a [choline or choline derivative]-peptide derivative formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0785]
[0714] In some embodiments, the compound comprises a GIP / GLP-1 receptor dual agonist or functional variant thereof comprising a [choline or choline derivative]-peptide ester formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
[0786]
[0715] In some embodiments, the compound comprises a dual GIP / GLP-1 receptor agonist or functional variant thereof that includes a diacid that is 18 or 20 carbons in length.
[0716] In some embodiments, the diacid is C 20 Contains fatty diacids.
[0787]
[0717] In some embodiments, the diacid comprises 1,20-icosane diacid.
[0718] In another aspect, the present specification provides compositions comprising a compound described herein and one or more ionic liquids.
[0788]
[0719] In some embodiments, the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
[0789]
[0720] In some embodiments, the one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine. In some embodiments, the one or more ionic liquids are independently selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid, and the like. Protocatechuic acid, 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)- Galactonic acid, decanoic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-ascorbic acid Partic acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), sorbic acid, stearic acid, succinic acid, syringic acid, tiglic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
[0790]
[0722] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydrocinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0791]
[0723] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0792]
[0724] In some embodiments, the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
[0793]
[0725] In some embodiments, the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
[0794]
[0726] In some embodiments, the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
[0795]
[0727] In some embodiments, the compositions described herein further comprise at least one penetration enhancer.
[0728] In some embodiments, the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
[0796]
[0729] In some embodiments, the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof.
[0797]
[0730] In some embodiments, the compositions described herein further comprise at least one pharmaceutically acceptable excipient.
[0731] In another aspect, the present specification provides a composition comprising a GIP / GLP-1 receptor dual agonist or a functional variant thereof and one or more ionic liquids.
[0798]
[0732] In some embodiments, the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
[0799]
[0733] In some embodiments, the one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine. In some embodiments, the one or more ionic liquids are independently selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid, and the like. Protocatechuic acid, 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)- Galactonic acid, decanoic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-ascorbic acid Partic acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), sorbic acid, stearic acid, succinic acid, syringic acid, tiglic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
[0800]
[0735] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydrocinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0801]
[0736] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0802]
[0737] In some embodiments, the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
[0803]
[0738] In some embodiments, the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
[0804]
[0739] In some embodiments, the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
[0805]
[0740] In some embodiments, the solubility of the GIP / GLP-1 receptor dual agonist or functional variant thereof is increased compared to the GIP / GLP-1 receptor dual agonist or functional variant thereof in a composition without the ionic liquid.
[0806]
[0741] In some embodiments, the delivery efficiency of the GIP / GLP-1 receptor dual agonist or functional variant thereof in a subject in need thereof is enhanced or improved when administered to a subject compared to the GIP / GLP-1 receptor dual agonist or functional variant thereof in a composition without the ionic liquid.
[0807]
[0742] In some embodiments, the composition further comprises at least one penetration enhancer.
[0743] In some embodiments, the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
[0808]
[0744] In some embodiments, the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof.
[0809]
[0745] Another aspect of the present specification provides a pharmaceutical composition comprising a compound described herein or a composition described herein and at least one pharmaceutically acceptable excipient.
[0810]
[0746] In some embodiments, the pharmaceutical composition further comprises at least one penetration enhancer.
[0747] In some embodiments, the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
[0811]
[0748] In some embodiments, the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof.
[0812]
[0749] In another aspect herein, there is provided a method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound described herein, a composition described herein, or a pharmaceutical composition described herein, wherein the administering step is effective to treat the disease or disorder in the subject.
[0813]
[0750] In some embodiments, the disease or disorder is a metabolic disease or disorder.
[0751] In some embodiments, the disease or disorder is diabetes.
[0814]
[0752] In some embodiments, the disease or disorder is type 2 diabetes mellitus (T2DM).
[0753] In some embodiments, the disease or disorder is obesity or overweight.
[0754] In some embodiments, the administration activates GIP receptor signaling, GLP-1 receptor signaling, or a combination thereof.
[0815]
[0755] In some embodiments, administration increases or improves glucose-dependent insulin secretion, improves glucose tolerance, or a combination thereof.
[0816]
[0756] In some embodiments, administration increases or improves glycemic control.
[0757] In some embodiments, administration decreases or reduces fasting serum glucose.
[0817]
[0758] In some embodiments, administration results in or reduces weight loss, reduces or reduces food intake, or a combination thereof.
[0818]
[0759] In some embodiments, administration effects improvement in glycemic control, body weight, or a combination thereof.
[0760] In some embodiments, the composition, compound, or pharmaceutical composition is administered via subcutaneous administration, intravenous administration, or oral administration.
[0819]
[0761] In some embodiments, the composition, compound, or pharmaceutical composition is administered orally.
[0762] In some embodiments, the composition, compound, or pharmaceutical composition is administered as a liquid-filled capsule.
[0820]
[0763] In some embodiments, the composition, compound, or pharmaceutical composition is administered in multiple doses.
[0764] In some embodiments, the composition, compound, or pharmaceutical composition is administered in a single dose.
[0821]
[0765] In some embodiments, the composition, compound, or pharmaceutical composition is administered to a mucosa.
[0766] In some embodiments, the composition, compound, or pharmaceutical composition is administered via subcutaneous administration, intravenous administration, or oral administration.
[0822]
[0767] In some embodiments, the concentration of a compound described herein is at least 0.1% weight per volume.
[0768] In some embodiments, the concentration of a compound described herein is at least 0.05M.
[0823]
[0769] In some embodiments, the composition further comprises one or more additional agents.
[0770] In some embodiments, the one or more additional agents are selected from the group consisting of nucleic acids, small molecules, and polypeptides.
[0824]
[0771] In some embodiments, the one or more additional agents are nucleic acids.
[0772] In some embodiments, the one or more additional agents are small molecules.
[0773] In some embodiments, the one or more additional agents is a polypeptide.
[0825]
[0774] In some embodiments, the one or more additional agents is a polypeptide.
[0775] In some embodiments, the one or more additional agents are therapeutic agents that treat a metabolic disease or disorder.
[0826]
[0776] In some embodiments, the one or more additional agents is a therapeutic agent that treats diabetes.
[0777] In some embodiments, the one or more additional agents is a therapeutic agent treating type 2 diabetes mellitus (T2DM).
[0827]
[0778] In some embodiments, the one or more additional agents is a therapeutic agent that treats obesity or overweight.
[0779] In another aspect herein, there is provided a method for increasing the solubility of a GIP / GLP-1 receptor dual agonist or a functional variant thereof, comprising administering to a patient a compound of Formula I:
[0828] [ka]
[0829] [In the formula, R 1 , R 2 , and R 3 are independently C1-C5 alkyl; R 4 is a C2-C5 alkyl, wherein the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls; R 5 is a GIP / GLP-1 receptor dual agonist or its functional variant] A method is presented comprising preparing a composition comprising a compound according to
[0830]
[0780] In another aspect herein, there is provided a method for enhancing or improving the delivery efficiency of a GIP / GLP-1 receptor dual agonist, or a functional variant thereof, in a subject in need thereof, comprising administering to said subject a compound of Formula I:
[0831] [ka]
[0832] [In the formula, R 1 , R 2 , and R 3 are independently C1-C5 alkyl; R 4 is a C2-C5 alkyl, wherein the C2-C5 alkyl is unsubstituted or substituted with one or more hydroxyls; R 5 is a GIP / GLP-1 receptor dual agonist or its functional variant] preparing a composition comprising a compound according to Administering the composition to a subject A method is presented that includes:
[0833] In some embodiments, R 1 , R 2 , and R 3 is methyl. In some embodiments, R 1 , R 2 , and R 3 is ethyl. In some embodiments, R 1 , R 2 , and R 3 is propyl.
[0834] In some embodiments, R 1 and R 2 is methyl and R 3 is ethyl. In some embodiments, R 1 and R 3 is methyl and R 2 is ethyl.
[0835] In some embodiments, R 1 and R 2 is ethyl, and R 3 is methyl. In some embodiments, R 1 and R 3 is ethyl, and R 2 is methyl.
[0836] In some embodiments, R 1 and R 2 is propyl, and R 3 is methyl. In some embodiments, R 1 and R 3 is propyl, and R 2 is methyl.
[0837] In some embodiments, R 4 is a C2-C5 alkyl substituted with hydroxyl. In some embodiments, R 4 teeth,
[0838] [ka]
[0839] is.
[0792] In some embodiments, the compound has Formula Ia:
[0840] [ka]
[0841] It is a compound according to the following:
[0793] In some embodiments, the compound has Formula Ib:
[0842] [ka]
[0843] It is a compound according to the following:
[0794] In some embodiments, the compound has Formula Ic:
[0844] [ka]
[0845] It is a compound according to the following: In some embodiments, R 5 comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0846] In some embodiments, R 5 comprises the sequence of SEQ ID NO:25. In some embodiments, R 5 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0847] In some embodiments, R 5 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO:25. In some embodiments, R 5 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25.
[0848] In some embodiments, the compound is
[0849] [ka]
[0850] of,
[0851] [ka]
[0852] The molar ratio to is about 1:1 to about 1:20.
[0801] In some embodiments, the compound is
[0853] [ka]
[0854] of,
[0855] [ka]
[0856] The molar ratio to is about 1:1.
[0802] In some embodiments, the compound is
[0857] [ka]
[0858] of,
[0859] [ka]
[0860] The molar ratio to is about 1:2.
[0803] In some embodiments, the compound is
[0861] [ka]
[0862] of,
[0863] [ka]
[0864] The molar ratio to is about 1:3.
[0804] In some embodiments, the compound is
[0865] [ka]
[0866] of,
[0867] [ka]
[0868] The molar ratio to is about 1:4.
[0805] In some embodiments, the compound is
[0869] [ka]
[0870] of,
[0871] [ka]
[0872] The molar ratio to is about 1:5.
[0806] In some embodiments, the compound is
[0873] [ka]
[0874] of,
[0875] [ka]
[0876] The molar ratio to is about 1:10.
[0807] In some embodiments, the compound is
[0877] [ka]
[0878] of,
[0879] [ka]
[0880] The molar ratio to is about 1:20.
[0808] In another aspect herein, there is provided a method for increasing the solubility of a GIP / GLP-1 receptor dual agonist or a functional variant thereof, comprising:
[0881] [ka]
[0882] [In the formula, R 6 is a GIP / GLP-1 receptor dual agonist or a functional variant thereof; R 7 , R 8 , and R 9 are independently unsubstituted C1-C5 alkyl or substituted C1-C5 alkyl; n is 1, 2, 3, 4, or 5] A method is presented comprising preparing a composition comprising a compound according to
[0883]
[0809] In another aspect herein, there is provided a method for enhancing or improving the delivery efficiency of a GIP / GLP-1 receptor dual agonist, or a functional variant thereof, in a subject in need thereof, comprising administering to said subject a compound of Formula II:
[0884] [ka]
[0885] [In the formula, R 6 is a GIP / GLP-1 receptor dual agonist or a functional variant thereof; R 7 , R 8 , and R 9 are independently unsubstituted C1-C5 alkyl or substituted C1-C5 alkyl; n is 1, 2, 3, 4, or 5] preparing a composition comprising a compound according to Administering the composition to a subject A method is presented that includes:
[0886] In some embodiments, R 7 , R 8 , and R 9 is methyl. In some embodiments, R 7 , R 8, and R 9 is ethyl. In some embodiments, R 7 , R 8 , and R 9 is propyl.
[0887] In some embodiments, R 7 and R 8 is methyl and R 9 is ethyl. In some embodiments, R 7 and R 9 is methyl and R 8 is ethyl.
[0888] In some embodiments, R 7 and R 8 is ethyl, and R 9 is methyl. In some embodiments, R 7 and R 9 is ethyl, and R 8 is methyl.
[0889] In some embodiments, R 7 and R 8 is propyl, and R 9 is methyl. In some embodiments, R 7 and R 9 is propyl, and R 8 is methyl.
[0890] In some embodiments, n is 1.
[0820] In some embodiments, the compound has Formula IIa:
[0891] [ka]
[0892] It is a compound according to the following:
[0821] In some embodiments, the compound has Formula IIb:
[0893] [ka]
[0894] It is a compound according to the following:
[0822] In some embodiments, the compound has Formula IIc:
[0895] [ka]
[0896] It is a compound according to the following: In some embodiments, R 6 comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0897] In some embodiments, R 6 comprises the sequence of SEQ ID NO:25. In some embodiments, R 6 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0898] In some embodiments, R 6 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO:25. In some embodiments, R 6 comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25.
[0899]
[0828] In some embodiments, the composition further comprises one or more ionic liquids.
[0829] In some embodiments, the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
[0900]
[0830] In some embodiments, the one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine. In some embodiments, the one or more ionic liquids are independently selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid, and the like. Protocatechuic acid, 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)- Galactonic acid, decanoic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-ascorbic acid Partic acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), sorbic acid, stearic acid, succinic acid, syringic acid, tiglic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
[0901]
[0832] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydrocinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0902]
[0833] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0903]
[0834] In some embodiments, the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
[0904]
[0835] In some embodiments, the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
[0905]
[0836] In some embodiments, the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
[0906]
[0837] In another aspect, the present specification provides a method for increasing the solubility of a GIP / GLP-1 receptor dual agonist or a functional variant thereof, the method comprising the step of preparing a composition comprising a GIP / GLP-1 receptor dual agonist or a functional variant thereof and one or more ionic liquids.
[0907]
[0838] In another aspect, the present specification provides a method for enhancing or improving the delivery efficiency of a GIP / GLP-1 receptor dual agonist, or a functional variant thereof, in a subject in need thereof, the method comprising the steps of preparing a composition comprising a GIP / GLP-1 receptor dual agonist, or a functional variant thereof, and one or more ionic liquids, and administering the composition to the subject.
[0908]
[0839] In some embodiments, the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
[0909]
[0840] In some embodiments, the one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine. In some embodiments, the one or more ionic liquids are independently selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid, and the like. Protocatechuic acid, 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)- Galactonic acid, decanoic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-ascorbic acid Partic acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), sorbic acid, stearic acid, succinic acid, syringic acid, tiglic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
[0910]
[0842] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydrocinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0911]
[0843] In some embodiments, the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
[0912]
[0844] In some embodiments, the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
[0913]
[0845] In some embodiments, the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
[0914]
[0846] In some embodiments, the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
[0915]
[0847] In another aspect herein, there is provided a method for increasing the hydrophobicity of a therapeutic agent, comprising: 12 to a therapeutic agent, 12 However, substitution C5~C 10 , or unsubstituted C5-C 10 and wherein the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
[0916] In some embodiments, R 12 is the therapeutic agent
[0917] [ka]
[0918] , -S-, or -NH-. In some embodiments, R 12 is linked to the therapeutic agent via a covalent bond or a linker.
[0919]
[0850] In some embodiments, the linker is a non-cleavable linker.
[0851] In some embodiments, the linker comprises a maleimidoalkane linker or a maleimidocyclohexane linker.
[0920]
[0852] In some embodiments, the linker is:
[0921] [ka]
[0922] Includes.
[0853] In some embodiments, the linker is a chemically cleavable linker.
[0854] In some embodiments, the linker comprises a hydrazone linker or a disulfide linker.
[0923]
[0855] In some embodiments, the linker is:
[0924] [ka]
[0925] Includes. In some embodiments, R 12 is a substitution C 10 or unsubstituted C 10 is.
[0857] In some embodiments, the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:25.
[0926]
[0858] In some embodiments, the therapeutic agent comprises the sequence of SEQ ID NO:25.
[0859] In some embodiments, the therapeutic agent comprises the C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 25.
[0927]
[0860] In some embodiments, the therapeutic agent comprises a C20 diacid -γ-Glu-(AEEA)2 conjugated to a residue of the sequence of SEQ ID NO:25.
[0861] In some embodiments, the therapeutic agent comprises a C20 diacid -γ-Glu-(AEEA)2 conjugated to a Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:25.
[0928]
[0862] In another aspect, the present specification provides a method for enhancing or improving the delivery efficiency of a therapeutic agent in a subject in need thereof, the method comprising adding at least one penetration enhancer to a compound described herein, a composition described herein, or a pharmaceutical composition described herein, and administering the composition, compound, or pharmaceutical composition to the subject.
[0929]
[0863] In some embodiments, the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
[0930]
[0864] In some embodiments, the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof. Antibodies or antibody fragments thereof As used herein, the term "antibody" refers to a protein or polypeptide derived from an immunoglobulin molecule that specifically binds to an antigen. In some embodiments, an antibody is a polyclonal antibody or a monoclonal antibody. In some embodiments, an antibody comprises multiple chains or a single chain. In some embodiments, an antibody comprises an intact immunoglobulin. In some embodiments, an antibody is a naturally occurring antibody. In some embodiments, an antibody is a recombinant antibody. In some embodiments, an antibody is in the form of a single domain antibody, maxibody, minibody, nanobody, intrabody, diabody, triabody, tetrabody, and multispecific antibody.
[0931] As used herein, the term "antibody fragment" refers to at least a portion of an intact antibody, or a recombinant variant thereof. In some embodiments, an antibody fragment is an antigen-binding domain that recognizes and specifically binds to an antigen. Exemplary antibody fragments include, but are not limited to, Fab, Fab', F(ab'), Fv fragments, scFv antibody fragments, single domain antibodies (sdAbs), camelid VhH domains, and shark single domain variable domains (BNARs).
[0932] In some embodiments, the antibody or antibody fragment thereof comprises an anti-tumor necrosis factor alpha (TNF-α) antibody or anti-TNF-α antibody fragment. In some embodiments, the antibody or antibody fragment thereof comprises an anti-TNF-α chimeric monoclonal antibody or antibody fragment thereof. In some embodiments, the antibody or antibody fragment thereof comprises infliximab or an antibody fragment thereof.
[0933]
[0868] As used herein, the term "infliximab" refers to a chimeric monoclonal antibody that binds to tumor necrosis factor alpha (TNF-α). In some embodiments, the anti-TNF-α chimeric monoclonal antibody or antibody fragment thereof neutralizes TNF-α by preventing TNF-α from interacting with its receptor on cells. In some embodiments, the anti-TNF-α chimeric monoclonal antibody or antibody fragment thereof is used to treat autoimmune diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behcet's disease.
[0934] In some embodiments, the anti-TNF-α chimeric monoclonal antibody or antibody fragment thereof is EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGT TLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 1) The heavy chain comprises a sequence of
[0935] In some embodiments, the anti-TNF-α chimeric monoclonal antibody or antibody fragment thereof is EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT (SEQ ID NO: 24) The heavy chain comprises a sequence of
[0936]
[0872] In some embodiments, the anti-TNF-α chimeric monoclonal antibody or antibody fragment thereof comprises a heavy chain comprising the sequence identified by Pubmed as PDB:4G3Y_H.
[0937] In some embodiments, the anti-TNF-α chimeric monoclonal antibody or antibody fragment thereof is DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 2) and a light chain comprising the sequence:
[0938] In some embodiments, Asn300 (asparagine at position 300) of the heavy chain of an anti-TNF-α chimeric monoclonal antibody or antibody fragment thereof is a glycosylation site. In some embodiments, Asn300 of the heavy chain of an anti-TNF-α chimeric monoclonal antibody or antibody fragment thereof is glycosylated.
[0939]
[0875] In some embodiments, the anti-TNF-α chimeric monoclonal antibody or antibody fragment thereof comprises a light chain comprising the sequence identified by Pubmed as PDB:4G3Y_L.
[0940] In some embodiments, the antibody or antibody fragment thereof comprises an anti-tumor necrosis factor alpha (TNF-α) antibody or anti-TNF-α antibody fragment. In some embodiments, the antibody or antibody fragment thereof comprises an anti-TNF-α monoclonal antibody or antibody fragment thereof. In some embodiments, the antibody or antibody fragment thereof comprises adalimumab or its antibody fragment.
[0941]
[0877] As used herein, the term "adalimumab" refers to a monoclonal antibody that binds to TNF-α. In some embodiments, the anti-TNF-α monoclonal antibody or antibody fragment thereof acts by inactivating TNF-α. In some embodiments, the anti-TNF-α monoclonal antibody or antibody fragment thereof is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. In some embodiments, the anti-TNF-α monoclonal antibody or antibody fragment thereof is a disease-modifying antirheumatic drug (DMARD).
[0942] In some embodiments, the anti-TNF-α monoclonal antibody or antibody fragment thereof is EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC (SEQ ID NO: 3) The heavy chain comprises a sequence of
[0943] In some embodiments, the anti-TNF-α monoclonal antibody or antibody fragment thereof is EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLDMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKI (SEQ ID NO: 4) The heavy chain comprises a sequence of
[0944] In some embodiments, the anti-TNF-α monoclonal antibody or antibody fragment thereof is EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 5) The heavy chain comprises a sequence of
[0945]
[0882] In some embodiments, the anti-TNF-α monoclonal antibody or antibody fragment thereof comprises a heavy chain comprising the sequence identified by Pubmed as PDB:3WD5_H. In some embodiments, the anti-TNF-α monoclonal antibody or antibody fragment thereof is DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 6) and a light chain comprising the sequence:
[0946] In some embodiments, the anti-TNF-α monoclonal antibody or antibody fragment thereof is DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTIQITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSGKKCA (SEQ ID NO: 7) and a light chain comprising the sequence:
[0947]
[0885] In some embodiments, the anti-TNF-α monoclonal antibody or antibody fragment thereof comprises a light chain comprising the sequence identified by Pubmed as PDB:3WD5_L. In some embodiments, the antibody or antibody fragment thereof comprises an anti-human interleukin-12 (IL-12) / interleukin-23 (IL-23) subunit antibody or antibody fragment thereof. In some embodiments, the antibody or antibody fragment thereof comprises ustekinumab or an antibody fragment thereof.
[0948]
[0887] As used herein, the term "ustekinumab" refers to a monoclonal antibody that targets subunits of human interleukin-12 (IL-12) and interleukin-23 (IL-23), which regulate the immune system and immune-mediated inflammatory disorders.
[0949]
[0888] In some embodiments, the anti-IL-12 / IL-23 subunit human antibody or antibody fragment thereof is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
[0950] In some embodiments, the anti-IL-12 / IL-23 subunit human antibody or antibody fragment thereof is EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSSSSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH (SEQ ID NO: 8) The heavy chain comprises a sequence of
[0951]
[0890] In some embodiments, the anti-IL-12 / IL-23 subunit human antibody or antibody fragment thereof comprises a heavy chain comprising the sequence identified by Pubmed as PDB:3HMX_H.
[0952] In some embodiments, the anti-IL-12 / IL-23 subunit human antibody or antibody fragment thereof is DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 9) and a light chain comprising the sequence:
[0953]
[0892] In some embodiments, the anti-IL-12 / IL-23 subunit human antibody or antibody fragment thereof comprises a light chain comprising the sequence identified by Pubmed as PDB:3HMX_L.
[0954] In some embodiments, the antibody or antibody fragment thereof comprises an anti-TNF-α monoclonal antibody or antibody fragment thereof. In some embodiments, the antibody or antibody fragment thereof comprises an anti-TNF-α human monoclonal antibody or antibody fragment thereof. In some embodiments, the antibody or antibody fragment thereof comprises golimumab or an antibody fragment thereof.
[0955]
[0894] As used herein, the term "golimumab" refers to a human monoclonal antibody that targets TNF-α. In some embodiments, the anti-TNF-α human monoclonal antibody or antibody fragment thereof acts as a TNF-α inhibitor. In some embodiments, the anti-TNF-α human monoclonal antibody or antibody fragment thereof functions as an effective modulator of inflammatory markers and bone metabolism. In some embodiments, the anti-TNF-α human monoclonal antibody or antibody fragment thereof is used as an immunosuppressive pharmaceutical.
[0956] In some embodiments, the anti-TNF-α human monoclonal antibody or antibody fragment thereof is SKLQVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS (SEQ ID NO: 10) The heavy chain comprises a sequence of
[0957]
[0897] In some embodiments, the anti-TNF-α human monoclonal antibody or antibody fragment thereof comprises a heavy chain comprising the sequence identified by Pubmed as PDB:5YOY_R.
[0958] In some embodiments, the anti-TNF-α human monoclonal antibody or antibody fragment thereof is AGSEIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIKTSENLYFQ (SEQ ID NO: 11) and a light chain comprising the sequence:
[0959]
[0899] In some embodiments, the anti-TNF-α human monoclonal antibody or antibody fragment thereof comprises a light chain comprising the sequence identified by Pubmed as PDB:5YOY_O.
[0960] In some embodiments, the antibody or antibody fragment thereof comprises an anti-integrin α4β1 antibody or antibody fragment thereof. In some embodiments, the antibody or antibody fragment thereof comprises an anti-integrin α4β1 monoclonal antibody or antibody fragment thereof. In some embodiments, the antibody or antibody fragment thereof comprises natalizumab or an antibody fragment thereof.
[0961]
[0901] As used herein, the term "natalizumab" refers to a monoclonal antibody that targets integrin α4β1. In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof targets integrin α4β1 on leukocytes involved in inflammation. In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof binds to the integrin, thereby stopping leukocyte invasion into brain and spinal cord tissues by reducing inflammation and resulting neuronal damage. In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof works by reducing the ability of inflammatory immune cells to adhere to and cross the inner wall cell layers of the gut and blood-brain barrier. In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof is used to treat symptoms of both gut and blood-brain barrier disease, thereby preventing relapses, blindness, and cognitive decline. In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof is used to treat multiple sclerosis and Crohn's disease. In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof increases the remission rate and prevents relapses in multiple sclerosis.
[0962] In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof is QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDEAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVE (SEQ ID NO: 12) The heavy chain comprises a sequence of
[0963] In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof is QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDEAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPENLYFQ (SEQ ID NO: 13) The heavy chain comprises a sequence of
[0964]
[0905] In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof comprises a heavy chain comprising the sequence identified by Pubmed as PDB:4IRZ_H. In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof is DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR (SEQ ID NO: 14) and a light chain comprising the sequence:
[0965] In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof is DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG (SEQ ID NO: 15) and a light chain comprising the sequence:
[0966]
[0908] In some embodiments, the anti-integrin α4β1 antibody or antibody fragment thereof comprises a light chain comprising the sequence identified by Pubmed as PDB:4IRZ_L. In some embodiments, the antibody or antibody fragment thereof comprises an anti-integrin α4β7 antibody or antibody fragment thereof. In some embodiments, the antibody or antibody fragment thereof comprises an anti-integrin α4β7 monoclonal antibody or antibody fragment thereof. In some embodiments, the antibody or antibody fragment thereof comprises vedolizumab or its antibody fragment.
[0967]
[0910] As used herein, the term "vedolizumab" refers to a monoclonal antibody that targets integrin α4β7. In some embodiments, the anti-integrin α4β7 antibody or antibody fragment thereof provides gut-selective anti-inflammatory activity as a result of blocking integrin α4β7. In some embodiments, the anti-integrin α4β7 antibody or antibody fragment thereof is used to treat ulcerative colitis and Crohn's disease.
[0968] In some embodiments, the anti-integrin α4β7 antibody or antibody fragment thereof is QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 16) The heavy chain comprises a sequence of
[0969] In some embodiments, the anti-integrin α4β7 antibody or antibody fragment thereof is DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 17) and a light chain comprising the sequence:
[0970] In some embodiments, the antibody or antibody fragment thereof comprises a fragment of an anti-TNF-α antibody. In some embodiments, the antibody or antibody fragment thereof comprises a fragment of an anti-TNF-α monoclonal antibody. In some embodiments, the antibody or antibody fragment thereof comprises certolizumab pegol.
[0971]
[0915] As used herein, the term "certolizumab pegol" refers to a fragment of a monoclonal antibody specific for TNF-α.
[0916] In some embodiments, fragments of anti-TNF-α antibodies are used to treat Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
[0972] In some embodiments, the fragment of an anti-TNF-α antibody is EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCAA (SEQ ID NO: 18) The heavy chain comprises a sequence of
[0973] In some embodiments, the fragment of an anti-TNF-α antibody is DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 19) and a light chain comprising the sequence:
[0974] In some embodiments, the therapeutic agent, or antibody or antibody fragment is (i) a sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO:1 or SEQ ID NO:24, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 99.9% sequence identity to the sequence of SEQ ID NO:2, (ii) a sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, or at least 60%, 65%, 70%, to the sequence of SEQ ID NO:6 or SEQ ID NO:7, (iii) a sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 8, SEQ ID NO: 9 (iv) a sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 10, or a combination thereof;9% sequence identity, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, (vi) a sequence with 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO:14 or SEQ ID NO:15, or any combination thereof; 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 17, a sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 60% to the sequence of SEQ ID NO: 18. , 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 19, a sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof.
[0975]
[0920] In some embodiments, the therapeutic agent comprises (i) the sequence of SEQ ID NO:1 or SEQ ID NO:24, the sequence of SEQ ID NO:2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO:8, the sequence of SEQ ID NO:9, or a combination thereof; (iv) the sequence of SEQ ID NO:10, the sequence of SEQ ID NO:11, or a combination thereof; (v) the sequence of SEQ ID NO:12 or SEQ ID NO:13, the sequence of SEQ ID NO:14 or SEQ ID NO:15, or any combination thereof; (vi) the sequence of SEQ ID NO:16, the sequence of SEQ ID NO:17, or a combination thereof; or (vii) the sequence of SEQ ID NO:18, the sequence of SEQ ID NO:19, or a combination thereof.
[0976]
[0921] In some embodiments, the therapeutic agent comprises (i) the sequence of SEQ ID NO:1 or SEQ ID NO:24, and the sequence of SEQ ID NO:2; (ii) the sequence of SEQ ID NO:3 and the sequence of SEQ ID NO:6, the sequence of SEQ ID NO:4 and the sequence of SEQ ID NO:6, or the sequence of SEQ ID NO:5 and the sequence of SEQ ID NO:7; (iii) the sequence of SEQ ID NO:8 and the sequence of SEQ ID NO:9; (iv) the sequence of SEQ ID NO:10 and the sequence of SEQ ID NO:11; (v) the sequence of SEQ ID NO:12 and the sequence of SEQ ID NO:14, or the sequence of SEQ ID NO:13 and the sequence of SEQ ID NO:15; (vi) the sequence of SEQ ID NO:16 and the sequence of SEQ ID NO:17; or (vii) the sequence of SEQ ID NO:18 and the sequence of SEQ ID NO:19.
[0977] As used herein, "TNF-α," also known as tumor necrosis factor alpha, TNF, DIF, TNF-alpha, TNFA, TNFSF2, tumor necrosis factor, and TNLG1F, refers to a member of the TNF superfamily, which consists of diverse transmembrane proteins with homologous TNF domains. In some embodiments, TNF-α as an adipokine promotes insulin resistance and is associated with obesity-induced type 2 diabetes. In some embodiments, TNF-α as a cytokine is used by the immune system for intracellular signaling. As used herein, TNF-α includes any recombinant or naturally occurring form of TNF-α or a variant or homolog thereof that has or maintains TNF-α activity (e.g., at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% activity). In some aspects, the variant or homolog has at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a portion of 50, 100, 150, or 200 contiguous amino acids) compared to naturally occurring TNF-α. In some embodiments, the TNF-α is substantially identical to a protein identified by UniProt reference number P01375, or a variant or homolog having substantial identity thereto.
[0978] As used herein, "IL-12," also known as interleukin-12, refers to a heterodimeric cytokine encoded by two separate genes, IL-12A (p35) and IL-12B (p40). In some embodiments, IL-12 is naturally produced by dendritic cells, macrophages, neutrophils, and human B lymphoblastoid cells in response to antigenic stimulation. IL-12 belongs to the IL-12 family, which includes heterodimeric cytokines including IL-12, IL-23, IL-27, and IL-35. As used herein, "IL-12A" includes any recombinant or naturally occurring form of IL-12A or a variant or homolog thereof that has or maintains IL-12A activity (e.g., at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% activity). In some embodiments, the variant or homolog has at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a portion of 50, 100, 150, or 200 contiguous amino acids) compared to naturally occurring IL-12A. In some embodiments, the IL-12A is substantially identical to a protein identified by UniProt reference number P29459, or a variant or homolog having substantial identity thereto. As used herein, "IL-12B" includes any recombinant or naturally occurring form of IL-12B or a variant or homolog thereof that has or maintains IL-12B activity (e.g., at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% activity).In some aspects, the variant or homolog has at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a portion of 50, 100, 150, or 200 contiguous amino acids) compared to naturally occurring IL-12B. In some embodiments, the IL-12B is substantially identical to a protein identified by UniProt reference number P29460, or a variant or homolog having substantial identity thereto.
[0979] As used herein, "IL-23," also known as interleukin-23, refers to a heterodimeric cytokine composed of the IL-12B (IL-12p40) and IL-23A (IL-23p19) subunits. IL-23 belongs to the IL-12 family of cytokines. In some embodiments, IL-23 is a proinflammatory cytokine that plays a key role in the maintenance and expansion of type 17 helper T cells (Th17 cells). As used herein, "IL-23A" includes any recombinant or naturally occurring form of IL-23A or a variant or homolog thereof that has or maintains IL-23A activity (e.g., at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% activity). In some aspects, variants or homologs have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a portion of 50, 100, 150, or 200 contiguous amino acids) compared to naturally occurring IL-23A. In some embodiments, the IL-23A is substantially identical to a protein identified by UniProt reference number Q9NPF7, or a variant or homolog having substantial identity thereto.
[0980] As used herein, "integrin α4β1," also known as VLA-4 (very late antigen-4), refers to an integrin dimer composed of CD49d (alpha 4) and CD29 (beta 1). As used herein, "integrin α4" includes any recombinant or naturally occurring form of integrin α4 or a variant or homolog thereof that has or maintains integrin α4 activity (e.g., at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% activity). In some aspects, the variant or homolog has at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a portion of 50, 100, 150, or 200 contiguous amino acids) compared to naturally occurring integrin alpha 4. In some embodiments, the integrin alpha 4 is substantially identical to a protein identified by UniProt reference number P13612, or a variant or homolog having substantial identity thereto. As used herein, "integrin β1" includes any recombinant or naturally occurring form of integrin β1 or a variant or homolog thereof that has or maintains integrin β1 activity (e.g., at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% activity). In some embodiments, the variant or homolog has at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a portion of 50, 100, 150, or 200 contiguous amino acids) compared to naturally occurring integrin β1.In some embodiments, the integrin β1 is substantially identical to the protein identified by UniProt reference number P05556, or a variant or homologue having substantial identity thereto.
[0981] As used herein, "integrin α4β7," also known as LPAM-1, LPAM-1 (lymphocyte Peyer's patch adhesion molecule 1), a dimer of integrin alpha 4 and integrin beta 7, refers to an integrin dimer composed of CD49d (alpha 4) and beta 7. As used herein, "integrin β7" includes any recombinant or naturally occurring form of integrin β1 or a variant or homolog thereof that has or maintains integrin β7 activity (e.g., at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% activity). In some aspects, the variant or homolog has at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a portion of 50, 100, 150, or 200 contiguous amino acids) compared to naturally occurring integrin β7. In some embodiments, the integrin β7 is substantially identical to a protein identified by UniProt reference number P26010, or a variant or homolog having substantial identity thereto.
[0982]
[0927] In some embodiments, the antibody or antibody fragment includes a polypeptide having a designated sequence or a sequence that is substantially identical or similar thereto, for example, a sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% or more identical to the designated sequence.
[0983] As used herein, the terms "homology" and "sequence identity" are used interchangeably and refer to the subunit sequence identity between two polypeptide molecules. The percent identity between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap. Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In some embodiments, percent identity between two amino acid sequences is determined using the algorithm by Needleman and Wunsch ((1970), J. Mol. Biol., 48:444-453), as incorporated into the GAP program in the GCG software package (available at http: / / www.gcg.com), using a Blosum 62 matrix or a PAM250 matrix, and gap weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6. In some embodiments, percent identity between two amino acid or nucleotide sequences may be determined using the algorithm by E. Meyers and W. Miller ((1989), CABIOS, 4:11-17), as incorporated into the ALIGN program (version 2.0), using a PAM120 weighted residue table with a gap length penalty of 12 and a gap penalty of 4. In some embodiments, percent identity may be determined using the "BLAST" program, a publicly available online homology algorithm at http: / / www.ncbi.nlm.nih.gov / BLAST / .
[0984]
[0929] The nucleic acid molecules described herein may be vectors, expression vectors, inhibitory nucleic acids, aptamers, template molecules or cassettes (e.g., for gene editing), or targeting molecules (e.g., for CRISPR-Cas technology), or any other natural or synthetic nucleic acid molecule intended for delivery to an organism.
[0985] As used herein, the term "unsubstituted" means that a specified group does not bear any substituents. Unless otherwise indicated, as used herein, the term "substituted" may refer to the individual and independent replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent.
[0986]
[0931] In any of the embodiments, the drug may be designed to treat a local tissue, e.g., the intestinal mucosa, or may be designed to treat a distant tissue, e.g., the liver, or may be designed to treat the systemic circulation.
[0987]
[0932] In some embodiments, compositions described herein, e.g., compositions comprising an ionic liquid and a drug, can further comprise a pharmaceutically acceptable excipient. Suitable excipients include, for example, water, saline, glycerol, ethanol, and the like, and combinations thereof. In addition, if desired, the composition can contain minor amounts of additional excipients, such as emulsifiers, surfactants, pH buffers, and the like, that enhance the effectiveness of the drug.
[0988]
[0933] In some embodiments, compositions comprising ionic liquids may be further encapsulated within dosage forms designed to facilitate delivery to an organism. Non-limiting examples of such dosage forms include capsules, tablets, or syrups.
[0989]
[0934] In some embodiments, the formulation may require excipients such as sugars, such as lactose; starches, such as corn starch; cellulose, cellulose derivatives, such as sodium carboxymethylcellulose; gelatin; and other compatible substances commonly considered in pharmaceutical formulations.
[0990]
[0935] As used herein, the term "effective amount" refers to the amount of a composition required to alleviate at least one or more symptoms of a disease or disorder, and relates to a sufficient amount of a pharmacological composition to produce the desired effect.
[0991]
[0936] In some embodiments, the composition comprises:
[0992] [ka]
[0993] of,
[0994] [ka]
[0995] In some embodiments, the composition has a molar ratio of from about 1:1 to about 1:164.
[0996] [ka]
[0997] of,
[0998] [ka]
[0999] the molar ratio to the compound is about 1:1 to about 1:500, about 1:1 to about 1:499, about 1:1 to about 1:498, about 1:1 to about 1:497, about 1:1 to about 1:496, about 1:1 to about 1:495, about 1:1 to about 1:494, about 1:1 to about 1:493, about 1:1 to about 1:492, about 1:1 to about 1:491, about 1:1 to about 1:490, about 1:1 to about 1:489, about 1:1 to about 1:488, about 1:1 to about 1:487, about 1:1 to about 1:486, about 1:1 to about 1:485, about 1:1 to about 1:484, about 1:1 to about 1:483, about 1:1 to about 1:482, about 1:1 to about 1:481, About 1:1 to about 1:480, about 1:1 to about 1:479, about 1:1 to about 1:478, about 1:1 to about 1:477, about 1:1 to about 1:476, about 1:1 to about 1:475, about 1:1 to about 1:474, about 1:1 to about 1:473, about 1:1 to about 1:472, about 1:1 to about 1:471, about 1:1 to about 1:470, about 1:1 to about 1:469, about 1:1 to about 1:468, about 1:1 to about 1:467, about 1:1 to about 1:466, about 1:1 to about 1:465, about 1:1 to about 1:464, about 1:1 to about 1:463, about 1:1 to about 1:462, about 1:1 to about 1:461, about 1:1 to about 1: 460, about 1:1 to about 1:459, about 1:1 to about 1:458, about 1:1 to about 1:457, about 1:1 to about 1:456, about 1:1 to about 1:455, about 1:1 to about 1:454, about 1:1 to about 1:453, about 1:1 to about 1:452, about 1:1 to about 1:451, about 1:1 to about 1:450, About 1:1 to about 1:449, about 1:1 to about 1:448, about 1:1 to about 1:447, about 1:1 to about 1:446, about 1:1 to about 1:445, about 1:1 to about 1:444, about 1:1 to about 1:443, about 1:1 to about 1:442, about 1:1 to about 1:441, about 1:1 to about 1:440, about 1:1 to about 1:439, about 1:1 to about 1:438, about 1:1 to about 1:437, about 1:1 to about 1:436, about 1:1 to about 1:435, about 1:1 to about 1:434, about 1:1 to about 1:433, about 1:1 to about 1:432, about 1:1 to about 1:431, about 1:1 to about 1:430, about 1:1 to about 1: 429, about 1:1 to about 1:428, about 1:1 to about 1:427, about 1:1 to about 1:426, about 1:1 to about 1:425, about 1:1 to about 1:424, about 1:1 to about 1:423, about 1:1 to about 1:422, about 1:1 to about 1:421, about 1:1 to about 1:420, about 1:1 to about 1:419,about 1:1 to about 1:418, about 1:1 to about 1:417, about 1:1 to about 1:416, about 1:1 to about 1:415, about 1:1 to about 1:414, about 1:1 to about 1:413, about 1:1 to about 1:412, about 1:1 to about 1:411, about 1:1 to about 1:410, about 1:1 to about 1:409, about 1:1 to about 1:408, about 1:1 to about 1:407, about 1:1 to about 1:406, about 1:1 to about 1:405, about 1:1 to about 1:404, about 1:1 to about 1:403, about 1:1 to about 1:402, about 1:1 to about 1:401, about 1:1 to about 1:400, about 1:1 to about 1:399, about 1:1 to about 1:398, about 1:1 to about 1:397, about 1:1 to about 1:396, about 1:1 to about 1:395, about 1:1 to about 1:394, about 1:1 to about 1:393, about 1:1 to about 1:392, about 1:1 to about 1:391, about 1:1 to about 1:390, about 1:1 to about 1:389, about 1:1 to about 1:388, about 1:1 to about 1:387, about 1:1 to about 1:386, about 1:1 to about 1:385, about 1:1 to about 1:384, about 1:1 to about 1:383, about 1:1 to about 1:382, about 1:1 to about 1:381, about 1:1 to about 1:380, about 1:1 to about 1:379, about 1:1 to about 1:378, about 1:1 to about 1:377, about 1:1 to about 1:376, about 1:1 to about 1:375, about 1:1 to about 1:374, about 1:1 to about 1:373, about 1:1 to about 1:372, about 1:1 to about 1:371, about 1:1 to about 1:370, about 1:1 to about 1:369, about 1:1 to about 1:368, about 1:1 to about 1:367, about 1:1 to about 1:366, about 1:1 to about 1:365, About 1:1 to about 1:364, about 1:1 to about 1:363, about 1:1 to about 1:362, about 1:1 to about 1:361, about 1:1 to about 1:360, about 1:1 to about 1:359, about 1:1 to about 1:358, about 1:1 to about 1:357, about 1:1 to about 1:356, about 1:1 to about 1:355, about 1:1 to about 1:354, about 1:1 to about 1:353, about 1:1 to about 1:352, about 1:1 to about 1:351, about 1:1 to about 1:350, about 1:1 to about 1:349, about 1:1 to about 1:348, about 1:1 to about 1:347, about 1:1 to about 1:346, about 1:1 to about 1:345, about 1:1 to about 1:3 44, about 1:1 to about 1:343, about 1:1 to about 1:342, about 1:1 to about 1:341, about 1:1 to about 1:340, about 1:1 to about 1:339, about 1:1 to about 1:338, about 1:1 to about 1:337, about 1:1 to about 1:336, about 1:1 to about 1:335, about 1:1 to about 1:334, about 1:1 to about 1:333, about 1:1 to about 1:332, about 1:1 to about 1:331, about 1:1 to about 1:330, about 1:1 to about 1:329, about 1:1 to about 1:328, about 1:1 to about 1:327, about 1:1 to about 1:326, about 1:1 to about 1:325, about 1:1 to about 1:324, about 1:1 to about 1:323, about 1:1 to about 1:322, about 1:1 to about 1:321, about 1:1 to about 1:320, about 1:1 to about 1:319, about 1:1 to about 1:318, about 1:1 to about 1:317, about 1:1 to about 1:316, about 1:1 to about 1:315, about 1:1 to about 1:314, about 1:1 to about 1:31 3, about 1:1 to about 1:312, about 1:1 to about 1:311, about 1:1 to about 1:310, about 1:1 to about 1:309, about 1:1 to about 1:308, about 1:1 to about 1:307, about 1:1 to about 1:306, about 1:1 to about 1:305, about 1:1 to about 1:304, about 1:1 to about 1:303, about 1: 1 to about 1:302, about 1:1 to about 1:301, about 1:1 to about 1:300, about 1:1 to about 1:299, about 1:1 to about 1:298, about 1:1 to about 1:297, about 1:1 to about 1:296, about 1:1 to about 1:295, about 1:1 to about 1:294, about 1:1 to about 1:293, about 1:1 to about 1 :292, about 1:1 to about 1:291, about 1:1 to about 1:290, about 1:1 to about 1:289, about 1:1 to about 1:288, about 1:1 to about 1:287, about 1:1 to about 1:286, about 1:1 to about 1:285, about 1:1 to about 1:284, about 1:1 to about 1:283, about 1:1 to about 1:282,about 1:1 to about 1:281, about 1:1 to about 1:280, about 1:1 to about 1:279, about 1:1 to about 1:278, about 1:1 to about 1:277, about 1:1 to about 1:276, about 1:1 to about 1:275, about 1:1 to about 1:274, about 1:1 to about 1:273, about 1:1 to about 1:272, about 1:1 to about 1:271, about 1:1 to about 1:270, about 1:1 to about 1:269, about 1:1 to about 1:268, about 1: 1 to about 1:267, about 1:1 to about 1:266, about 1:1 to about 1:265, about 1:1 to about 1:264, about 1:1 to about 1:263, about 1:1 to about 1:262, about 1:1 to about 1:261, about 1:1 to about 1:260, about 1:1 to about 1:259, about 1:1 to about 1:258, about 1:1 to about 1:257, about 1:1 to about 1:256, about 1:1 to about 1:255, about 1:1 to about 1:254, about 1:1 to about 1:253, about 1:1 to about 1:252, about 1:1 to about 1:251, about 1:1 to about 1:250, about 1:1 to about 1:249, about 1:1 to about 1:248, about 1:1 to about 1:247, about 1:1 to about 1:246, about 1:1 to about 1:245, about 1:1 to about 1:244, about 1:1 to about 1:243, about 1:1 to about 1:242, about 1:1 to about 1:241, about 1:1 to about 1:240, about 1:1 to about 1:2 39, about 1:1 to about 1:238, about 1:1 to about 1:237, about 1:1 to about 1:236, about 1:1 to about 1:235, about 1:1 to about 1:234, about 1:1 to about 1:233, about 1:1 to about 1:232, about 1:1 to about 1:231, about 1:1 to about 1:230, about 1:1 to about 1:229, about 1:1 to about 1:228, about 1:1 to about 1:227, about 1:1 to about 1:226, about 1:1 to about 1:225, About 1:1 to about 1:224, about 1:1 to about 1:223, about 1:1 to about 1:222, about 1:1 to about 1:221, about 1:1 to about 1:220, about 1:1 to about 1:219, about 1:1 to about 1:218, about 1:1 to about 1:217, about 1:1 to about 1:216, about 1:1 to about 1:215, about 1:1 to about 1:214, about 1:1 to about 1:213, about 1:1 to about 1:212, about 1:1 to about 1:211, about 1:1 to about 1:210, about 1:1 to about 1:209, about 1:1 to about 1:208, about 1:1 to about 1:207, about 1:1 to about 1:206, about 1:1 to about 1:205, about 1:1 to about 1:2 04, about 1:1 to about 1:203, about 1:1 to about 1:202, about 1:1 to about 1:201, about 1:1 to about 1:200, about 1:1 to about 1:199, about 1:1 to about 1:198, about 1:1 to about 1:197, about 1:1 to about 1:196, about 1:1 to about 1:195, about 1:1 to about 1:194, about 1:1 to about 1:193, about 1:1 to about 1:192, about 1:1 to about 1:191, about 1:1 to about 1:190, about 1:1 to about 1:189, about 1:1 to about 1:188, about 1:1 to about 1:187, about 1:1 to about 1:186, about 1:1 to about 1:185, about 1:1 to about 1:184, about 1:1 to about 1:183, about 1:1 to about 1:182, about 1:1 to about 1:181, about 1:1 to about 1:180, about 1:1 to about 1:179, about 1:1 to about 1:178, about 1:1 to about 1:177, about 1:1 to about 1:176, about 1:1 to about 1:175, about 1:1 to about 1:174, about 1:1 to about 1:17 3, about 1:1 to about 1:172, about 1:1 to about 1:171, about 1:1 to about 1:170, about 1:1 to about 1:169, about 1:1 to about 1:168, about 1:1 to about 1:167, about 1:1 to about 1:166, about 1:1 to about 1:165, about 1:1 to about 1:164, about 1:1 to about 1:163, about 1: 1 to about 1:162, about 1:1 to about 1:161, about 1:1 to about 1:160, about 1:1 to about 1:159, about 1:1 to about 1:158, about 1:1 to about 1:157, about 1:1 to about 1:156, about 1:1 to about 1:155, about 1:1 to about 1:154, about 1:1 to about 1:153, about 1:1 to about 1 :152, about 1:1 to about 1:151, about 1:1 to about 1:150, about 1:1 to about 1:149, about 1:1 to about 1:148, about 1:1 to about 1:147, about 1:1 to about 1:146, about 1:1 to about 1:145, about 1:1 to about 1:144, about 1:1 to about 1:143, about 1:1 to about 1:142,about 1:1 to about 1:141, about 1:1 to about 1:140, about 1:1 to about 1:139, about 1:1 to about 1:138, about 1:1 to about 1:137, about 1:1 to about 1:136, about 1:1 to about 1:135, about 1:1 to about 1:134, about 1:1 to about 1:133, about 1:1 to about 1:132, about 1:1 to about 1:131, about 1:1 to about 1:130, about 1:1 to about 1:129, about 1:1 to about 1:128, about 1:1 to about 1:127, about 1:1 to about 1:126, about 1:1 to about 1:125, about 1:1 to about 1:124, about 1:1 to about 1:123, about 1:1 to about 1:122, about 1:1 to about 1:1 21, about 1:1 to about 1:120, about 1:1 to about 1:119, about 1:1 to about 1:118, about 1:1 to about 1:117, about 1:1 to about 1:116, about 1:1 to about 1:115, about 1:1 to about 1:114, about 1:1 to about 1:113, about 1:1 to about 1:112, about 1:1 to about 1:111, about 1 :1 to about 1:110, about 1:1 to about 1:109, about 1:1 to about 1:108, about 1:1 to about 1:107, about 1:1 to about 1:106, about 1:1 to about 1:105, about 1:1 to about 1:104, about 1:1 to about 1:103, about 1:1 to about 1:102, about 1:1 to about 1:101, about 1:1 to about 1 :100, about 1:1 to about 1:99, about 1:1 to about 1:98, about 1:1 to about 1:97, about 1:1 to about 1:96, about 1:1 to about 1:95, about 1:1 to about 1:94, about 1:1 to about 1:93, about 1:1 to about 1:92, about 1:1 to about 1:91, about 1:1 to about 1:90, about 1:1 to about 1:89 , about 1:1 to about 1:88, about 1:1 to about 1:87, about 1:1 to about 1:86, about 1:1 to about 1:85, about 1:1 to about 1:84, about 1:1 to about 1:83, about 1:1 to about 1:82, about 1:1 to about 1:81, about 1:1 to about 1:80, about 1:1 to about 1:79, about 1:1 to about 1:78, about 1: 1 to about 1:77, about 1:1 to about 1:76, about 1:1 to about 1:75, about 1:1 to about 1:74, about 1:1 to about 1:73, about 1:1 to about 1:72, about 1:1 to about 1:71, about 1:1 to about 1:70, about 1:1 to about 1:69, about 1:1 to about 1:68, about 1:1 to about 1:67, about 1:1 to about 1 :66, about 1:1 to about 1:65, about 1:1 to about 1:64, about 1:1 to about 1:63, about 1:1 to about 1:62, about 1:1 to about 1:61, about 1:1 to about 1:60, about 1:1 to about 1:59, about 1:1 to about 1:58, about 1:1 to about 1:57, about 1:1 to about 1:56, about 1:1 to about 1:55,about 1:1 to about 1:54, about 1:1 to about 1:53, about 1:1 to about 1:52, about 1:1 to about 1:51, about 1:1 to about 1:50, about 1:1 to about 1:49, about 1:1 to about 1:48, about 1:1 to about 1:47, about 1:1 to about 1:46, about 1:1 to about 1:45, about 1:1 to about 1:44, about 1:1 to about 1:43, about 1:1 to about 1:42, about 1 1:1 to about 1:41, about 1:1 to about 1:40, about 1:1 to about 1:39, about 1:1 to about 1:38, about 1:1 to about 1:37, about 1:1 to about 1:36, about 1:1 to about 1:35, about 1:1 to about 1:34, about 1:1 to about 1:33, about 1:1 to about 1:32, about 1:1 to about 1:31, about 1:1 to about 1:30, about 1:1 to about 1:29, about 1:1 to about 1:28, about 1:1 to about 1:27, about 1:1 to about 1:26, about 1:1 to about 1:25, about 1:1 to about 1:24, about 1:1 to about 1:23, about 1:1 to about 1:22, about 1:1 to about 1:21, about 1:1 to about 1:20, about 1:1 to about 1:19, about 1:1 to about 1:18, about 1:1 to about 1:17, about 1:1 to about 1:16, about 1:1 to about 1:15, about 1:1 to about 1:14, about 1:1 to about 1:13, about 1:1 to about 1:12, about 1:1 to about 1:11, about 1:1 to about 1:10, about 1:1 to about 1:9, about 1:1 to about 1:8, about 1:1 to about 1:7, about 1:1 to about 1:6, about 1:1 to about 1:5, about 1:1 to about 1:4, about 1:1 to about 1:3, or about 1:1 to about 1:2.
[1000]
[0937] In some embodiments, the composition comprises:
[1001] [ka]
[1002] of,
[1003] [ka]
[1004] about 1:479, about 1:478, about 1:477, about 1:476, about 1:475, about 1:474, about 1:473, about 1:472, about 1:471, about 1:470, about 1:469, about 1:468, about 1:467, about 1:474, about 1:475, about 1:476, about 1:478, about 1:479, about 1:478, about 1:477, about 1:476, about 1:475, about 1:474, about 1:475, about 1:476, about 1:478, about 1:479, about 1:478, about 1:479, about 1:478, about 1:479, about 1:476, about 1:475, about 1:474, about 1:475, about 1:476, about 1:478, about 1:479 ... :466, approximately 1:465, approximately 1:464, approximately 1:463, approximately 1:462, approximately 1:461, approximately 1:460, approximately 1:459, approximately 1:458, approximately 1:457, approximately 1:456, approximately 1:455, approximately 1:454, approximately 1:453, approximately 1:452, approximately 1:451, approximately 1:450, approximately 1:449, Approximately 1:448, approximately 1:447, approximately 1:446, approximately 1:445, approximately 1:444, approximately 1:443, approximately 1:442, approximately 1:441, approximately 1:440, approximately 1:439, approximately 1:438, approximately 1:437, approximately 1:436, approximately 1:435, approximately 1:434, approximately 1:433, approximately 1:432, approximately 1:431 , about 1:430, about 1:429, about 1:428, about 1:427, about 1:426, about 1:425, about 1:424, about 1:423, about 1:422, about 1:421, about 1:420, about 1:419, about 1:418, about 1:417, about 1:416, about 1:415, about 1:414, about 1:4 13, approx. 1:412, approx. 1:411, approx. 1:410, approx. 1:409, approx. 1:408, approx. 1:407, approx. 1:406, approx. 1:405, approx. 1:404, approx. 1:403, approx. 1:402, approx. 1:401, approx. 1:400, approx. 1:399, approx. 1:398, approx. 1:397, approx. 1:396, approx. 1: 395, approx. 1:394, approx. 1:393, approx. 1:392, approx. 1:391, approx. 1:390, approx. 1:389, approx. 1:388, approx. 1:387, approx. 1:386, approx. 1:385, approx. 1:384, approx. 1:383, approx. 1:382, approx. 1:381, approx. 1:380, approx. 1:379, approx....
Claims
1. Formula I: 【Chemical 1】 [In the formula, R 1 , R 2 , and R 3 are independently 1 ~C 5 is alkyl; R 4 is C 2 ~C 5 alkyl, C 2 ~C 5 The alkyl is unsubstituted or substituted with one or more hydroxyl groups; R 5 is a therapeutic agent] Compounds that comply with
2. R 1 , R 2 , and R 3 The compound of claim 1 , wherein is methyl.
3. R 1 , R 2 , and R 3 The compound of claim 1 , wherein is ethyl.
4. R 1 , R 2 , and R 3 The compound of claim 1 , wherein is propyl.
5. R 1 and R 2 is methyl, and R 3 The compound of claim 1 , wherein is ethyl.
6. R 1 and R 3 is methyl, and R 2 The compound of claim 1 , wherein is ethyl.
7. R 1 and R 2 is ethyl, and R 3 The compound of claim 1 , wherein is methyl.
8. R 1 and R 3 is ethyl, and R 2 The compound of claim 1 , wherein is methyl.
9. R 1 and R 2 is propyl, and R 3 The compound of claim 1 , wherein is methyl.
10. R 1 and R 3 is propyl, and R 2 The compound of claim 1 , wherein is methyl.
11. R 4 is substituted with hydroxyl 2 ~C 5 11. The compound of any one of claims 1 to 10, wherein the compound is alkyl.
12. R 4 but, 【Chemistry 2】 12. The compound of any one of claims 1 to 11, wherein
13. Formula Ia: 【Chemistry 3】 13. The compound according to any one of claims 1 to 12, wherein the compound is according to
14. Formula Ib: 【Chemistry 4】 13. The compound according to any one of claims 1 to 12, wherein the compound is according to
15. Formula Ic: 【Chemistry 5】 13. The compound according to any one of claims 1 to 12, wherein the compound is according to
16. 16. The compound of any one of claims 1 to 15, wherein the therapeutic agent is a GLP-1 analogue or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
17. The compound of any one of claims 1 to 16, wherein the therapeutic agent is a GLP-1 analogue or a functional variant thereof, or a mimetic thereof.
18. 18. The compound of any one of claims 1 to 17, comprising the structure shown in Figure 16.
19. 【Chemical 6】 of, 【Chemistry 7】 19. The compound of any one of claims 16 to 18, wherein the molar ratio to is from about 1:1 to about 1:
60.
20. [Chemical 8] of, 【Chemistry 9】 20. The compound of any one of claims 16 to 19, wherein the molar ratio to is from about 1:1 to about 1:
30.
21. [Catalog 10] of, 【Chemistry 11】 21. The compound of any one of claims 16 to 20, wherein the molar ratio to is about 1:
1.
22. [Chemical 12] of, 【Chemistry 13】 21. The compound of any one of claims 16 to 20, wherein the molar ratio to is about 1:
3.
23.
14. of, 【Chemistry 15】 21. The compound of any one of claims 16 to 20, wherein the molar ratio to is about 1:
4.
24. 【Catalog 16】 21. The compound of any one of claims 16 to 20, wherein the molar ratio of
25. 【Catalog 17】 21. The compound of any one of claims 16 to 20, wherein the molar ratio of
26. 【Catalog 18】 21. The compound of any one of claims 16 to 20, wherein the molar ratio of
27. 【Catalog 19】 21. The compound of any one of claims 16 to 20, wherein the molar ratio of
28.
20. 21. The compound of any one of claims 16 to 20, wherein the molar ratio of
29. 16. The compound of any one of claims 1 to 15, wherein the therapeutic agent is amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof.
30. 30. The compound of any one of claims 1 to 15 and 29, wherein the therapeutic agent is an amylin analog or a functional variant thereof, or a mimetic or analog thereof.
31. The therapeutic agent, [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide 31. The compound of any one of claims 1 to 15, 29, and 30, which is an amylin analog having the sequence:
32. A compound described in any one of claims 1 to 15 and 29 to 31, wherein the therapeutic agent is an amylin analog having a structure shown in Figure 2, Figure 3, or Figure 4, or a functional variant thereof, or a mimetic or analog thereof.
33. 33. The compound of any one of claims 29 to 32, wherein the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
34. 34. The compound of any one of claims 29 to 33, wherein the therapeutic agent is an amylin analog or functional variant thereof comprising an N14E amino acid substitution, or a mimetic or analog thereof.
35. 【Catalog 21】 of, 【Chemical 22】 35. The compound of any one of claims 29 to 34, wherein the molar ratio to is from about 1:1 to about 1:
30.
36. 【Catalog 23】 of, 【Chemistry 24】 36. The compound of any one of claims 29 to 35, wherein the molar ratio to is about 1:
1.
37. 【Catalog 25】 of, 【Chemical 26】 36. The compound of any one of claims 29 to 35, wherein the molar ratio to is about 1:
3.
38. 【Catalog 27】 36. The compound of any one of claims 29 to 35, wherein the molar ratio of
39.
28. of, 【Chemical 29】 36. The compound of any one of claims 29 to 35, wherein the molar ratio to is about 1:
12. 【Request 40】 【Chemical 30】 36. The compound of any one of claims 29 to 35, wherein the molar ratio of
41. 16. The compound of any one of claims 1 to 15, wherein the therapeutic agent is an antibody or an antibody fragment thereof.
42. 42. The compound of any one of claims 1 to 15 and 41, wherein the therapeutic agent is any one selected from the group consisting of infliximab or an antibody fragment thereof, adalimumab or an antibody fragment thereof, ustekinumab or an antibody fragment thereof, golimumab or an antibody fragment thereof, natalizumab or an antibody fragment thereof, vedolizumab or an antibody fragment thereof, and certolizumab pegol or an antibody fragment thereof.
43. The therapeutic agent, (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof.
43. The compound of any one of claims 1 to 15, 41, and 42, comprising:
44. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof 44. The compound of any one of claims 1 to 15 and 41 to 43, comprising:
45. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences SEQ ID NO: 3 and SEQ ID NO: 6, the sequences SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 45. The compound of any one of claims 1 to 15 and 41 to 44, comprising:
46. 46. The compound of any one of claims 1 to 15 and 41 to 45, wherein the therapeutic agent is infliximab or an antibody fragment thereof.
47. 47. The compound of any one of claims 1 to 15 and 41 to 46, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO:
2.
48. 【Catalog 31】 of, 【Chemical 32】 48. The compound of claim 46 or 47, wherein the molar ratio of
49. 【Catalog 33】 of, 【Chemical 34】 49. The compound of any one of claims 46, 47, and 48, wherein the molar ratio to is about 1:
1.
50. 【Catalog 35】 of, 【Chemical 36】 49. The compound of any one of claims 46, 47, and 48, wherein the molar ratio to is about 1:
33.
51. 【Catalog 37】 of, 【Chemical 38】 49. The compound of any one of claims 46, 47, and 48, wherein the molar ratio to is about 1:
41.
52. 【Catalog 39】 of, 【Chemistry 40】 49. The compound of any one of claims 46, 47, and 48, wherein the molar ratio to is about 1:
66.
53. 【Catalog 41】 of, 【Chemistry 42】 49. The compound of any one of claims 46, 47, and 48, wherein the molar ratio to is about 1:
82. 【Request 54】 【Chemical 43】 of, 【Chemical 44】 49. The compound of any one of claims 46, 47, and 48, wherein the molar ratio of
55. 【Catalog 45】 of, 【Chemistry 46】 49. The compound of any one of claims 46, 47, and 48, wherein the molar ratio of
56. 46. The compound of any one of claims 1 to 15 and 41 to 45, wherein the therapeutic agent is adalimumab or an antibody fragment thereof.
57. 57. The compound of any one of claims 1 to 15, 41 to 45, and 56, wherein the therapeutic agent comprises the sequences of SEQ ID NO: 3 and SEQ ID NO: 6, the sequences of SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences of SEQ ID NO: 5 and SEQ ID NO:
7.
58.
47. of, 【Chemistry 48】 58. The compound of claim 56 or 57, wherein the molar ratio of
59. 46. The compound of any one of claims 1 to 15 and 41 to 45, wherein the therapeutic agent is ustekinumab or an antibody fragment thereof.
60. 60. The compound of any one of claims 1 to 15, 41 to 45, and 59, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO:
9.
61.
49. of, 【Chemistry 50】 61. The compound of claim 59 or 60, wherein the molar ratio to is from about 1:1 to about 1:
140.
62. 46. The compound of any one of claims 1 to 15 and 41 to 45, wherein the therapeutic agent is golimumab or an antibody fragment thereof.
63. 63. The compound of any one of claims 1 to 15, 41 to 45, and 62, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO:
11.
64. 【Catalog 51】 of, 【Chemistry 52】 64. The compound of claim 62 or 63, wherein the molar ratio of
65. 46. The compound of any one of claims 1 to 15 and 41 to 45, wherein the therapeutic agent is natalizumab or an antibody fragment thereof.
66. 66. The compound of any one of claims 1 to 15, 41 to 45, and 65, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO:
15.
67. 【Catalog 53】 of, 【Chemical 54】 67. The compound of claim 65 or 66, wherein the molar ratio of
68. 46. The compound of any one of claims 1 to 15 and 41 to 45, wherein the therapeutic agent is vedolizumab or an antibody fragment thereof.
69. 69. The compound of any one of claims 1 to 15, 41 to 45, and 68, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO:
17.
70. 【Chemical 55】 of, 【Chemical Formula 56】 70. The compound of claim 68 or 69, wherein the molar ratio of
71. 46. The compound of any one of claims 1 to 15 and 41 to 45, wherein the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
72. 72. The compound of any one of claims 1 to 15, 41 to 45, and 71, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO:
19. 【Request 73】 【Chemical 57】 of, 【Chemistry 58】 73. The compound of claims 71 and 72, wherein the molar ratio of
74. 74. The compound of any one of claims 41 to 73, wherein the therapeutic agent is an antibody or antibody fragment thereof comprising a [one or more choline or choline derivatives]-peptide salt formed at the C-terminus of the light chain, the C-terminus of the heavy chain, or a combination thereof.
75. The compound according to any one of claims 1 to 15, wherein the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
76. 76. The compound of any one of claims 1 to 75, wherein the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:
25.
77. 77. The compound of any one of claims 1 to 76, wherein the therapeutic agent comprises the sequence of SEQ ID NO:
25.
78. A therapeutic agent is conjugated to a residue of a C20 diacid-γ-Glu-(AEEA) with at least 75% sequence identity to the sequence of SEQ ID NO:
25. 2 78. The compound of any one of claims 1 to 77, comprising:
79. The therapeutic agent is conjugated to the residue of the sequence of SEQ ID NO: 25, C20 diacid -γ-Glu-(AEEA) 2 79. The compound of any one of claims 1 to 78, comprising:
80. The therapeutic agent is conjugated to the Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO: 25, the C20 diacid -γ-Glu-(AEEA) 2 80. The compound of any one of claims 1 to 79, comprising:
81. 【Catalog 59】 of, 【Chemistry 60】 81. The compound of any one of claims 1 to 80, wherein the molar ratio to is from about 1:1 to about 1:
20. 【Request 82】 【Chemical 61】 of, 【Hua 62】 81. The compound of any one of claims 1 to 80, wherein the molar ratio to is about 1:
1. 【Request 83】 【Chemical 63】 of, 【Hua 64】 81. The compound of any one of claims 1 to 80, wherein the molar ratio to is about 1:
2. 【Request 84】 【Chemical 65】 of, 【Hua 66】 81. The compound of any one of claims 1 to 80, wherein the molar ratio of
85.
67. of, 【Chemistry 68】 81. The compound of any one of claims 1 to 80, wherein the molar ratio of
86.
69. of, 【Chemistry 70】 81. The compound of any one of claims 1 to 80, wherein the molar ratio to is about 1:
5.
87.
71. of, 【Chemical Formula 72】 81. The compound of any one of claims 1 to 80, wherein the molar ratio to is about 1:
10. 【Request 88】 【Chemical 73】 of, 【Chemical 74】 81. The compound of any one of claims 1 to 80, wherein the molar ratio to is about 1:
20.
89. 89. A compound according to any one of claims 1 to 88, comprising a therapeutic agent having a modified structure.
90. 90. A compound according to any one of claims 1 to 89, comprising a therapeutic agent having a modified structure of choline or a choline derivative.
91. 91. The compound of any one of claims 1 to 90, comprising a therapeutic agent having a cationic moiety comprising a choline or a choline derivative.
92. 92. The compound of any one of claims 1 to 91, comprising a therapeutic agent having a cationic moiety that includes a choline or choline derivative-like residue.
93. 93. The compound of any one of claims 1 to 92, comprising a therapeutic agent comprising one or more choline or choline derivatives]-peptide derivatives formed at Glu residues, Asp residues, or combinations thereof.
94. 94. The compound of any one of claims 1 to 93, comprising a therapeutic agent comprising a linker comprising one or more gamma glutamic acid (γGlu) residues, one or more 8-amino-3,6-dioxaoctanoic acid (OEG) residues, or a combination thereof.
95. 95. The compound of any one of claims 1 to 94, comprising a therapeutic agent comprising a linker comprising one or more gamma glutamic acid (γGlu) residues.
96. 96. The compound of any one of claims 1 to 95, comprising a therapeutic agent comprising a [choline or choline derivative]-peptide salt formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
97. 97. The compound of any one of claims 1 to 96, comprising a therapeutic agent comprising a [choline or choline derivative]-peptide ester formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
98. 98. The compound of any one of claims 1 to 97, comprising a therapeutic agent comprising a diacid 10, 12, 14, 16, 18, or 20 carbons in length.
99. 99. The compound of claim 98, wherein the diacid comprises a C10, C12, C14, C16, C18, or C20 fatty diacid.
100. 100. The compound of claim 98 or 99, wherein the diacid comprises 1,20-icosane diacid.
101. Formula II: 【Chemistry 75】 [In the formula, R 6 is a therapeutic agent; R 7 , R 8 , and R 9 are independently 1 ~C 5 is alkyl; n is 1, 2, 3, 4, or 5. Compounds that comply with
102. R 7 , R 8 , and R 9 is methyl.
103. R 7 , R 8 , and R 9 is ethyl.
104. R 7 , R 8 , and R 9 is propyl.
105. R 7 and R 8 is methyl, and R 9 is ethyl.
106. R 7 and R 9 is methyl, and R 8 is ethyl.
107. R 7 and R 8 is ethyl, and R 9 is methyl.
108. R 7 and R 9 is ethyl, and R 8 is methyl.
109. R 7 and R 8 is propyl, and R 9 is methyl.
110. R 7 and R 9 is propyl, and R 8 is methyl.
111. 111. The compound of any one of claims 101 to 110, wherein n is 1.
112. Formula IIa: 【Chemical Formula 76】 112. The compound according to any one of claims 101 to 111, wherein the compound is according to
113. Formula IIb: 【Chemical 77】 112. The compound according to any one of claims 101 to 111, wherein the compound is according to
114. Formula IIc: 【Chemical 78】 112. The compound according to any one of claims 101 to 111, wherein the compound is according to
115. The compound of any one of claims 101 to 114, wherein the therapeutic agent is a GLP-1 analogue or a functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
116. 116. The compound of any one of claims 101 to 115, wherein the therapeutic agent is a GLP-1 analogue or a functional variant thereof, or a mimetic thereof.
117. 117. The compound of claim 115 or 116, comprising the structure shown in Figure 17B.
118. 115. A compound according to any one of claims 101 to 114, wherein the therapeutic agent is amylin or a mimetic or analogue thereof, or an amylin analogue or functional variant thereof, or a mimetic or analogue thereof.
119. 119. A compound according to any one of claims 101 to 114 and 118, wherein the therapeutic agent is an amylin analogue or a functional variant thereof, or a mimetic or analogue thereof.
120. The therapeutic agent, [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide 120. The compound of any one of claims 101 to 114, 118, and 119, which is an amylin analog having the sequence: or a functional variant thereof, or a mimetic or analog thereof.
121. A compound according to any one of claims 101 to 114 and 118 to 120, wherein the therapeutic agent is an amylin analogue having a structure shown in Figure 2, Figure 3, or Figure 4, or a functional variant thereof, or a mimetic or analogue thereof.
122. 122. A compound according to any one of claims 118 to 121, wherein the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
123. 123. A compound according to any one of claims 118 to 122, wherein the therapeutic agent is an amylin analogue or functional variant thereof comprising an N14E amino acid substitution, or a mimetic or analogue thereof.
124. 115. The compound of any one of claims 101 to 114, wherein the therapeutic agent is an antibody or an antibody fragment thereof.
125. 125. The compound of any one of claims 101 to 114 and 124, wherein the therapeutic agent is any one selected from the group consisting of infliximab or an antibody fragment thereof, adalimumab or an antibody fragment thereof, ustekinumab or an antibody fragment thereof, golimumab or an antibody fragment thereof, natalizumab or an antibody fragment thereof, vedolizumab or an antibody fragment thereof, and certolizumab pegol or an antibody fragment thereof.
126. The therapeutic agent, (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof.
126. The compound of any one of claims 101 to 114, 124, and 125, comprising:
127. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof 127. The compound of any one of claims 101 to 114 and 124 to 126, comprising:
128. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences SEQ ID NO: 3 and SEQ ID NO: 6, the sequences SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 128. The compound of any one of claims 101 to 114 and 124 to 127, comprising:
129. 129. The compound of any one of claims 101-114 and 124-128, wherein the therapeutic agent is infliximab or an antibody fragment thereof.
130. 130. A compound according to any one of claims 101 to 114 and 124 to 129, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO:
2.
131. 129. The compound of any one of claims 101-114 and 124-128, wherein the therapeutic agent is adalimumab or an antibody fragment thereof.
132. 132. A compound according to any one of claims 101 to 114, 124 to 128, and 131, wherein the therapeutic agent comprises the sequences of SEQ ID NO: 3 and SEQ ID NO: 6, the sequences of SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences of SEQ ID NO: 5 and SEQ ID NO:
7.
133. 129. The compound of any one of claims 101-114 and 124-128, wherein the therapeutic agent is ustekinumab or an antibody fragment thereof.
134. 134. The compound of any one of claims 101 to 114, 124 to 128, and 133, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO:
9.
135. 129. The compound of any one of claims 101-114 and 124-128, wherein the therapeutic agent is golimumab or an antibody fragment thereof.
136. 136. The compound of any one of claims 101 to 114, 124 to 128, and 135, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO:
11.
137. 129. The compound of any one of claims 101-114 and 124-128, wherein the therapeutic agent is natalizumab or an antibody fragment thereof.
138. 138. The compound of any one of claims 101 to 114, 124 to 128, and 137, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO:
15.
139. 129. The compound of any one of claims 101-114 and 124-128, wherein the therapeutic agent is vedolizumab or an antibody fragment thereof.
140. 140. The compound of any one of claims 101 to 114, 124 to 128, and 139, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO:
17.
141. 129. The compound of any one of claims 101-114 and 124-128, wherein the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
142. 142. The compound of any one of claims 101 to 114, 124 to 128, and 141, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO:
19.
143. The compound of any one of claims 101 to 142, wherein the therapeutic agent is an antibody or antibody fragment thereof comprising a [one or more choline or choline derivatives]-peptide ester formed at the C-terminus of the light chain, the C-terminus of the heavy chain, or a combination thereof.
144. The compound of any one of claims 101 to 143, wherein the therapeutic agent is an antibody or antibody fragment thereof comprising a [one or more choline or choline derivatives]-peptide ester formed at a Cys residue, a Lys residue, or any combination thereof.
145. The compound of claim 144, wherein the [one or more choline or choline derivatives]-peptide esters formed at Cys residues have a linker-to-antibody ratio of 2 to 8, and the [one or more choline or choline derivatives]-peptide esters formed at Lys residues have a linker-to-antibody ratio of 2 to 4, or a combination thereof.
146. The compound of any one of claims 101 to 114, wherein the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
147. 147. A compound according to any one of claims 101 to 146, wherein the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:
25.
148. 148. A compound according to any one of claims 101 to 147, wherein the therapeutic agent comprises the sequence of SEQ ID NO:
25.
149. A therapeutic agent is conjugated to a residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:
25. 20 Diacid-γ-Glu-(AEEA) 2 149. The compound of any one of claims 101 to 148, comprising:
150. A therapeutic agent is conjugated to a residue of the sequence of SEQ ID NO:
25. 20 Diacid-γ-Glu-(AEEA) 2 150. The compound of any one of claims 101 to 149, comprising:
151. A C16-16C16 polypeptide in which a therapeutic agent is conjugated to the Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO:
25. 20 Diacid-γ-Glu-(AEEA) 2 151. The compound of any one of claims 101 to 150, comprising:
152. A compound according to any one of claims 1 to 151, comprising a therapeutic agent having a modified structure of choline or a choline derivative.
153. 153. A compound according to any one of claims 1 to 152, comprising a therapeutic agent having a salt structure modified with choline or a choline derivative.
154. 154. The compound of any one of claims 1 to 153, comprising a therapeutic agent having a cationic moiety comprising a choline or a choline derivative.
155. 155. A compound according to any one of claims 1 to 154, comprising a therapeutic agent having an ester structure modified with choline or a choline derivative.
156. 156. The compound of any one of claims 1 to 155, comprising a therapeutic agent having a cationic moiety that includes a choline or choline derivative-like residue.
157. 157. The compound of any one of claims 1 to 156, comprising a therapeutic agent comprising a [one or more choline or choline derivatives]-peptide ester formed at a Cys residue, a Lys residue, or any combination thereof.
158. The compound of claim 157, wherein the [one or more choline or choline derivatives]-peptide ester formed at a Cys residue has a linker to therapeutic agent ratio of 2 to 8, and the [one or more choline or choline derivatives]-peptide ester formed at a Lys residue has a linker to therapeutic agent ratio of 2 to 4, or a combination thereof.
159. 159. The compound of any one of claims 1 to 158, comprising a therapeutic agent comprising a linker comprising one or more gamma glutamic acid (γGlu) residues, one or more 8-amino-3,6-dioxaoctanoic acid (OEG) residues, or a combination thereof.
160. 160. The compound of any one of claims 1 to 159, comprising a therapeutic agent comprising a linker comprising one or more gamma glutamic acid (γGlu) residues.
161. 161. The compound of any one of claims 1 to 160, comprising a therapeutic agent comprising a [choline or choline derivative]-peptide salt formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
162. 162. The compound of any one of claims 1 to 161, comprising a therapeutic agent comprising a [choline or choline derivative]-peptide ester formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
163. 163. The compound of any one of claims 101 to 162, comprising a therapeutic agent comprising a diacid 10, 12, 14, 16, 18, or 20 carbons in length.
164. The diacid is C 10 , C 12 , C 14 , C 16 , C 18 , or C 20 164. The compound of claim 163, comprising a fatty diacid of
165. 165. The compound of claim 163 or 164, wherein the diacid comprises 1,20-icosane diacid.
166. Formula III: 【Chemical 79】 [In the formula, R 10 is a therapeutic agent; R 11 is a substitution C 5 ~C 10 , or unsubstituted C 5 ~C 10 and X 1 teeth, 【Chemistry 80】 , —S—, or —NH—; L 1 is a covalent bond or a linker. Compounds that comply with
167. L 1 is a non-cleavable linker.
168. L 1 168. The compound of claim 167, wherein comprises a maleimidoalkane linker or a maleimidocyclohexane linker.
169. L 1 but, 【Chemistry 81】 169. The compound of claim 167 or 168, comprising:
170. L 1 is a chemically cleavable linker.
171. L 1 171. The compound of claim 170, wherein comprises a hydrazone linker or a disulfide linker.
172. L 1 but, 【Chemistry 82】 169. The compound of claim 167 or 168, comprising:
173. R 11 But substitution C 10 or unsubstituted C 10 173. The compound of any one of claims 166 to 172, wherein:
174. The compound according to any one of claims 166 to 173, wherein the therapeutic agent is a GLP-1 analogue or a functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
175. The compound of any one of claims 166 to 174, wherein the therapeutic agent is a GLP-1 analogue or a functional variant thereof, or a mimetic thereof.
176. 174. A compound according to any one of claims 166 to 173, wherein the therapeutic agent is amylin or a mimetic or analogue thereof, or an amylin analogue or functional variant thereof, or a mimetic or analogue thereof.
177. 177. A compound according to any one of claims 166 to 173 and 176, wherein the therapeutic agent is an amylin analogue or a functional variant thereof, or a mimetic or analogue thereof.
178. The therapeutic agent, [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide 178. A compound according to any one of claims 166 to 173, 176 and 177, which is an amylin analogue having the sequence:
179. A compound according to any one of claims 176 to 178, wherein the therapeutic agent is an amylin analogue or functional variant thereof, or a mimetic or analogue thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
180. 180. The compound of any one of claims 176 to 179, wherein the therapeutic agent is an amylin analog or functional variant thereof comprising an N14E amino acid substitution, or a mimetic or analog thereof.
181. 174. The compound of any one of claims 166 to 173, wherein the therapeutic agent is an antibody or an antibody fragment thereof.
182. The compound of any one of claims 166 to 173 and 181, wherein the therapeutic agent is any one selected from the group consisting of infliximab or an antibody fragment thereof, adalimumab or an antibody fragment thereof, ustekinumab or an antibody fragment thereof, golimumab or an antibody fragment thereof, natalizumab or an antibody fragment thereof, vedolizumab or an antibody fragment thereof, and certolizumab pegol or an antibody fragment thereof.
183. The therapeutic agent, (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof.
183. The compound of any one of claims 166 to 173, 181, and 182, comprising:
184. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof 184. The compound of any one of claims 166 to 173 and 181 to 183, comprising:
185. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences SEQ ID NO: 3 and SEQ ID NO: 6, the sequences SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 185. The compound of any one of claims 166 to 173 and 181 to 184, comprising:
186. 186. The compound of any one of claims 166-173 and 181-185, wherein the therapeutic agent is infliximab or an antibody fragment thereof.
187. A compound according to any one of claims 166 to 173 and 181 to 186, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO:
2.
188. 186. The compound of any one of claims 166-173 and 181-185, wherein the therapeutic agent is adalimumab or an antibody fragment thereof.
189. A compound described in any one of claims 166 to 173, 181 to 185, and 188, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 3 and the sequence of SEQ ID NO: 6, the sequence of SEQ ID NO: 4 and the sequence of SEQ ID NO: 6, or the sequence of SEQ ID NO: 5 and the sequence of SEQ ID NO:
7.
190. 186. The compound of any one of claims 166-173 and 181-185, wherein the therapeutic agent is ustekinumab or an antibody fragment thereof.
191. 190. A compound according to any one of claims 166 to 173, 181 to 185, and 190, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO:
9.
192. 186. The compound of any one of claims 166-173 and 181-185, wherein the therapeutic agent is golimumab or an antibody fragment thereof.
193. 192. A compound according to any one of claims 166 to 173, 181 to 185, and 192, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO:
11.
194. The compound of any one of claims 166-173 and 181-185, wherein the therapeutic agent is natalizumab or an antibody fragment thereof.
195. A compound described in any one of claims 166 to 173, 181 to 185, and 194, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO:
15.
196. 186. The compound of any one of claims 166-173 and 181-185, wherein the therapeutic agent is vedolizumab or an antibody fragment thereof.
197. 197. A compound according to any one of claims 166 to 173, 181 to 185, and 196, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO:
17.
198. 186. The compound of any one of claims 166-173 and 181-185, wherein the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
199. 199. A compound according to any one of claims 166 to 173, 181 to 185, and 198, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO:
19.
200. A therapeutic agent is linked to the C-terminus of the light chain, the C-terminus of the heavy chain, or a combination thereof. 11 200. The compound of any one of claims 166 to 199, which is an antibody or antibody fragment thereof comprising:
201. The compound of any one of claims 166 to 173, wherein the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
202. 202. A compound according to any one of claims 166 to 201, wherein the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:
25.
203. 203. A compound according to any one of claims 166 to 202, wherein the therapeutic agent comprises the sequence of SEQ ID NO:
25.
204. A therapeutic agent is conjugated to a residue of a C20 diacid-γ-Glu-(AEEA) with at least 75% sequence identity to the sequence of SEQ ID NO:
25. 2 204. The compound of any one of claims 166 to 203, comprising:
205. The therapeutic agent is conjugated to the residue of the sequence of SEQ ID NO: 25, C20 diacid -γ-Glu-(AEEA) 2 205. The compound of any one of claims 166 to 204, comprising:
206. The therapeutic agent is conjugated to the Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO: 25, the C20 diacid -γ-Glu-(AEEA) 2 206. The compound of any one of claims 166 to 205, comprising:
207. A compound according to any one of claims 166 to 206, comprising a therapeutic agent having a modified structure of choline or a choline derivative.
208. A compound according to any one of claims 166 to 207, comprising a therapeutic agent having a salt structure modified with choline or a choline derivative.
209. 209. The compound of any one of claims 166 to 208, comprising a therapeutic agent having a cationic moiety comprising a choline or a choline derivative.
210. A compound according to any one of claims 166 to 209, comprising a therapeutic agent having an ester structure modified with choline or a choline derivative.
211. 211. The compound of any one of claims 166 to 210, comprising a therapeutic agent having a cationic moiety comprising a choline or choline derivative-like residue.
212. one or more R linked to a Lys residue, a Cys residue, or any combination thereof 11 212. The compound of any one of claims 166 to 211, comprising a therapeutic agent comprising:
213. R 11 is linked to a Lys residue with a linker to therapeutic agent ratio of 2-4, or R 11 is linked to a Cys residue at a linker to therapeutic agent ratio of 2 to 8, or at a linker to therapeutic agent ratio of 4, or a combination thereof.
214. 214. A compound according to any one of claims 166 to 213, comprising a therapeutic agent comprising a dual conjugation.
215. The compound of claim 214, wherein the dual conjugation has a linker to therapeutic agent ratio of 1 to 2.
216. 216. The compound of any one of claims 166 to 215, comprising a therapeutic agent comprising a linker comprising one or more gamma glutamic acid (γGlu) residues, one or more 8-amino-3,6-dioxaoctanoic acid (OEG) residues, or a combination thereof.
217. 217. The compound of any one of claims 166 to 216, comprising a therapeutic agent comprising a linker comprising one or more gamma glutamic acid (γGlu) residues.
218. 218. The compound of any one of claims 166 to 217, comprising a therapeutic agent comprising a [choline or choline derivative]-peptide salt formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
219. 219. The compound of any one of claims 166 to 218, comprising a therapeutic agent comprising a [choline or choline derivative]-peptide ester formed at the carboxylic acid of one or more gamma glutamic acid residues of the linker.
220. 220. The compound of any one of claims 166 to 219, comprising a therapeutic agent comprising a diacid 10, 12, 14, 16, 18, or 20 carbons in length.
221. The diacid is C 10 , C 12 , C 14 , C 16 , C 18 , or C 20 221. The compound of claim 220, comprising a fatty diacid of
222. 222. The compound of claim 220 or 221, wherein the diacid comprises 1,20-icosane diacid.
223. 223. A composition comprising a compound of any one of claims 1 to 222 and one or more ionic liquids.
224. 224. The composition of claim 223, wherein the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
225. 224. The composition of claim 223, wherein the one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine.
226. The one or more ionic liquids may independently be selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid (protocatechuic acid), 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)-galactonic acid, de Canic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-asparagine Acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,The composition of any one of claims 223 to 225, comprising an anion selected from the group consisting of trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
227. 227. The composition of any one of claims 223 to 226, wherein the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydrocinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
228. 226. The composition of any one of claims 223 to 225, wherein the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
229. 229. The composition of any one of claims 223 to 228, wherein the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
230. 229. The composition of any one of claims 223-228, wherein the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
231. 229. The composition of any one of claims 223 to 228, wherein the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
232. 232. The composition of any one of claims 223 to 231, further comprising at least one penetration enhancer.
233. 233. The composition of claim 232, wherein the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
234. 234. The composition of claim 233, wherein the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof.
235. 235. The composition of any one of claims 223 to 234, further comprising at least one pharmaceutically acceptable excipient.
236. a therapeutic agent and one or more ionic liquids, wherein the therapeutic agent is (i) a GLP-1 analogue or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) a GIP / GLP-1 receptor dual agonist or a functional variant thereof The composition.
237. The composition of claim 236, wherein the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
238. 238. The composition of claim 236 or 237, wherein one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine.
239. The one or more ionic liquids may independently be selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid (protocatechuic acid), 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)-galactonic acid, de Canic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-asparagine Acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,The composition of any one of claims 236 to 238, comprising an anion selected from the group consisting of trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
240. 240. The composition of any one of claims 236 to 239, wherein the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydrocinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
241. 240. The composition of any one of claims 236 to 239, wherein the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
242. 242. The composition of any one of claims 236-241, wherein the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
243. 242. The composition of any one of claims 236-241, wherein the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
244. 242. The composition of any one of claims 236-241, wherein the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
245. 245. The composition of any one of claims 236 to 244, wherein the solubility of the therapeutic agent is increased compared to the therapeutic agent in the composition without the ionic liquid.
246. 246. The composition of any one of claims 236 to 245, wherein the delivery efficiency of the therapeutic agent in a subject in need thereof is enhanced or improved compared to the therapeutic agent in a composition without the ionic liquid when administered to the subject.
247. 247. The composition of any one of claims 236 to 246, further comprising at least one penetration enhancer.
248. 248. The composition of claim 247, wherein the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
249. The composition of claim 248, wherein the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof.
250. 249. A pharmaceutical composition comprising a compound of any one of claims 1 to 222 or a composition of any one of claims 223 to 249 and at least one pharmaceutically acceptable excipient.
251. 251. The pharmaceutical composition of claim 250, further comprising at least one penetration enhancer.
252. 252. The pharmaceutical composition of claim 251, wherein the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
253. 253. The pharmaceutical composition of claim 252, wherein the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof.
254. A method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 222, a composition of any one of claims 223 to 249, or a pharmaceutical composition of claims 250 to 253, wherein the administering is effective to treat the disease or disorder in the subject.
255. 255. The method of claim 254, wherein the disease or disorder is a metabolic disease or disorder.
256. 256. The method of claim 254 or 255, wherein the disease or disorder is diabetes.
257. 257. The method of any one of claims 254 to 256, wherein the disease or disorder is type 1 diabetes mellitus (T1DM).
258. 257. The method of any one of claims 254 to 256, wherein the disease or disorder is type 2 diabetes mellitus (T2DM).
259. 257. The method of any one of claims 254 to 256, wherein the disease or disorder is nonalcoholic steatohepatitis (NASH).
260. 256. The method of claim 254 or 255, wherein the disease or disorder is obesity or overweight.
261. 261. The method of any one of claims 254 to 260, wherein administering activates GIP receptor signaling, GLP-1 receptor signaling, or a combination thereof.
262. 262. The method of any one of claims 254 to 261, wherein administration increases or improves glucose-dependent insulin secretion, improves glucose tolerance, or a combination thereof.
263. 263. The method of any one of claims 254 to 262, wherein administration increases or improves glycemic control.
264. 264. The method of any one of claims 254 to 263, wherein administering reduces or decreases fasting serum glucose.
265. 265. The method of any one of claims 254 to 264, wherein administration results in or reduces weight loss, or reduces or reduces food intake, or a combination thereof.
266. 266. The method of any one of claims 254 to 265, wherein administration effects improvement in glycemic control, body weight, or a combination thereof.
267. 255. The method of claim 254, wherein the disease or disorder is an autoimmune disease or disorder, or an immune disease or disorder.
268. The method of claim 254 or 267, wherein the disease or disorder is Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Behcet's disease, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis, plaque psoriasis, multiple sclerosis, or eosinophilic esophagitis.
269. A method for treating obesity, preventing weight gain, or reducing weight in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 222, a composition of any one of claims 223 to 249, or a pharmaceutical composition of claims 250 to 253, wherein the administering is effective to treat a disease or disorder in the subject.
270. 269. The method of any one of claims 254 to 269, wherein the composition, compound, or pharmaceutical composition is administered via subcutaneous administration, intravenous administration, or oral administration.
271. 271. The method of any one of claims 254 to 270, wherein the composition, compound, or pharmaceutical composition is administered orally.
272. 272. The method of any one of claims 254 to 271, wherein the composition, compound, or pharmaceutical composition is administered as a liquid-filled capsule.
273. 273. The method of any one of claims 254 to 272, wherein the composition, compound, or pharmaceutical composition is administered in multiple doses.
274. 273. The method of any one of claims 254 to 272, wherein the composition, compound, or pharmaceutical composition is administered in a single dose.
275. 275. The method of any one of claims 254 to 274, wherein the composition, compound, or pharmaceutical composition is administered to a mucosa.
276. 276. The method of any one of claims 254 to 275, wherein the composition, compound, or pharmaceutical composition is administered via subcutaneous administration, intravenous administration, or oral administration.
277. 277. The method of any one of claims 254 to 276, wherein the concentration of the compound of any one of claims 101 to 222 is at least 0.1% weight per volume.
278. 278. The method of any one of claims 254 to 277, wherein the concentration of the compound of any one of claims 101 to 222 is at least 0.05M.
279. 279. The method of any one of claims 254 to 278, wherein the composition further comprises one or more additional agents.
280. 280. The method of claim 279, wherein the one or more additional agents are selected from the group consisting of nucleic acids, small molecules, and polypeptides.
281. 281. The method of claim 280, wherein the one or more additional agents are nucleic acids.
282. The method of claim 280, wherein the one or more additional agents are small molecules.
283. 281. The method of claim 280, wherein the one or more additional agents are polypeptides.
284. 281. The method of claim 280, wherein the one or more additional agents are polypeptides.
285. 285. The method of any one of claims 279 to 284, wherein the one or more additional agents are therapeutic agents that treat a metabolic disease or disorder.
286. 286. The method of any one of claims 279 to 285, wherein the one or more additional agents are therapeutic agents for treating diabetes.
287. 287. The method of any one of claims 279 to 286, wherein the one or more additional agents are therapeutic agents for treating type 2 diabetes mellitus (T2DM).
288. 286. The method of any one of claims 279 to 285, wherein the one or more additional agents are therapeutic agents for treating obesity or overweight.
289. 1. A method for increasing the solubility of a therapeutic agent, comprising: 【Chemistry 83】 [In the formula, R 1 , R 2 , and R 3 are independently 1 ~C 5 is alkyl; R 4 is C 2 ~C 5 alkyl, C 2 ~C 5 The alkyl is unsubstituted or substituted with one or more hydroxyl groups; R 5 is a therapeutic agent; The therapeutic agent is (i) a GLP-1 analogue or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; (iv) a GIP / GLP-1 receptor dual agonist or a functional variant thereof is] 20. A method comprising the step of preparing a composition comprising a compound according to claim 19.
290. 1. A method for enhancing or improving the delivery efficiency of a therapeutic agent in a subject in need thereof, comprising administering to a subject a compound of Formula I: 【Chemistry 84】 [In the formula, R 1 , R 2 , and R 3 are independently 1 ~C 5 is alkyl; R 4 is C 2 ~C 5 alkyl, C 2 ~C 5 The alkyl is unsubstituted or substituted with one or more hydroxyl groups; R 5 is a therapeutic agent; The therapeutic agent is (i) a GLP-1 analogue or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; (iv) a GIP / GLP-1 receptor dual agonist or a functional variant thereof is] 20. A method comprising the step of preparing a composition comprising a compound according to claim 19.
291. R 1 , R 2 , and R 3 The method of claim 289 or 290, wherein is methyl.
292. R 1 , R 2 , and R 3 The method of claim 289 or 290, wherein is ethyl.
293. R 1 , R 2 , and R 3 The method of claim 289 or 290, wherein is propyl.
294. R 1 and R 2 is methyl, and R 3 The method of claim 289 or 290, wherein is ethyl.
295. R 1 and R 3 is methyl, and R 2 The method of claim 289 or 290, wherein is ethyl.
296. R 1 and R 2 is ethyl, and R 3 The method of claim 289 or 290, wherein is methyl.
297. R 1 and R 3 is ethyl, and R 2 The method of claim 289 or 290, wherein is methyl.
298. R 1 and R 2 is propyl, and R 3 The method of claim 289 or 290, wherein is methyl.
299. R 1 and R 3 is propyl, and R 2 The method of claim 289 or 290, wherein is methyl.
300. R 4 is substituted with hydroxyl 2 ~C 5 300. The method of any one of claims 289 to 299, wherein the alkyl is alkyl.
301. R 4 but, 【Chemistry 85】 301. The method of any one of claims 289 to 300, wherein
302. The compound has the formula Ia: 【Chemistry 86】 302. The method of any one of claims 289 to 301, wherein the compound is according to
303. The compound has the formula Ib: 【Hua 87】 302. The method of any one of claims 289 to 301, wherein the compound is according to
304. The compound has the formula Ic: 【Hua 88】 302. The method of any one of claims 289 to 301, wherein the compound is according to
305. The method of any one of claims 289 to 304, wherein the therapeutic agent is a GLP-1 analogue or a functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
306. The method of any one of claims 289 to 305, wherein the therapeutic agent is a GLP-1 analogue or a functional variant thereof, or a mimetic thereof.
307. 307. The method of claim 305 or 306, wherein the compound comprises the structure shown in Figure 16.
308. The compound is 【Chemistry 89】 of, 【Chemistry 90】 The method of claim 305 or 306, wherein the molar ratio of is from about 1:1 to about 1:
60.
309. The compound is 【Chemistry 91】 of, 【Chemistry 92】 The method of any one of claims 305 to 308, wherein the molar ratio of
310. The compound is 【Chemistry 93】 of, 【Chemistry 94】 310. The method of any one of claims 305 to 309, wherein the molar ratio of
311. The compound is 【Chemistry 95】 of, 【Chemistry 96】 310. The method of any one of claims 305 to 309, wherein the molar ratio of
312. The compound is 【Chemistry 97】 of, 【Chemistry 98】 310. The method of any one of claims 305 to 309, wherein the molar ratio of
313. The compound is 【Hua99】 The method of any one of claims 305 to 309, wherein the molar ratio of
314. The compound is 【Chemistry 100】 The method of any one of claims 305 to 309, wherein the molar ratio of is about 1:
12.
315. The compound is 【Chemistry 101】 The method of any one of claims 305 to 309, wherein the molar ratio of
316. The compound is 【Chemistry 102】 The method of any one of claims 305 to 309, wherein the molar ratio of
317. The compound is 【Chemistry 103】 The method of any one of claims 305 to 309, wherein the molar ratio of
318. 305. The method of any one of claims 289 to 304, wherein the therapeutic agent is amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof.
319. The method of any one of claims 289 to 304 and 318, wherein the therapeutic agent is an amylin analog or a functional variant thereof, or a mimetic or analog thereof.
320. The therapeutic agent, [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide 320. The method of any one of claims 289 to 304, 318, and 319, wherein the amylin analog has the sequence:
321. The method of any one of claims 289 to 304 and 318 to 320, wherein the therapeutic agent is an amylin analog having a structure shown in Figure 2, Figure 3, or Figure 4, or a functional variant thereof, or a mimetic or analog thereof.
322. The method of any one of claims 318 to 321, wherein the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
323. 323. The method of any one of claims 318 to 322, wherein the therapeutic agent is an amylin analog or functional variant thereof comprising an N14E amino acid substitution, or a mimetic or analog thereof.
324. The compound is 【Chemistry 104】 of, 【Chemistry 105】 The method of any one of claims 318 to 323, wherein the molar ratio of
325. The compound is 【Chemistry 106】 of, 【Chemistry 107】 325. The method of any one of claims 318 to 324, wherein the molar ratio of
326. The compound is 【Chemistry 108】 of, 【Chemistry 109】 326. The method of any one of claims 318 to 325, wherein the molar ratio of
327. The compound is 【Chemistry 110】 The method of any one of claims 318 to 326, wherein the molar ratio of
328. The compound is 【Chemistry 111】 of, 【Chemistry 112】 328. The method of any one of claims 318 to 327, wherein the molar ratio of
329. The compound is 【Chemistry 113】 The method of any one of claims 318 to 328, wherein the molar ratio of
330. The method of any one of claims 289 to 304, wherein the therapeutic agent is an antibody or an antibody fragment thereof.
331. The method of any one of claims 289 to 304 and 330, wherein the therapeutic agent is any one selected from the group consisting of infliximab or an antibody fragment thereof, adalimumab or an antibody fragment thereof, ustekinumab or an antibody fragment thereof, golimumab or an antibody fragment thereof, natalizumab or an antibody fragment thereof, vedolizumab or an antibody fragment thereof, and certolizumab pegol or an antibody fragment thereof.
332. The therapeutic agent, (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof.
332. The method of any one of claims 289 to 304, 330, and 331, comprising:
333. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof 332。 The method of any one of claims 289 to 304 and 330 to 332, comprising:
334. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences SEQ ID NO: 3 and SEQ ID NO: 6, the sequences SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 333. The method of any one of claims 289 to 304 and 330 to 333, comprising:
335. The method of any one of claims 289-304 and 330-334, wherein the therapeutic agent is infliximab or an antibody fragment thereof.
336. The method of any one of claims 289 to 304 and 330 to 335, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO:
2.
337. The compound is 【Chemistry 114】 of, 【Chemistry 115】 The method of claim 335 or 336, wherein the molar ratio of is from about 1:1 to about 1:
164.
338. The compound is 【Chemistry 116】 of, 【Chemistry 117】 The method of any one of claims 335, 336, and 337, wherein the molar ratio of
339. The compound is 【Chemistry 118】 of, 【Chemistry 119】 The method of any one of claims 335, 336, and 337, wherein the molar ratio of
340. The compound is 【Chemistry 120】 of, 【Chemistry 121】 The method of any one of claims 335, 336, and 337, wherein the molar ratio of
341. The compound is 【Chemistry 122】 of, 【Chemical 123】 The method of any one of claims 335, 336, and 337, wherein the molar ratio of
342. The compound is 【Chemical 124】 of, 【Chemistry 125】 The method of any one of claims 335, 336, and 337, wherein the molar ratio of
343. The compound is 【126】 of, 【Chemistry 127】 The method of any one of claims 335, 336, and 337, wherein the molar ratio of
344. The compound is 【128】 of, 【129】 The method of any one of claims 335, 336, and 337, wherein the molar ratio of
345. The method of any one of claims 289-304 and 330-334, wherein the therapeutic agent is adalimumab or an antibody fragment thereof.
346. The method of any one of claims 289 to 304, 330 to 334, and 345, wherein the therapeutic agent comprises the sequences of SEQ ID NO: 3 and SEQ ID NO: 6, the sequences of SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences of SEQ ID NO: 5 and SEQ ID NO:
7.
347. The compound is 【Chemistry 130】 of, 【Chemistry 131】 The method of claim 345 or 346, wherein the molar ratio of is from about 1:1 to about 1:
144.
348. The method of any one of claims 289-304 and 330-334, wherein the therapeutic agent is ustekinumab or an antibody fragment thereof.
349. The method of any one of claims 289 to 304, 330 to 334, and 348, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO:
9.
350. The compound is 【132】 of, 【Chemistry 133】 The method of claim 348 or 349, wherein the molar ratio of is from about 1:1 to about 1:
140.
351. The method of any one of claims 289-304 and 330-334, wherein the therapeutic agent is golimumab or an antibody fragment thereof.
352. The method of any one of claims 289 to 304, 330 to 334, and 351, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO:
11.
353. The compound is 【134】 of, 【Chemistry 135】 The method of claim 351 or 352, wherein the molar ratio of is from about 1:1 to about 1:
80.
354. The method of any one of claims 289-304 and 330-334, wherein the therapeutic agent is natalizumab or an antibody fragment thereof.
355. The method of any one of claims 289 to 304, 330 to 334, and 354, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO:
15.
356. The compound is 【Chemistry 136】 of, 【Chemistry 137】 The method of claim 354 or 355, wherein the molar ratio of is from about 1:1 to about 1:
156.
357. The method of any one of claims 289-304 and 330-334, wherein the therapeutic agent is vedolizumab or an antibody fragment thereof.
358. The method of any one of claims 289 to 304, 330 to 334, and 357, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO:
17.
359. The compound is 【Chemistry 138】 of, 【Chemistry 139】 The method of claim 357 or 358, wherein the molar ratio of is from about 1:1 to about 1:
256.
360. The method of any one of claims 289-304 and 330-334, wherein the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
361. The method of any one of claims 289 to 304, 330 to 334, and 360, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO:
19.
362. The compound is 【Chemistry 140】 of, 【Chemistry 141】 The method of claims 360 and 361, wherein the molar ratio of is from about 1:1 to about 1:
70.
363. The method of any one of claims 289 to 304, wherein the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
364. R 5 The method of claim 363, wherein said sequence comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:
25.
365. R 5 The method of claim 363 or 364, wherein said sequence comprises the sequence of SEQ ID NO:
25.
366. R 5 is attached to the residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:
25. 2 366. The method of any one of claims 363 to 365, comprising:
367. R 5 C20 diacid -γ-Glu-(AEEA) conjugated to the residue of the sequence of SEQ ID NO: 25 2 367. The method of any one of claims 363 to 366, comprising:
368. R 5 is attached to the Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO: 25, 2 368. The method of any one of claims 363 to 367, comprising:
369. The compound is 【142】 of, 【Chemistry 143】 The method of any one of claims 363 to 368, wherein the molar ratio of
370. The compound is 【Chemical 144】 of, 【Chemistry 145】 The method of any one of claims 363 to 368, wherein the molar ratio of
371. The compound is 【Chemistry 146】 of, 【147】 The method of any one of claims 363 to 368, wherein the molar ratio of
372. The compound is 【148】 of, 【149】 The method of any one of claims 363 to 368, wherein the molar ratio of
373. The compound is 【Chemistry 150】 of, 【Chemistry 151】 The method of any one of claims 363 to 368, wherein the molar ratio of
374. The compound is 【Chemistry 152】 of, 【Chemistry 153】 The method of any one of claims 363 to 368, wherein the molar ratio of
375. The compound is 【Chemistry 154】 of, 【Chemistry 155】 The method of any one of claims 363 to 368, wherein the molar ratio of
376. The compound is 【Chemistry 156】 of, 【Chemistry 157】 The method of any one of claims 363 to 368, wherein the molar ratio of
377. 1. A method of increasing the solubility of a therapeutic agent, comprising: 【158】 [In the formula, R 6 is a therapeutic agent, and the therapeutic agent is (i) a GLP-1 analogue or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) a GIP / GLP-1 receptor dual agonist or a functional variant thereof and R 7 , R 8 , and R 9 are independently unsubstituted C 1 ~C 5 Alkyl, or substituted C 1 ~C 5 is alkyl; n is 1, 2, 3, 4, or 5.
20. A method comprising the step of preparing a composition comprising a compound according to claim 19.
378. 1. A method for enhancing or improving the delivery efficiency of a therapeutic agent in a subject in need thereof, comprising administering to a subject a compound of formula II: 【Chemistry 159】 [In the formula, R 6 is a therapeutic agent, and the therapeutic agent is (i) a GLP-1 analogue or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) a GIP / GLP-1 receptor dual agonist or a functional variant thereof and R 7 , R 8 , and R 9 are independently unsubstituted C 1 ~C 5 Alkyl, or substituted C 1 ~C 5 is alkyl; n is 1, 2, 3, 4, or 5. preparing a composition comprising a compound according to Administering the composition to a subject A method comprising:
379. R 7 , R 8 , and R 9 The method of claim 377 or 378, wherein is methyl.
380. R 7 , R 8 , and R 9 The method of claim 377 or 378, wherein is ethyl.
381. R 7 , R 8 , and R 9 The method of claim 377 or 378, wherein is propyl.
382. R 7 and R 8 is methyl, and R 9 The method of claim 377 or 378, wherein is ethyl.
383. R 7 and R 9 is methyl, and R 8 The method of claim 377 or 378, wherein is ethyl.
384. R 7 and R 8 is ethyl, and R 9 The method of claim 377 or 378, wherein is methyl.
385. R 7 and R 9 is ethyl, and R 8 The method of claim 377 or 378, wherein is methyl.
386. R 7 and R 8 is propyl, and R 9 The method of claim 377 or 378, wherein is methyl.
387. R 7 and R 9 is propyl, and R 8 The method of claim 377 or 378, wherein is methyl.
388. The method of claim 377 or 378, wherein n is 1.
389. The compound has the formula IIa: 【Chemistry 160】 379. The method of claim 377 or 378, wherein the compound is according to
390. The compound has the formula IIb: 【Chemistry 161】 379. The method of claim 377 or 378, wherein the compound is according to
391. The compound has the formula IIc: 【Chemistry 162】 379. The method of claim 377 or 378, wherein the compound is according to
392. The method of any one of claims 377 to 391, wherein the therapeutic agent is a GLP-1 analog or a functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
393. The method of any one of claims 377 to 392, wherein the therapeutic agent is a GLP-1 analogue or a functional variant thereof, or a mimetic thereof.
394. The method of claim 392 or 393, wherein the compound comprises the structure shown in Figure 17B.
395. 392. The method of any one of claims 377 to 391, wherein the therapeutic agent is amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof.
396. The method of any one of claims 377 to 391 and 395, wherein the therapeutic agent is an amylin analog or a functional variant thereof, or a mimetic or analog thereof.
397. The therapeutic agent, [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide 397. The method of any one of claims 377 to 391, 395, and 396, wherein the amylin analog has the sequence:
398. The method of any one of claims 377 to 391 and 395 to 397, wherein the therapeutic agent is an amylin analog having a structure shown in Figure 2, Figure 3, or Figure 4, or a functional variant thereof, or a mimetic or analog thereof.
399. The method of any one of claims 395 to 398, wherein the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
400. 400. The method of any one of claims 395 to 399, wherein the therapeutic agent is an amylin analog or functional variant thereof comprising an N14E amino acid substitution, or a mimetic or analog thereof.
401. The method of any one of claims 377 to 391, wherein the therapeutic agent is an antibody or an antibody fragment thereof.
402. The method of any one of claims 377 to 391 and 401, wherein the therapeutic agent is any one selected from the group consisting of infliximab or an antibody fragment thereof, adalimumab or an antibody fragment thereof, ustekinumab or an antibody fragment thereof, golimumab or an antibody fragment thereof, natalizumab or an antibody fragment thereof, vedolizumab or an antibody fragment thereof, and certolizumab pegol or an antibody fragment thereof.
403. The therapeutic agent, (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof.
403. The method of any one of claims 377 to 391, 401, and 402, comprising:
404. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof The method of any one of claims 377 to 391 and 401 to 403, comprising:
405. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences SEQ ID NO: 3 and SEQ ID NO: 6, the sequences SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 The method of any one of claims 377 to 391 and 401 to 404, comprising:
406. The method of any one of claims 377-391 and 401-405, wherein the therapeutic agent is infliximab or an antibody fragment thereof.
407. The method of any one of claims 377 to 391 and 401 to 406, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO:
2.
408. The method of any one of claims 377-391 and 401-405, wherein the therapeutic agent is adalimumab or an antibody fragment thereof.
409. The method of any one of claims 377 to 391, 401 to 405, and 131, wherein the therapeutic agent comprises the sequences of SEQ ID NO: 3 and SEQ ID NO: 6, the sequences of SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences of SEQ ID NO: 5 and SEQ ID NO:
7.
410. The method of any one of claims 377-391 and 401-405, wherein the therapeutic agent is ustekinumab or an antibody fragment thereof.
411. The method of any one of claims 377 to 391, 401 to 405, and 410, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO:
9.
412. The method of any one of claims 377-391 and 401-405, wherein the therapeutic agent is golimumab or an antibody fragment thereof.
413. The method of any one of claims 377 to 391, 401 to 405, and 412, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO:
11.
414. The method of any one of claims 377-391 and 401-405, wherein the therapeutic agent is natalizumab or an antibody fragment thereof.
415. The method of any one of claims 377 to 391, 401 to 405, and 414, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO:
15.
416. The method of any one of claims 377-391 and 401-405, wherein the therapeutic agent is vedolizumab or an antibody fragment thereof.
417. The method of any one of claims 377 to 391, 401 to 405, and 416, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO:
17.
418. The method of any one of claims 377-391 and 401-405, wherein the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
419. The method of any one of claims 377 to 391, 401 to 405, and 418, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO:
19.
420. The method of any one of claims 377 to 391, wherein the therapeutic agent is a GLP-1 analogue or a functional variant thereof, or a mimetic thereof, liraglutide.
421. R 6 The method of claim 420, wherein said sequence comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:
25.
422. R 6 The method of claim 420 or 421, wherein said sequence comprises the sequence of SEQ ID NO:
25.
423. R 6 is attached to the residue of a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:
25. 2 423. The method of any one of claims 420 to 422, comprising:
424. R 6 C20 diacid -γ-Glu-(AEEA) conjugated to the residue of the sequence of SEQ ID NO: 25 2 424. The method of any one of claims 420 to 423, comprising:
425. R 6 is attached to the Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO: 25, 2 425. The method of any one of claims 420 to 424, comprising:
426. 426. The method of any one of claims 289 to 425, wherein the composition further comprises one or more ionic liquids.
427. 427. The method of claim 426, wherein the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
428. 427. The method of claim 426, wherein the one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine.
429. The one or more ionic liquids may independently be selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid (protocatechuic acid), 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)-galactonic acid, de Canic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-asparagine Acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), sorbic acid, stearic acid, succinic acid, syringic acid, tiglic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
430. 429. The method of any one of claims 426 to 428, wherein the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydrocinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
431. 429. The method of any one of claims 426 to 428, wherein the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
432. 432. The method of any one of claims 426-431, wherein the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
433. 432. The method of any one of claims 426-431, wherein the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
434. 432. The method of any one of claims 426-431, wherein the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
435. 1. A method of increasing the solubility of a therapeutic agent, comprising preparing a composition comprising the therapeutic agent and one or more ionic liquids; The therapeutic agent, (i) a GLP-1 analogue or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) a GIP / GLP-1 receptor dual agonist or a functional variant thereof How to be.
436. 1. A method of enhancing or improving delivery efficiency of a therapeutic agent in a subject in need thereof, comprising the steps of preparing a composition comprising the therapeutic agent and one or more ionic liquids; administering the composition to a subject; The therapeutic agent, (i) a GLP-1 analogue or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) a GIP / GLP-1 receptor dual agonist or a functional variant thereof How to be.
437. 437. The method of claim 435 or 436, wherein the one or more ionic liquids independently comprise a cation selected from the group consisting of aminoguanidine, choline or a choline derivative, carnitine, acetylcholine, ammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, and a guanidine derivative.
438. 438. The method of any one of claims 435 to 437, wherein the one or more ionic liquids independently comprise choline or a choline derivative, carnitine, or acetylcholine.
439. The one or more ionic liquids may independently be selected from the group consisting of (R)-α-lipoic acid, 12-hydroxystearic acid, 2-(4-isobutylphenyl)propionic acid, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoic acid, 2-aminoethanesulfonic acid (tauric acid), 2-hexyldecanoic acid, 2-hydroxyhippuric acid, 3-(4-hydroxyphenyl)propionic acid, 3-methylcrotonic acid, 3,3-diphenylpropionic acid, 3,4-dihydroxybenzoic acid (protocatechuic acid), 3,7-dimethyloctanoic acid, 4-hydroxybenzenesulfonic acid, 4-hydroxybenzoic acid, 4-methylhexanoic acid, 4-methyloctanoic acid, 4-methylvaleric acid, 5-norbornene-2-carboxylic acid, 8-[(2-hydroxybenzoyl)amino]octanoic acid, abietic acid, acetic acid, acetylcysteine, aconitic acid, arachidonic acid, behenic acid, benzoic acid, caffeic acid, chenodeoxycholic acid, cis-cinnamic acid, citric acid, citronellic acid, crotonic acid, D-(+)-galactonic acid, de Canic acid, deoxycholic acid, dihydrocaffeic acid, DL-2-phenylpropionic (hydratropic) acid, DL-tartaric acid, DL-tropic acid, eicosandioic acid, eicosapentanoic acid (EPA), elaidic acid, ellagic acid, erucic acid, ethylenediaminetetraacetic acid (EDTA), formic acid, fumaric acid, geranic acid, glutaric acid, glycolic acid, heptanoic acid, hexanoic acid, hydrocinnamic acid (3-phenylpropionic acid), isobutyric acid, isovaleric acid, L-(+)-tartaric acid, L-ascorbic acid, L-asparagine Acid, L-glutamic acid, L-glutathione (reduced), lactic acid, lauric acid, levulinic acid, linoleic acid, linolenic acid, lithocholic acid, maleic acid, malic acid, malonic acid, mandelic acid, mesaconic acid, nicotinic acid, nonanoic acid, octanoic acid, oleic acid, oxalic acid, p-coumaric acid, p-toluenesulfonic acid, palmitic acid, perillic acid, phosphoric acid, pimelic acid, pivalic acid, propionic acid, pyroglutamic acid, pyruvic acid, ricinoleic acid, salicylic acid (2-hydroxybenzoic acid), sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), sorbic acid, stearic acid, succinic acid, syringic acid, tiglic acid, trans-2-decenoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, trans-7-octenoic acid, trans-cinnamic acid, trans-ferulic acid, undecanoic acid, valeric acid, vanillic acid, and α-ketoglutaric acid.
440. 440. The method of any one of claims 435 to 439, wherein the one or more ionic liquids independently comprise anions selected from the group consisting of glycolic acid, tartaric acid, malic acid, hydrocinnamic acid, citric acid, cinnamic acid, mandelic acid, mesaconic acid, ricinoleic acid, linoleic acid, and tiglic acid.
441. 441. The method of any one of claims 435 to 440, wherein the one or more ionic liquids independently comprise anions selected from the group consisting of cinnamic acid, mandelic acid, citric acid, ricinoleic acid, linoleic acid, and tiglic acid.
442. 442. The method of any one of claims 435-441, wherein the one or more ionic liquids independently comprise [choline or choline derivative]-cinnamic acid, [choline or choline derivative]-mandelic acid, [choline or choline derivative]-citric acid, [choline or choline derivative]-ricinoleic acid, [choline or choline derivative]-linoleic acid, or [choline or choline derivative]-tiglic acid.
443. 442. The method of any one of claims 435-441, wherein the one or more ionic liquids independently comprise carnitine-cinnamic acid, carnitine-mandelic acid, carnitine-citric acid, carnitine-ricinoleic acid, carnitine-linoleic acid, or carnitine-tiglic acid.
444. 442. The method of any one of claims 435-441, wherein the one or more ionic liquids independently comprise acetylcholine-cinnamic acid, acetylcholine-mandelic acid, acetylcholine-citric acid, acetylcholine-ricinoleic acid, acetylcholine-linoleic acid, or acetylcholine-tiglic acid.
445. 1. A method for enhancing the hydrophobicity of a therapeutic agent, comprising: 12 to a therapeutic agent, R 12 But substitution C 5 ~C 10 , or unsubstituted C 5 ~C 10 and The therapeutic agent, (i) a GLP-1 analogue or functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin; (ii) amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof; (iii) an antibody or antibody fragment thereof; or (iv) a GIP / GLP-1 receptor dual agonist or a functional variant thereof How to be.
446. R 12 However, the therapeutic agent 【163】 , -S-, or -NH-.
447. R 12 The method of claim 445 or 446, wherein is linked to the therapeutic agent via a covalent bond or a linker.
448. The method of claim 447, wherein the linker is a non-cleavable linker.
449. The method of claim 448, wherein the linker comprises a maleimidoalkane linker or a maleimidocyclohexane linker.
450. The linker 【Chemical 164】 The method of claim 448 or 449, comprising:
451. The method of claim 447, wherein the linker is a chemically cleavable linker.
452. The method of claim 451, wherein the linker comprises a hydrazone linker or a disulfide linker.
453. The linker 【Chemistry 165】 The method of claim 451 or 452, comprising:
454. R 12 But substitution C 10 or unsubstituted C 10 The method of any one of claims 445 to 453, wherein
455. The method of any one of claims 445 to 454, wherein the therapeutic agent is a GLP-1 analog or a functional variant thereof, or a mimetic thereof, liraglutide, exenatide, peptide YY (tyrosine tyrosine), glucagon, GIP (gastric inhibitory polypeptide), or amylin.
456. The method of any one of claims 445 to 455, wherein the therapeutic agent is a GLP-1 analogue or a functional variant thereof, or a mimetic thereof.
457. The method of any one of claims 445 to 454, wherein the therapeutic agent is amylin or a mimetic or analog thereof, or an amylin analog or functional variant thereof, or a mimetic or analog thereof.
458. The method of any one of claims 445 to 454 and 457, wherein the therapeutic agent is an amylin analog or a functional variant thereof, or a mimetic or analog thereof.
459. The therapeutic agent, [diacid]-[linker]-KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide The method of any one of claims 445 to 454, 457, and 458, wherein the amylin analog has the sequence:
460. The method of any one of claims 445 to 454 and 457 to 459, wherein the therapeutic agent is an amylin analog having a structure shown in Figure 2, Figure 3, or Figure 4, or a functional variant thereof, or a mimetic or analog thereof.
461. The method of any one of claims 457 to 460, wherein the therapeutic agent is an amylin analog or functional variant thereof, or a mimetic or analog thereof, comprising an amino acid substitution of N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof.
462. The method of any one of claims 457 to 461, wherein the therapeutic agent is an amylin analog or functional variant thereof comprising an N14E amino acid substitution, or a mimetic or analog thereof.
463. The method of any one of claims 445 to 454, wherein the therapeutic agent is an antibody or an antibody fragment thereof.
464. The method of any one of claims 445 to 454 and 463, wherein the therapeutic agent is any one selected from the group consisting of infliximab or an antibody fragment thereof, adalimumab or an antibody fragment thereof, ustekinumab or an antibody fragment thereof, golimumab or an antibody fragment thereof, natalizumab or an antibody fragment thereof, vedolizumab or an antibody fragment thereof, and certolizumab pegol or an antibody fragment thereof.
465. The therapeutic agent, (i) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 2, or a combination thereof; (ii) a sequence with at least 75% sequence identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, a sequence with at least 75% sequence identity to SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 8, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 9, or a combination thereof; (iv) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 10, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 11, or a combination thereof; (v) a sequence with at least 75% sequence identity to SEQ ID NO: 12 or SEQ ID NO: 13, a sequence with at least 75% sequence identity to SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 16, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 18, a sequence with at least 75% sequence identity to the sequence of SEQ ID NO: 19, or a combination thereof.
465. The method of any one of claims 445 to 454, 463, and 464, comprising:
466. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, the sequence of SEQ ID NO: 2, or a combination thereof; (ii) the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, the sequence of SEQ ID NO:6 or SEQ ID NO:7, or any combination thereof; (iii) the sequence of SEQ ID NO: 8, the sequence of SEQ ID NO: 9, or a combination thereof; (iv) the sequence of SEQ ID NO: 10, the sequence of SEQ ID NO: 11, or a combination thereof; (v) the sequence of SEQ ID NO: 12 or SEQ ID NO: 13, the sequence of SEQ ID NO: 14 or SEQ ID NO: 15, or any combination thereof; (vi) the sequence of SEQ ID NO: 16, the sequence of SEQ ID NO: 17, or a combination thereof; or (vii) the sequence of SEQ ID NO: 18, the sequence of SEQ ID NO: 19, or a combination thereof 466. The method of any one of claims 445 to 454 and 463 to 465, comprising:
467. The therapeutic agent, (i) the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO: 2; (ii) the sequences SEQ ID NO: 3 and SEQ ID NO: 6, the sequences SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences SEQ ID NO: 5 and SEQ ID NO: 7; (iii) the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9; (iv) the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO: 11; (v) the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO: 15; (vi) the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO: 17; or (vii) the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO: 19 The method of any one of claims 445 to 454 and 463 to 466, comprising:
468. The method of any one of claims 445-454 and 463-467, wherein the therapeutic agent is infliximab or an antibody fragment thereof.
469. The method of any one of claims 445 to 454 and 463 to 468, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 24, and the sequence of SEQ ID NO:
2.
470. The method of any one of claims 445-454 and 463-467, wherein the therapeutic agent is adalimumab or an antibody fragment thereof.
471. The method of any one of claims 445 to 454, 463 to 467, and 470, wherein the therapeutic agent comprises the sequences of SEQ ID NO: 3 and SEQ ID NO: 6, the sequences of SEQ ID NO: 4 and SEQ ID NO: 6, or the sequences of SEQ ID NO: 5 and SEQ ID NO:
7.
472. The method of any one of claims 445-454 and 463-467, wherein the therapeutic agent is ustekinumab or an antibody fragment thereof.
473. The method of any one of claims 445 to 454, 463 to 467, and 472, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO:
9.
474. The method of any one of claims 445-454 and 463-467, wherein the therapeutic agent is golimumab or an antibody fragment thereof.
475. The method of any one of claims 445 to 454, 463 to 467, and 474, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 10 and the sequence of SEQ ID NO:
11.
476. The method of any one of claims 445-454 and 463-467, wherein the therapeutic agent is natalizumab or an antibody fragment thereof.
477. The method of any one of claims 445 to 454, 463 to 467, and 476, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 12 and the sequence of SEQ ID NO: 14, or the sequence of SEQ ID NO: 13 and the sequence of SEQ ID NO:
15.
478. The method of any one of claims 445-454 and 463-467, wherein the therapeutic agent is vedolizumab or an antibody fragment thereof.
479. The method of any one of claims 445 to 454, 463 to 467, and 478, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 16 and the sequence of SEQ ID NO:
17.
480. The method of any one of claims 445-454 and 463-467, wherein the therapeutic agent is certolizumab pegol or an antibody fragment thereof.
481. The method of any one of claims 445 to 454, 463 to 467, and 480, wherein the therapeutic agent comprises the sequence of SEQ ID NO: 18 and the sequence of SEQ ID NO:
19.
482. The method of any one of claims 445 to 454, wherein the therapeutic agent is a GIP / GLP-1 receptor dual agonist or a functional variant thereof.
483. The method of claim 482, wherein the therapeutic agent comprises a sequence with at least 75% sequence identity to the sequence of SEQ ID NO:
25.
484. The method of claim 482 or 483, wherein the therapeutic agent comprises the sequence of SEQ ID NO:
25.
485. A therapeutic agent is conjugated to a residue of a C20 diacid-γ-Glu-(AEEA) with at least 75% sequence identity to the sequence of SEQ ID NO:
25. 2 485. The method of any one of claims 482 to 484, comprising:
486. The therapeutic agent is conjugated to the residue of the sequence of SEQ ID NO: 25, C20 diacid -γ-Glu-(AEEA) 2 486. The method of any one of claims 482 to 485, comprising:
487. The therapeutic agent is conjugated to the Lys residue at position 20 from the N-terminus of the sequence of SEQ ID NO: 25, the C20 diacid -γ-Glu-(AEEA) 2 487. The method of any one of claims 482 to 486, comprising:
488. The method of claim 445, wherein the therapeutic agent is linked to one or more fatty acids or carboxylic acid-containing molecules.
489. The method of claim 488, wherein the therapeutic agent is linked to one or more fatty acids or carboxylic acid-containing molecules via dual conjugation.
490. The method of claim 455 or 488, wherein the one or more fatty acid or carboxylic acid-containing molecules include cinnamic acid.
491. 491. The method of any one of claims 488 to 490, wherein one or more fatty acids or carboxylic acid-containing molecules are non-covalently associated with a free amine of the therapeutic agent.
492. 492. The method of any one of claims 488 to 491, wherein one or more fatty acids or carboxylic acid-containing molecules are non-covalently associated with the N-terminal amine within the peptide backbone of the therapeutic agent.
493. The method of any one of claims 488 to 492, wherein one or more fatty acid or carboxylic acid-containing molecules are non-covalently associated with an amine group of a Gln residue, an amine group of an Asn residue, an amine group of an Arg residue, an amine group of a Lys residue, an amine group of a His residue, or a combination thereof, of the therapeutic agent.
494. The method of any one of claims 488 to 493, wherein one or more fatty acids or carboxylic acid-containing molecules are covalently conjugated to a free amine of the therapeutic agent.
495. The method of any one of claims 488 to 494, wherein one or more fatty acids or carboxylic acid-containing molecules are covalently conjugated to the N-terminal amine within the peptide backbone of the therapeutic agent.
496. The method of any one of claims 488 to 495, wherein one or more fatty acid or carboxylic acid-containing molecules are covalently conjugated to an amine group of a Gln residue, an amine group of an Asn residue, an amine group of an Arg residue, an amine group of a Lys residue, an amine group of a His residue, or a combination thereof, of the therapeutic agent.
497. A method of enhancing or improving the delivery efficiency of a therapeutic agent in a subject in need thereof, comprising the steps of adding at least one penetration enhancer to a compound of any one of claims 1 to 222, a composition of any one of claims 223 to 249, or a pharmaceutical composition of claims 250 to 253, and administering the composition, compound, or pharmaceutical composition to the subject.
498. 498. The method of claim 497, wherein the at least one penetration enhancer is selected from the group consisting of sulcaprozate sodium (SNAC), sodium caprylate, sodium caprate, bile salts, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis-(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 3-[N,N-dimethyl(3-palmitoylaminopropyl)-ammonio]-propanesulfonate (PPS), and any combination thereof.
499. 499. The method of claim 498, wherein the bile salt is selected from the group consisting of sodium deoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, and combinations thereof.
